

```

chain nodes :
  7 15
ring nodes :
  1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
  2-7 4-15 7-10
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
  2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
  containing 1 :

```

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:Atom 15:Atom
Generic attributes :
  15:
  Saturation : Unsaturated

```

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10552317.str



chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 15:Atom 16:Atom

Generic attributes :

15:


Saturation : Unsaturated

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

```
=> d l4
L4 HAS NO ANSWERS
L1          SCR 1840
L2          SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3          STR
```



Structure attributes must be viewed using STN Express query preparation.
 L4 QUE L3 AND L1 NOT L2

```
=> s l4 sss sam
SAMPLE SEARCH INITIATED 12:28:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2625 TO ITERATE

76.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                      BATCH **COMPLETE**
PROJECTED ITERATIONS: 49427 TO 55573
PROJECTED ANSWERS: 1219 TO 2351
```

```
L5 50 SEA SSS SAM L3 AND L1 NOT L2
```

```
=> => ....Testing the current file.... screen
```

```
ENTER SCREEN EXPRESSION OR (END):end
```

```
=> screen 1840
```

```
L6 SCREEN CREATED
```

```
=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
```

```
L7 SCREEN CREATED
```

```
=>
Uploading C:\Program Files\Stnexp\Queries\10552317 (a).str
```



```

chain nodes :
7 15
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
2-7 4-15 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 15:Atom
Generic attributes :
15:
Saturation : Unsaturated

```

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> s l9 sss sam

SAMPLE SEARCH INITIATED 12:34:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2625 TO ITERATE

76.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 49427 TO 55573

PROJECTED ANSWERS: 1131 TO 2229

L10 50 SEA \$\$\$ SAM L8 AND L6 NOT L7

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10552317 (b).str



chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 4-15 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 15:Atom

Generic attributes :

15:

Saturation : Unsaturated

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12


=> d l14

L14 HAS NO ANSWERS

L11 SCR 1840

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR



Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 12:34:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2625 TO ITERATE

76.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 49427 TO 55573

PROJECTED ANSWERS: 1131 TO 2229

L15 50 SEA SSS SAM L13 AND L11 NOT L12

=> s l10 sss ful

FULL SEARCH INITIATED 12:35:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 55025 TO ITERATE

100.0% PROCESSED 55025 ITERATIONS

1559 ANSWERS

SEARCH TIME: 00.00.01

L16 1559 SEA SSS FUL L8 AND L6 NOT L7

=> => s l16

10/552,317

L17 74 L16

=> d 117 1-74 bib,ab,hitstr

L17 ANSWER 1 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:1280561 CAPLUS

DN 149:493700

TI 2-(Morpholin-4-yl)pyrimidine derivatives as PI3K inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Baker, Stewart James; Goldsmith, Paul John; Hancox, Timothy Colin; Pegg, Neil Anthony; Shuttleworth, Stephen Joseph; Dechaux, Elsa Amandine; Krintel, Sussie Lerche; Price, Stephen; Large, Jonathan Martin; McDonald, Edward

PA Piramed Limited, UK; The Institute of Cancer Research

SO PCT Int. Appl., 93pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008125833	A1	20081023	WO 2008-GB1292	20080414
W:	AE, AG, AL, AM, AN, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI GB 2007-7086	A	20070412		
GB 2007-7613	A	20070419		

OS MARPAT 149:493700

AB The invention provides compds. of formula I and their pharmaceutically acceptable salts. These compds. are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurol. disorders. Compds. of formula I wherein R2 is bonded at position 2, R1 is bonded at position 5 or 6; or R1 is bonded at position 2, R2 is bonded at position 6; R1 is (un)substituted -(CH2)m-Y-R3, (un)substituted -[(hetero)arylene-(CH2)n]pNH2 and derivs., -CONH2 and derivs. and -O(CRaRb)n-R3; R2 is (un)substituted indolyl; Y is a direct bond, (un)substituted -O(CH2)n-, (un)substituted -O(CH2)nNH- and derivs., (un)substituted -NH(CH2)n- and derivs., (un)substituted NH(CH2)nO(CH2)n- and derivs., etc.; m is 1-3; n is 0-3; p is 0-1; one of Ra and Rb is H, the other one is (un)substituted C1-6 alkyl; or each of Ra and Rb is independently (un)substituted C1-6 alkyl; R3 is unsatd. 5- to 12-membered carbocyclic or heterocyclic ring and (un)substituted saturated 5- to 7-membered N-containing heterocyclic ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by Suzuki coupling of (6-chloro-2-morpholin-4-yl)pyrimidin-4-yl)-(2-pyridin-3-ylethyl)amine with 6-fluoro-4-(4,4,5,5-tetramethyl[1,2,3]dioxaborolan-2-yl)-1H-indole. All the invention compds. were evaluated for their PI3K inhibitory activity. From the assay, it was determined that II and other

tested compds. exhibited the IC50 values of 5 - 500 nM.


IT 1072269-15-8P, N-(1-Benzylpiperidin-4-yl)-N-[4-(1H-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-2-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of morpholinylpyrimidine derivs. as PI3K inhibitors useful in the treatment of diseases)

RN 1072269-15-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-4-yl)-6-(4-morpholinyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:1248534 CAPLUS

DN 149:471494

TI Preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and their combinations useful for treating neoplasms

IN Lamb, Peter

PA Exelixis, Inc., USA

SO PCT Int. Appl., 623pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008124085	A2	20081016	WO 2008-US4434	20080403
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2007-921878P P 20070403

OS MARPAT 149:471494

AB The invention provides methods of treating a disease, particularly cancer, by administering a therapeutically effective amount of a MEK inhibitor, e.g., I [A = (un)substituted phenylene; X = halo; R3 = H, halo, OH, alkoxy, amino; R4 = H, NH2 and derivs., CONH2 and derivs., cycloalkyl, etc.; or R3CR4 = CO, C(NOH); R7 = halo] or a pharmaceutically acceptable salt or solvate, or a pharmaceutical composition containing I and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a KAK-2 inhibitor II [D, E = independently halo, CF3, (heterocyclo)alkyl; or DCCE = 5-7 membered heteroaryl, heterocycloalkyl; L = a bond, O, NH; Z = alkoxy, cycloalkyl, (un)substituted heteroaryl, heterocycloalkyl; Z and R25 together with the C's to which they are attached form an (un)substituted 5-6 membered heterocycloalkyl, heteroaryl, cycloalkyl; n = 0-4 and each n is independently selected when >1 n is present; R1 = H; R2 = substituted Ph, 6-aminopyridin-2-yl, 4-aminopyrimidin-6-yl, phenylsulfonylamino, etc.] or a pharmaceutically acceptable salt or solvate, or a pharmaceutical composition containing II and a pharmaceutically acceptable carrier and in combination with other cancer treatments. Example compound III was prepared by amidation of 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoic acid with azetidin-3-ol hydrochloride. Example compound IV was prepared by cross-coupling of 2,4-dichloropyrimidine with 4-(acetylamino)phenylboronic acid; the resulting N-[4-(2-chloropyrimidin-4-yl)phenyl]acetamide underwent amination with N-Boc-1,3-diaminobenzene to give compound IV. I were evaluated for their MEK inhibitory activity and II for their JAK-2 inhibitory activity.


IT 945754-01-8P, Ethyl 4-[[4-[4-(acetylamino)phenyl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 945754-03-0P,

1,1-Dimethylethyl 4-[[4-[4-(acetylamino)phenyl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 945755-25-9P,
 N-[4-[2-[(Piperidin-4-yl)amino]pyrimidin-4-yl]phenyl]acetamide 945755-26-0P, N-[4-[2-[[1-[(2,6-Dichlorophenyl)carbonyl]piperidin-4-yl]amino]pyrimidin-4-yl]phenyl]acetamide 945756-08-1P, (2,6-Dichlorophenyl) 4-[[4-[4-(methyl)thiophen-2-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methanone 945756-10-5P, (2,6-Dichlorophenyl) 4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]methanone 945756-14-9P, (2,6-Dichlorophenyl) 4-[[4-[5-(methyl)thiophen-2-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methanone 1071297-52-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(JAK-2 inhibitor; preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and methods of using their combinations for treating neoplasm)


RN 945754-01-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 945754-03-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 945755-25-9 CAPLUS

CN Acetamide, N-[4-[2-(4-piperidinylamino)-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945755-26-0 CAPLUS

CN Acetamide, N-[4-[2-[[1-(2,6-dichlorobenzoyl)-4-piperidinyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945756-08-1 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 945756-10-5 CAPLUS


CN Methanone, (2,6-dichlorophenyl)[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 945756-14-9 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(5-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)

pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1071297-52-3 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 945756-08-1

CMF C21 H20 Cl2 N4 O S



CM 2

CRN 64-19-7

CMF C2 H4 O2



IT 945756-45-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and methods of using their combinations for treating neoplasm)

RN 945756-45-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thienyl)-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)

10/552,317



● HCl

L17 ANSWER 3 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:1039048 CAPLUS
 DN 149:307871
 TI 4-(Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives as cell proliferation inhibitors, their preparation, pharmaceutical compositions, and use as antitumor agents
 IN Dorsch, Dieter; Sirrenberg, Christian; Mueller, Thomas J. J.; Merkul, Eugen
 PA Merck Patent G.m.b.H., Germany
 SO Ger. Offen., 32pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102007008419	A1	20080828	DE 2007-102007008419	20070221
	WO 2008101587	A1	20080828	WO 2008-EP634	20080128
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	DE 2007-102007008419 A		20070221		

AB The invention relates to 4-(pyrrolopyridinyl)pyrimidin-2-ylamines of formula I, which are inhibitors of cell proliferation/cell vitality and can be used for treatment of tumors. In compds. I, R1 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; A is C1-10 alkyl, where one or two CH2 groups may be replaced by O- or S-atoms and/or by -CH=CH- groups and 1-7 H atoms may be replaced by F; n is 0-2; R6 is H or C1-6 alkyl; Ar is (un)substituted C5-14 aryl; Het is (un)substituted mono- or bicyclic heterocyclyl or heteroaryl containing 1-4 heteroatoms selected from N, O, and S; R2 is H or A; R3 and R4 are independently selected from H, halo, cyano, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, and -[C(R6)2]n-cycloalkyl; R5 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; including pharmaceutically acceptable derivs., solvates, salts, tautomers, and stereoisomers thereof. The invention also relates the preparation of I, pharmaceutical compns. comprising at least one compound I, optionally in combination with other active agents, along with carriers and/or adjuvants, if necessary, as well as to the use of the compns. for the treatment of tumors, tumor growth, tumor metastasis, and/or AIDS. Palladium-catalyzed carbonylation of tert-Bu 3-iodopyrrolo[3,2-c]pyridine-1-carboxylate with trimethylsilylacetylene and carbon monoxide resulted in the formation of ketone II, which underwent heterocyclization with phenylguanidinium carbonate to give pyrimidine III. The compds. of the invention have antiproliferative activity, e.g., compound III expressed IC50 values between 10 nM and 1 µM for inhibition of cell proliferation of intestinal, ovarian, prostate, and breast cancer cell lines.

IT 1050373-17-5P, 2-((4-Pyridinyl)amino)-4-(1H-pyrrolo[3,2-c]pyridin-


3-yl)pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of (pyrrolopyridinyl)pyrimidinylamines as cell
proliferation inhibitors useful as antitumor agents)

RN 1050373-17-5 CAPLUS


CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)- (CA
INDEX NAME)



L17 ANSWER 4 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:1039047 CAPLUS
 DN 149:307870
 TI 4-(Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives as cell proliferation inhibitors, their preparation, pharmaceutical compositions, and use as antitumor agents
 IN Dorsch, Dieter; Sirrenberg, Christian; Mueller, Thomas J. J.; Merkul, Eugen
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 70pp.
 CODEN: P1XXD2
 DT Patent
 LA German
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008101587	A1	20080828	WO 2008-EP634	20080128
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CG, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
DE 102007008419	A1	20080828	DE 2007-102007008419	20070221
FRAI DE 2007-102007008419	A	20070221		
OS MARPAT 149:307870				
AB	<p>The invention relates to 4-(pyrrolopyridinyl)pyrimidin-2-ylamines of formula I, which are inhibitors of cell proliferation/cell vitality and can be used for treatment of tumors. In compds. I, R1 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; A is C1-10 alkyl, where one or two CH2 groups may be replaced by O- or S-atoms and/or by -CH=CH- groups and 1-7 H atoms may be replaced by F; n is 0-2; R6 is H or C1-6 alkyl; Ar is (un)substituted C5-14 aryl; Het is (un)substituted mono- or bicyclic heterocyclyl or heteroaryl containing 1-4 heteroatoms selected from N, O, and S; R2 is H or A; R3 and R4 are independently selected from H, halo, cyano, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, and -[C(R6)2]n-cycloalkyl; R5 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; including pharmaceutically acceptable derivs., solvates, salts, tautomers, and stereoisomers thereof. The invention also relates the preparation of I, pharmaceutical compns. comprising at least one compound I, optionally in combination with other active agents, along with carriers and/or adjuvants, if necessary, as well as to the use of the compns. for the treatment of tumors, tumor growth, tumor metastasis, and/or AIDS. Palladium-catalyzed carbonylation of tert-Bu 3-iodopyrrolo[3,2-c]pyridine-1-carboxylate with trimethylsilylacetylene and carbon monoxide resulted in the formation of ketone II, which underwent heterocyclization with phenylguanidium carbonate to give pyrimidine III. The compds. of the invention have antiproliferative activity, e.g., compound III expressed IC50 values between 10 nM and 1 µM for inhibition of cell proliferation of intestinal, ovarian, prostate, and breast cancer cell lines.</p>			

IT 1050373-17-5P, 2-((4-Pyridinyl)amino)-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)pyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of (pyrrolopyridinyl)pyrimidinylamines as cell proliferation inhibitors useful as antitumor agents)
 RN 1050373-17-5 CAPLUS
 CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:979351 CAPLUS

DN 149:268069

TI Pyridine derivatives as PI3K inhibitors and their preparation,
pharmaceutical compositions and use in the treatment of diseasesIN Pecchi, Sabina; Ni, Zhi-Jie; Burger, Matthew; Wagman, Allan; Atallah,
Gordana; Bartulis, Sarah; Ng, Simon; Pfister, Keith B.; Smith, Aaron;
Zhang, Yanchen; Merritt, Hanne; Voliva, Charles

PA Novartis Vaccines and Diagnostics, Inc., USA

SO PCT Int. Appl., 99pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008098058	A1	20080814	WO 2008-US53190	20080206
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			


FRAI US 2007-888465P

P 20070206


OS MARPAT 149:268069

AB The invention relates to compds. of formula I and their pharmaceutically acceptable salts and prodrugs thereof, which are phosphatidylinositol 3 kinase (PI3K) inhibitors; to compns. of the compds., either alone or in combination with at least one addnl. therapeutic agent, with a pharmaceutically acceptable carrier; to uses of the compds., either alone or in combination with at least one addnl. therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases. Compds. of formula I wherein X is N, Y is (un)substituted CH; or Y is N, X is (un)substituted CH; Z is N and (un)substituted CH; R1 is H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted alkoxy, (un)substituted (hetero)aryl, etc.; R2 and R4 are independently H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted alkoxy, (un)substituted (hetero)aryl, (un)substituted (un)substituted heterocyclyl, (un)substituted cycloalkyl, etc.; R3 is H, (un)substituted alkyl, (un)substituted -CO-alkyl, (un)substituted 3- to 7-membered cycloalkyl and (un)substituted 4- to 7-membered heterocyclyl; and their stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by Suzuki coupling of 2-chloro-4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yloxy)pyrimidine with 5-[4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl)]-4-(trifluoromethyl)-2-pyridylamine. All the invention compds. were evaluated for their PI3K inhibitory activity.


IT 1045860-82-9P, 6-(Morpholin-4-yl)-2-[[3-(trifluoromethyl)pyridin-4-yl]amino]-4,5'-bipyrimidine-2'-amine 1045860-84-1P, 6-(Morpholin-4-yl)-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]-4,5'-bipyrimidine-2'-amine 1045860-94-3P, 2'-(Methylamino)-6-(morpholin-4-yl)-2-[[3-(trifluoromethyl)pyridin-4-yl]amino]-4,5'-bipyrimidine 1045860-96-5P, 2'-(Methylamino)-6-(morpholin-4-yl)-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]-4,5'-bipyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyridine derivs. as PI3K inhibitors useful in the treatment of diseases)
 RN 1045860-82-9 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, 6-(4-morpholinyl)-N2-[3-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)



RN 1045860-84-1 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, 6-(4-morpholinyl)-N2-[8-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)




RN 1045860-94-3 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, N2'-methyl-6-(4-morpholinyl)-N2-[3-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)



RN 1045860-96-5 CAPLUS

CN [4,5'-Bipyrimidine]-2,2'-diamine, N2'-methyl-6-(4-morpholinyl)-N2-[8-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:806540 CAPLUS
 DN 149:128862
 TI Preparation of pyridinyl-substituted pyrimidine derivatives as inhibitors of cyclin-dependently kinase (CDK)
 IN Beckwith, Rohan Eric John; Curtis, Daniel Tim; Harrington, Edmund; Hinrichs, Jurgen Hans-Hermann; Tallarico, John Anthony
 PA Novartis AG, Switz.
 SO PCT Int. Appl., 113pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008079933	A2	20080703	WO 2007-US88292	20071220
WO 2008079933	A3	20081204		
W: AE, AG, AL, AM, AI, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI US 2006-871471P	P	20061222		

OS MARPAT 149:128862
 AB Title comds. I [m = 0-1; n = 0-1; A1, A2, A3 and A4 independently = C, CH or N; R1-9 independently = H, halo, (un)substituted amino, alkyl, alkoxy, aryl or cycloalkyl], and their pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates are prepared as inhibitors of cyclin-dependently kinase (CDK). Thus, e.g., II was prepared by Suzuki reaction of 2,4-dichloropyrimidine with (3-methoxy-4-pyridinyl)boronic acid followed by condensation reaction with 2-chloro-4-(3-methoxypyridin-4-yl)pyrimidine. Select comds. of I were tested for their inhibitory activity in CDKs kinase assays, e.g., II showed IC50 value of < 5 μ M for CDK1. As inhibitor of CDK, I should prove useful for the treatment, prevention and/or amelioration of protein kinases CDKs-associated diseases such as cancer, inflammation, cardiac hypertrophy, and HIV.

IT 1035944-57-0P, [4-(2-Methoxypyridin-3-yl)pyrimidin-2-yl](pyridin-4-yl)amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridinyl-substituted pyrimidine derivs. as inhibitors of cyclin-dependently kinase (CDK))
 RN 1035944-57-0 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-methoxy-3-pyridinyl)-N-4-pyridinyl- (CA INDEX NAME)



L17 ANSWER 7 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:796822 CAPLUS

DN 149:128848

TI Preparation of 5-cyano-4-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidines as polo-like kinase (PLK) inhibitors.

IN Mortimore, Michael; Young, Stephen Clinton; Everitt, Simon Robert Lorrie; Knegtel, Ronald; Pinder, Joanne Louise; Rutherford, Alistair Peter;

Durrant, Steven; Brechley, Guy; Charrier, Jean Damien; O'Donnell, Michael

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 191pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079346	A1	20080703	WO 2007-US26190	20071221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-876307P	P	20061221		
	US 2007-922291P	P	20070406		
	US 2007-947707P	P	20070703		
	US 2007-989014P	P	20071119		
OS	MARPAT 149:128848				
AB	Title compds. [I; R1 = H, halo, (substituted) alipharyl, aliphatyloxy; R2 = NR4R5, OR6, SR6, etc.; R4 = H, (substituted) alipharyl; R5 = (substituted) alipharyl, mono- or bicycyl; R4R5 = atoms to form (substituted) mono- or bicycyl; R6 = H, (substituted) alkyl, aryl(alkyl), heteroaryl(alkyl), were prepared Thus, 2-methylsulfonyl-4-(1-tosyl-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile (preparation given) was microwaved with PhCH2NH2 and diisopropylamine in THF at 100° for 10 min. to give a residue which was stirred with LiOH in THF/H2O for 1 h to give 36% 2-benzylamino-4-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile. I inhibited PLK1 with Ki in the range of <3 nM to >40 nM.				
IT	1036024-59-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyanopyrrolopyridinylpyrimidines as polo-like kinase inhibitors)				
RN	1036024-59-5 CAPLUS				
CN	5-Pyrimidinocarbonitrile, 2-[(1-methyl-4-piperidinyl)amino]-4-[5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (CA INDEX NAME)				




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 8 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:668211 CAPLUS
 DN 149:215067
 TI IRAK-4 inhibitors. Part II: A structure-based assessment of
 imidazo[1,2-a]pyridine binding
 AU Buckley, George M.; Ceska, Thomas A.; Fraser, Joanne L.; Gowers, Lewis;
 Groom, Colin R.; Higuero, Alicia Perez; Jenkins, Kerry; Mack, Stephen
 R.; Morgan, Trevor; Parry, David M.; Pitt, William R.; Rausch, Oliver;
 Richard, Marianna D.; Sabin, Verity
 CS UCB, Cambridge, CB21 6GS, UK
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(11), 3291-3295
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB A potent IRAK-4 inhibitor was identified through routine project cross
 screening. The binding mode was inferred using a combination of in silico
 docking into an IRAK-4 homol. model, surrogate crystal structure anal. and
 chemical analog SAR.
 IT 882732-18-5P 1042224-61-2P
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (IRAK-4 inhibitors: structure-based assessment of
 imidazo[1,2-a]pyridine binding)
 RN 882732-18-5 CAPLUS
 CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl- (CA INDEX
 NAME)



RN 1042224-61-2 CAPLUS
 CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-methyl-N-4-piperidinyl-
 (CA INDEX NAME)



IT 882562-92-7
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (IRAK-4 inhibitors: structure-based assessment of
 imidazo[1,2-a]pyridine binding)
 RN 882562-92-7 CAPLUS
 CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-
 pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)




IT 882563-97-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(IRAK-4 inhibitors: structure-based assessment of imidazo[1,2-a]pyridine binding)

RN 882563-97-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 9 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:398762 CAPLUS
 DN 148:552748
 TI Pyrimidine-based inhibitors of CaMKII δ
 AU Mavunkel, Babu; Xu, Yong-jin; Goyal, Bindu; Lim, Don; Lu, Qing; Chen, Zheng; Wang, Dan-Xiong; Higaki, Jeffrey; Chakraborty, Indrani; Liclican, Albert; Sideris, Steve; Laney, Maureen; Delling, Ulrike; Catalano, Rosanne; Higgins, Linda S.; Wang, Hui; Wang, Jing; Feng, Ying; Dugar, Sundee; Levy, Daniel E.
 CS Scios, Inc., Fremont, CA, 94555, USA
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(7), 2404-2408
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 148:552748
 AB Non-ATP competitive pyrimidine-based inhibitors of CaMKII δ were identified. Computational studies were enlisted to predict the probable mode of binding. The results of the computational studies led to the design of ATP competitive inhibitors with optimized hinge interactions. Inhibitors of this class possessed improved enzyme and cellular activity compared to early leads.
 IT 1026028-75-0P 1026028-77-2P 1026028-78-3P
 1026028-79-4P 1026028-81-8P 1026028-82-9P
 1026028-84-1P 1026028-85-2P 1026028-88-5P
 1026028-90-9P 1026028-91-0P 1026028-92-1P
 1026028-94-3P 1026028-95-4P
 RL: PAC (Pharmacological study); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyrimidine-based inhibitors of CaMKII δ)
 RN 1026028-75-0 CAPLUS
 CN 2,4-Pyridinediamine, N4-[4-(3-fluorophenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1026028-77-2 CAPLUS
 CN 2,4-Pyridinediamine, N4-(4-[1,1'-biphenyl]-3-yl-2-pyrimidinyl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-78-3 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-(3-methylphenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1026028-79-4 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-(4-chlorophenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 1026028-85-2 CAPLUS

CN Benzenecarboxylic acid, 4-[2-[[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-88-5 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-[4-(dimethylamino)phenyl]-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-90-9 CAPLUS

CN Benzamide, N-methyl-4-[2-[[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-91-0 CAPLUS

CN 2,4-Pyridinediamine, N2-[(1S)-1-phenylethyl]-N4-[4-[4-(2H-tetrazol-5-yl)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1026028-92-1 CAPLUS

CN Benzamide, N-hydroxy-4-[2-[[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1026028-94-3 CAPLUS
 CN Benzoic acid, 4-[2-[(2-amino-4-pyridinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1026028-95-4 CAPLUS
 CN Benzoic acid, 4-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)




IT 1026029-53-7P 1026029-57-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (pyrimidine-based inhibitors of CaMKIIδ)
 RN 1026029-53-7 CAPLUS
 CN Benzoic acid, 4-[2-[(2-amino-4-pyridinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 1026029-57-1 CAPLUS


CN Benzoic acid, 4-[2-(4-pyridinylamino)-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:319382 CAPLUS
 DN 148:331703
 TI Preparation of aminopyrimidinylbenzotriazoles as kinase modulators
 IN Goldstein, David Michael; Gong, Leyi; Michoud, Christophe; Palmer, Wylie
 Solang; Sidduri, Achyutharao
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 91pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008028860	A1	20080313	WO 2007-EP59040	20070830
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080103142 A1 20080501 US 2007-899758 20070907 PRAI US 2006-843090P P 20060908 OS MARPAT 148:331703 AB Title compds. [I; R = alkyl, hydroxyalkyl, (substituted) triazolylalkyl, tetrazolylalkyl, dioxopyrrolidinylalkyl, etc.; R1 = H, halo, alkyl, amino; R2 = H, alkyl; R3 = halo, NO2, alkyl, cyano, amino, OH, alkoxy, etc.; n = 0-2], were prepared Thus, title compound (II) showed JNK kinase inhibitory activity with p(JNK1) = 0.0194. IT 1011529-79-5P 1011530-00-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of aminopyrimidinylbenzotriazoles as kinase modulators) RN 1011529-79-5 CAPLUS CN 2-Pyrimidinamine, 4-[(1H-benzotriazol-1-yl)-N-4-piperidinyl]- (CA INDEX NAME)				



RN 1011530-00-9 CAPLUS
 CN 1-Piperidineacetamide, 4-[[4-(1H-benzotriazol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




IT 1011530-73-6P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prophetic intermediate; preparation of aminopyrimidinylbenzotriazoles as kinase modulators)

RN 1011530-73-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzotriazol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:163603 CAPLUS
 DN 148:230184
 TI Compositions and methods for treating, reducing, ameliorating, or
 alleviating posterior-segment ophthalmic diseases
 IN Ward, Keith W.; Hu, Zhenze; Phillips, Gary; Kerppola, Raili
 PA USA
 SO U.S. Pat. Appl. Publ., 53pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080031884	A1	20080207	US 2007-832294	20070801
	WO 2008021729	A2	20080221	WO 2007-US74943	20070801
	WO 2008021729	A3	20081009		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRAI US 2006-836078P P 20060807

OS MARPAT 148:230184


AB A composition for treating, reducing, ameliorating, or alleviating a
 back-of-the-eye condition or disorder that has an etiol. in inflammation
 comprises a dissociated glucocorticoid receptor agonist ("DIGRA"). The
 comps. also can include other anti-inflammatory agents, anti-angiogenic
 agents, or combinations thereof. The composition can be formulated for topical
 application, injection, or implantation. The composition can be administered
 alone or in combination with another procedure chosen to enhance the
 outcome of the treatment.

IT 496795-25-6, 4-(2-Phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-
 2-amine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. for treating, reducing, ameliorating, or alleviating
 posterior-segment ophthalmic diseases)

RN 496795-25-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX
 NAME)




L17 ANSWER 12 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:9637 CAPLUS
 DN 148:121721
 TI Preparation of imidazolyl-pyrimidine derivatives as GSK3 inhibitors
 IN Burrows, Jeremy; Huerta, Fernando; Rein, Tobias; Rotticci, Didier; Staaf, Karin; Turek, Dominika
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008002245	A2	20080103	WO 2007-SE621	20070626
	WO 2008002245	A3	20080214		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080188503 A1 20080807 US 2007-769113 20070627 PRAI US 2006-816755P P 20060627				
OS	MARPAT 148:121721				


AB Title compds. I [ring A = (un)substituted heterocyclyl or carbocyclyl; R2 = halo, NO2, CF3, OCF3 or CN; R3 = Me, (un)substituted alkyl, alkenyl, alkynyl, 6-membered non-aromatic carbocyclyl or heterocyclyl; R4 = H, CN, (un)substituted alkyl or haloalkyl], and their pharmaceutically acceptable salts, are prepared and disclosed as glycogen synthase kinase 3 (GSK3) inhibitors. Thus, e.g., a multi-step synthesis was given to prepare II starting from 5-methyl-4-aminoisoxazole and tetrahydro-2H-pyran-4-one. All the exemplar compds. were evaluated for their GSK3 inhibitory activity in GSK3 β inhibition assays with typical Ki values ranging from 0.001 to 10,000 nM. For instance, II exhibited a Ki value of 49 nM. I should prove useful in treatment and prevention of GSK3 associated diseases including Alzheimer's disease.

IT 1000773-98-7P, [5-Fluoro-4-[2-methyl-3-(tetrahydropyran-4-yl)-3H-imidazol-4-yl]pyrimidin-2-yl] (pyridin-4-yl)amine 1000774-00-4P, (tert-Butyl 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate
 RL: RAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of imidazolyl-pyrimidine derivs. as GSK3 inhibitors in treatment and prevention of GSK3 associated diseases including Alzheimer's disease)

RN 1000773-98-7 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-4-pyridinyl- (CA INDEX NAME)



RN 1000774-00-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 1000774-02-6P, N-(1-Acetylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-04-8P, N-(1-Benzylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-05-9P, N-(1-Benzoylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-06-0P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylacetyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-07-1P, Benzyl 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate
 1000774-08-2P, 5-Fluoro-N-[1-(methylsulfonyl)piperidin-4-yl]-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-09-3P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(trifluoroacetyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-10-6P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylsulfonyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-11-7P, N-[1-(Benzylsulfonyl)piperidin-4-yl]-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-17-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of imidazolyl-pyrimidine derivs. as GSK3 inhibitors in treatment and prevention of GSK3 associated diseases including Alzheimer's disease)

RN 1000774-02-6 CAPLUS
 CN Ethanone, 1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1000774-04-8 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidiny]- (CA INDEX NAME)




RN 1000774-05-9 CAPLUS

CN Methanone, [4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]phenyl- (CA INDEX NAME)




RN 1000774-06-0 CAPLUS

CN Ethanone, 1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]-2-phenyl- (CA INDEX NAME)




RN 1000774-07-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester
(CA INDEX NAME)




RN 1000774-08-2 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-(methylsulfonyl)-4-piperidinyl]-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 1000774-09-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1000774-10-6 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1000774-11-7 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-[(phenylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 1000774-17-3 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-4-pyridinyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

L17 ANSWER 13 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1396177 CAPLUS
 DN 148:55085
 TI 2-Heterocyclylamino-4-imidazolylpyrimidines as agents for the inhibition
 of cell proliferation and their preparation
 IN Jones, Clifford; Pass, Martin; Rudge, David
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 131pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007138268	A1	20071206	WO 2007-GB1906	20070524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-803283P	P	20060526		
	US 2006-868540P	P	20061204		
OS	MARPAT 148:55085				
AB	Compds. of formula I: which possess cell cycle inhibitory activity are described. Compds. of formula I wherein ring A is 5- to 7-membered saturated heterocycle; R1 is H, C1-6 alkyl, C1-6 alkanoyl, carbamoyl, etc.; R2 is halo, NO2, CN, OH, amino, carboxyl, carbamoyl, etc.; m is 0 - 4; R3 is halo, CN and amino; n is 0 - 2; R4 is Et, n-Pr, i-Pr, Bu, i-Bu, s-Bu, t-Bu, cyclopropyl, etc.; R5 is Me, Et, i-Pr, CF3, CHF2, etc.; and their pharmaceutically acceptable salts, and in vivo hydrolyzable esters thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their inhibitory activity of cell proliferation (some data given).				
IT	959790-81-9P 959790-82-0P 959790-83-1P 959791-15-2P 959791-49-2P 959791-50-5P 959791-51-6P 959791-52-7P 959791-53-8P 959791-54-9P 959791-60-7P 959791-98-1P 959791-99-2P 959792-08-6P 959792-09-7P 959792-11-1P 959792-13-3P 959792-26-8P 959792-28-0P 959792-34-8P 959792-75-7P 959792-76-8P 959792-79-1P 959792-80-4P 959792-99-5P 959793-00-1P 959793-04-5P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate and intermediate; preparation of (heterocyclylamino)imidazolylpyrimidines as cell proliferation inhibitors)				
RN	959790-81-9 CAPLUS				
CN	1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-				

5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959790-82-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 959790-83-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-15-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-(ethenylsulfonyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-49-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-50-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[4-[[4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-51-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[4-[[4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959791-52-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-4-[[4-[[4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959791-53-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959791-54-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-60-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-98-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-99-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 959792-08-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(3-methyl-3-nitrobutyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-09-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-amino-3-methylbutyl)sulfonyl]-4-piperidinyl]-5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-11-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-amino-3-methylbutyl)sulfonyl]-4-piperidinyl]-5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-13-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-amino-3-methylbutyl)sulfonyl]-4-piperidiny]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-26-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959792-28-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidiny- (CA INDEX NAME)




RN 959792-34-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidiny]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-75-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 959792-76-8 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(4-piperidylsulfonyl)-4-piperidyl]- (CA INDEX NAME)



RN 959792-79-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-80-4 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1*a*,5*a*,6*a*)- (CA INDEX NAME)

Relative stereochemistry.




RN 959792-99-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959793-00-1 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-4-piperidinyl- (CA INDEX NAME)



RN 959793-04-5 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidinyl]-4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro- (CA INDEX NAME)



IT 959790-84-2P 959790-85-3P 959790-86-4P
 959790-87-5P 959790-88-6P 959790-89-7P
 959790-90-0P 959790-91-1P 959790-92-2P
 959790-93-3P 959790-94-4P 959790-95-5P
 959790-96-6P 959790-97-7P 959790-98-8P
 959790-99-9P 959791-00-5P 959791-01-6P
 959791-02-7P 959791-03-8P 959791-04-9P
 959791-05-0P 959791-06-1P 959791-07-2P
 959791-08-3P 959791-09-4P 959791-10-7P
 959791-11-8P 959791-12-9P 959791-13-0P
 959791-14-1P 959791-16-3P 959791-17-4P
 959791-18-5P 959791-19-6P 959791-20-9P
 959791-21-0P 959791-23-2P 959791-24-3P
 959791-25-4P 959791-26-5P 959791-27-6P
 959791-28-7P 959791-29-8P 959791-30-1P
 959791-31-2P 959791-32-3P 959791-33-4P
 959791-34-5P 959791-35-6P 959791-36-7P
 959791-37-8P 959791-38-9P 959791-39-0P
 959791-40-3P 959791-41-4P 959791-42-5P
 959791-43-6P 959791-44-7P 959791-45-8P
 959791-46-9P 959791-47-0P 959791-48-1P
 959791-55-0P 959791-56-1P 959791-57-2P
 959791-58-3P 959791-59-4P 959791-61-8P
 959791-62-9P 959791-63-0P 959791-64-1P


959791-65-2P 959791-66-3P 959791-67-4P
 959792-00-8P 959792-01-9P 959792-02-0P
 959792-04-2P 959792-06-4P 959792-15-5P
 959792-17-7P 959792-19-9P 959792-21-3P
 959792-22-4P 959792-24-6P 959792-25-7P
 959792-27-9P 959792-29-1P 959792-30-4P
 959792-31-5P 959792-32-6P 959792-33-7P
 959792-35-9P 959792-36-0P 959792-37-1P
 959792-38-2P 959792-39-3P 959792-40-6P
 959792-41-7P 959792-42-8P 959792-43-9P
 959792-44-0P 959792-45-1P 959792-46-2P
 959792-47-3P 959792-48-4P 959792-49-5P
 959792-50-8P 959792-51-9P 959792-52-0P
 959792-53-1P 959792-54-2P 959792-55-3P
 959792-56-4P 959792-57-5P 959792-58-6P
 959792-59-7P 959792-60-0P 959792-61-1P
 959792-62-2P 959792-63-3P 959792-64-4P
 959792-65-5P 959792-66-6P 959792-67-7P
 959792-68-8P 959792-69-9P 959792-70-2P
 959792-71-3P 959792-72-4P 959792-73-5P
 959792-74-6P 959792-77-9P 959792-78-0P
 959792-81-5P 959792-82-6P 959792-83-7P
 959792-85-9P 959792-87-1P 959792-89-3P
 959792-91-7P 959792-93-9P 959792-95-1P
 959792-97-3P 959793-01-2P 959793-02-3P
 959793-03-4P 959793-05-6P 959793-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of (heterocyclamino)imidazolylypyrimidines as
 cell proliferation inhibitors)


RN 959790-84-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-
 (phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959790-85-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-
 (1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-86-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-methyl-1-piperazinyl)propylsulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-87-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-morpholinyl)propylsulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-88-6 CAPLUS

CN 1-Piperazineethanol, 4-[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]- (CA INDEX NAME)




RN 959790-89-7 CAPLUS

CN 1-Butanol, 2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-90-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-[(2-methoxy-1-methylethyl)amino]propyl)sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959790-91-1 CAPLUS

CN 2-Propanol, 1-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-92-2 CAPLUS

CN 1-Propanol, 2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-93-3 CAPLUS

CN 1-Butanol, 3-methyl-2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-94-4 CAPLUS

CN 1-Propanol, 2-methyl-2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-95-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-[(2-methoxyethyl)amino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959790-96-6 CAPLUS

CN 1-Propanol, 3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 959790-97-7 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959790-98-8 CAPLUS

CN 1-Piperidinesulfonamide, N,N-dimethyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959790-99-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959791-00-5 CAPLUS

CN 1-Piperidinecarboxamide, N,N-dimethyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959791-01-6 CAPLUS

CN 1-Piperidinecarboxamide, N-methyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959791-02-7 CAPLUS

CN Methanone, (hexahydro-4-methyl-1H-1,4-diazepin-1-yl) [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 959791-03-8 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 959791-04-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959791-05-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 959791-06-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 959791-07-2 CAPLUS


CN Methanone, [(3S)-3-(dimethylamino)-1-pyrrolidinyl][4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-08-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 959791-09-4 CAPLUS
 CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-10-7 CAPLUS
 CN 1-Butanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 959791-11-8 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 959791-12-9 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(1-methylethyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-13-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(2-phenylethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959791-14-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-16-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-17-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-18-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[(2-methoxyethyl)amino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-19-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-thiomorpholinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-20-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-21-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[methyl(1-methylethyl)amino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-23-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(1-azetidiny)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-24-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-morpholinyl)ethyl]sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 959791-25-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-methyl-1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-26-5 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-(hexahydro-1H-azepin-1-yl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959791-27-6 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-(diethylamino)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-

[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-28-7 CAPLUS

CN 2-Piperazinone, 4-[2-[[4-[[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)



RN 959791-29-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[2-(tetrahydro-1,4-oxazepin-4(5H)-yl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-30-1 CAPLUS


CN 2-Pyrimidinamine, N-[1-[2-[(3R)-3-fluoro-1-pyrrolidinyl]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-31-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(4-fluoro-1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-32-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-33-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(cyclopropylmethylamino)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-34-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[(cyclopropylmethyl)methylamino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-35-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 959791-36-7 CAPLUS

CN Ethanone, 1-[4-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 959791-37-8 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 959791-38-9 CAPLUS

CN Ethanone, 1-[[hexahydro-4-[[2-[[[4-[[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]ethyl]-1H-1,4-diazepin-1-yl]-1- (CA INDEX NAME)




RN 959791-39-0 CAPLUS

CN 2-Pyrimidinamine, 4-[[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[[1-[[2-(4-propyl-1-piperidiny]ethyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)



RN 959791-40-3 CAPLUS


CN 2-Pyrimidinamine, 4-[[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[[1-[[2-(tetrahydro-1,4-thiazepin-4(5H)-yl)ethyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)



RN 959791-41-4 CAPLUS


CN 2-Pyrimidinamine, N-[[1-[[2-(2-azabicyclo[2.2.2]oct-2-yl)ethyl)sulfonyl]-4-

piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959791-42-5 CAPLUS


CN 4-Piperidinecarbonitrile, 1-[2-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)



RN 959791-43-6 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-[(3S)-3-fluoro-1-pyrrolidinyl]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-44-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 959791-45-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 959791-46-9 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 959791-47-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-(2-methoxyethyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 959791-55-0 CAPLUS

CN Ethanone, 2-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-56-1 CAPLUS

CN 1-Propanone, 3-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-57-2 CAPLUS

CN 1-Butanone, 4-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 959791-58-3 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-3-piperidinyl)- (CA INDEX NAME)



RN 959791-59-4 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl][(2S)-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-61-8 CAPLUS

CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-piperidinyl)- (CA INDEX NAME)




RN 959791-62-9 CAPLUS

CN 1-Propanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-(1-piperazinyl)- (CA INDEX NAME)




RN 959791-63-0 CAPLUS

CN 1-Propanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-(4-piperidinyl)- (CA INDEX NAME)



RN 959791-64-1 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](4-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 959791-65-2 CAPLUS

CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3S)-3-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959791-66-3 CAPLUS


CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3R)-3-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-67-4 CAPLUS

CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-morpholinyl- (CA INDEX NAME)




RN 959792-00-8 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959792-01-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-morpholinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-02-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-[[2-(4-methyl-1-piperidiny)ethyl]sulfonyl]-4-piperidiny]- (CA
INDEX NAME)




RN 959792-04-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[2-(dimethylamino)ethyl]sulfonyl]-4-
piperidiny]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX
NAME)




RN 959792-06-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-[[2-(1-pyrrolidiny)ethyl]sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 959792-15-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[3-(dimethylamino)-3-methylbutyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-17-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(dimethylamino)-3-methylbutyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-19-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[3-(dimethylamino)propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-21-3 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-22-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-piperidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-24-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-methyl-1-piperazinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-25-7 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-morpholinyl)propylsulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 959792-27-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959792-29-1 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidiny]- (CA INDEX NAME)




RN 959792-30-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(dimethylamino)ethylsulfonyl]-4-piperidiny]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-31-5 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-32-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-33-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(2-azabicyclo[2.2.2]oct-2-yl)ethyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-35-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(dimethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-36-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-37-1 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-piperidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-38-2 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-[[3-(4-methyl-1-piperazinyl)propylsulfonyl]-4-piperidinyl]- (CA
INDEX NAME)

RN 959792-39-3 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-[[3-(4-morpholinyl)propylsulfonyl]-4-piperidinyl]- (CA INDEX NAME)

RN 959792-40-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(2-azabicyclo[2.2.2]oct-2-yl)propylsulfonyl]-4-
piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)


RN 959792-41-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(7-azabicyclo[2.2.1]hept-7-yl)propylsulfonyl]-4-
piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-42-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopropylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-43-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopentylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-44-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclobutylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-45-1 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[3-[(1-methylethyl)amino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-46-2 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-[(2-methylpropyl)amino]propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-47-3 CAPLUS

CN Propanenitrile, 3-[[[3-[[4-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]methylamino]- (CA INDEX NAME)




RN 959792-48-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(1-azetidiny)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-49-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(ethylmethyamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-50-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(diethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-51-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-[(cyclopropylmethyl)amino]propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-(CA INDEX NAME)




RN 959792-52-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[3-[(2-methoxyethyl)methylamino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-(CA INDEX NAME)




RN 959792-53-1 CAPLUS

CN Propanenitrile, 3-[ethyl[3-[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]-(CA INDEX NAME)




RN 959792-54-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopentylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-(CA INDEX NAME)




RN 959792-55-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopropylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-(CA INDEX NAME)




RN 959792-56-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclobutylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-(CA INDEX NAME)




RN 959792-57-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-
[(cyclopropylmethyl)methylamino]propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-
[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-58-6 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-
imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA
INDEX NAME)




RN 959792-59-7 CAPLUS

CN 1-Piperidinesulfonamide, N-[2-(diethylamino)ethyl]-4-[[5-fluoro-4-[2-
methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA
INDEX NAME)




RN 959/92-60-0 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 959/92-61-1 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 959/92-62-2 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 959792-63-3 CAPLUS

CN 1-Piperidinesulfonamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 959792-64-4 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 959792-65-5 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-[(3S)-3-fluoro-1-pyrrolidinyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959792-66-6 CAPLUS

CN 1-Piperidinesulfonamide, N-[3-(dimethylamino)propyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 959792-67-7 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 959792-68-8 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 959792-69-9 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[1-(1-methylethyl)-4-piperidiny]-
(CA INDEX NAME)

RN 959792-70-2 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 959792-71-3 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-72-4 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(4-methyl-1-piperazinyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-73-5 CAPLUS

CN 1-Piperidinesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959792-74-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]methyl]-, phenylmethyl ester (CA INDEX NAME)




RN 959792-77-9 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(1-methyl-4-piperidynyl)sulfonyl]-4-piperidynyl]- (CA INDEX NAME)



RN 959792-78-0 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[1-(1-methylethyl)-4-piperidynyl)sulfonyl]-4-piperidynyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959792-81-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-(methylsulfonyl)-, (1α,5α,6α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-82-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[2-(1-pyrrolidiny)ethyl]sulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-83-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[2-(dimethylamino)ethyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-85-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-87-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[3-(1-pyrrolidinyl)propylsulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-89-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[3-(1-piperidinyl)propylsulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-91-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(cyclopentylmethylamino)propylsulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-93-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1*a*,5*a*,6*a*)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-95-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(dimethylamino)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1*a*,5*a*,6*a*)- (CA INDEX NAME)


Relative stereochemistry.




RN 959792-97-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(7-azabicyclo[2.2.1]hept-7-yl)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1*a*,5*a*,6*a*)- (CA INDEX NAME)


Relative stereochemistry.



RN 959793-01-2 CAPLUS


CN 2-Pyrimidinamine, 4-((1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-
[1-(methylsulfonyl)-4-piperidinyl]propyl)- (CA INDEX NAME)

RN 959793-02-3 CAPLUS

CN 2-Pyrimidinamine, 4-((1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-
[1-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-4-piperidinyl]propyl)- (CA INDEX NAME)


RN 959793-03-4 CAPLUS

CN 2-Pyrimidinamine, 4-((1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-N-([2-(
dimethylamino)ethyl]sulfonyl)-4-piperidinyl]-5-fluoro- (CA INDEX NAME)




RN 959793-05-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1-(2-(dimethylamino)ethyl)-4-piperidinyl)-5-fluoro-1-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-N-[[3-(dimethylamino)propyl]sulfonyl]- (CA INDEX NAME)



RN 959793-06-7 CAPLUS

CN 2-Pyrimidinamine, 4-(1-(2-(dimethylamino)propyl)-4-piperidinyl)-5-fluoro-1-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-N-[[3-(dimethylamino)propyl]sulfonyl]- (CA INDEX NAME)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1303167 CAPLUS

DN 147:541894

TI 4-Pyrimidine-5-aminopyrazole compounds as JNK modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Chen, Peng; Hong, Yufeng; Humphries, Paul Stuart; Johnson, Theodore Otto, Jr.; Lafontaine, Jennifer Anne; Liu, Song; Lunney, Elizabeth Ann

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 196pp.

CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007/129195	A2	2007/1115	WO 2007-IB1158	2007/0427
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2006-746464P P 20060504

OS MARPAT 147:541894

AB The invention relates to compds. with the formula I, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compns. comprising the compds. of formula I and methods of treating a condition that is mediated by the modulation of JNK, the method comprising administering to a mammal an effective amount of a compound of formula I. Compds. of formula I wherein Z is C and N; R1 is H and halo; R2 is H, CF3, CHF2, CH2F, CF3O, C1-6 alkoxy, etc.; R3 is H, C1-6 alkyl, CF3, CHF2, CH2F, CF3O, etc.; R3 is C1-6 alkyl, (un)substituted C0-5alkyl-C3-10 cycloalkyl, (un)substituted C0-6 alkyl-C6-10 aryl, etc.; R7 is H and C16 alkyl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their JNK modulatory activity. From the assay, it was determined that compound II exhibited Ki values of 7 nM and

40

nM against JNK-1 and JNK-2, resp.

IT 956715-04-1P 956715-10-9P 956715-14-3P

956715-26-7P 956715-36-9P 956715-52-9P

956715-53-0P 956715-86-9P 956715-87-0P

956715-98-3P 956716-43-1P 956716-47-5P

956716-48-6P 956716-49-7P 956716-50-0P

956716-51-1P 956716-53-3P 956716-54-4P

956716-56-6P 956716-58-8P 956716-60-2P

956716-62-4P 956716-73-7P 956716-75-9P

956716-77-1P 956716-79-3P 956719-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(drug candidate; preparation of (aminopyrazolyl)pyrimidinamines as JNK modulators useful in the treatment of diseases)

RN 956715-04-1 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]-3-(methylsulfonyl)-, (1 α ,5 α ,6 α)- (CA INDEX NAME)

Relative stereochemistry.




RN 956715-10-9 CAPLUS

CN Benzonitrile, 3-[[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]- (CA INDEX NAME)




RN 956715-14-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridinylsulfonyl)-4-piperidiny]- (CA INDEX NAME)




RN 956715-26-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 956715-36-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridazinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956715-52-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(2-pyridinylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956715-53-0 CAPLUS

CN Ethanone, 1-[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 956715-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)methyl]-4-piperidiny]- (CA INDEX NAME)




RN 956715-87-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(2-methoxyethyl)-4-piperidiny]- (CA INDEX NAME)




RN 956715-98-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(1-methylethyl)-4-piperidiny]- (CA INDEX NAME)




RN 956716-43-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, 2-methylpropyl ester (CA INDEX NAME)




RN 956716-47-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 956716-48-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-49-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-50-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(phenylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-51-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-53-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(2-methylpropyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-54-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-56-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-58-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956716-60-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-62-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-73-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(5-thiazolylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-75-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridinylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-77-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 956716-79-3 CAPLUS

CN 1-Butanone, 1-[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)



RN 956719-12-3 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-5-(methlamino)-1H-pyrazol-4-yl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



IT 956722-16-0P 956722-17-1P 956722-18-2P


956722-19-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (aminopyrazolyl)pyrimidinamines as JNK modulators useful in the treatment of diseases)


RN 956722-16-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-4-piperidinyl-
(CA INDEX NAME)




RN 956722-17-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 956722-18-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 956722-19-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L17 ANSWER 15 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1274821 CAPLUS
 DN 147:491698
 TI Combination therapy for diseases involving angiogenesis comprising agents
 inhibiting VEGF activity, agents blocking VEGF receptor, and agents
 reducing VEGF expression
 IN Ward, Keith W.; Tyle, Praveen
 PA USA
 SO U.S. Pat. Appl. Publ., 14pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070258976	A1	20071108	US 2007-733282	20070410
WO 2007130842	A2	20071115	WO 2007-US67497	20070426
WO 2007130842	A3	20080529		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI US 2006-797608P	P	20060504		

AB A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compds. that interact with and inhibit a downstream activity of extracellular VEGF, compds. that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compds. that reduce a level of expression of VEGF. More particularly, the present invention relates to such compns. and methods that target two or more modes of action of VEGF in ocular diseases involving angiogenesis. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition. Thus, a composition of the present invention comprised (in wt%): Macugen 0.2, trehalose 2, sodium acetate 0.24, 4-(2-phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-2-amine (a tyrosine kinase inhibitor) 0.3, normal saline 97.26.

IT 496795-25-6, 4-(2-Phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-2-amine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy for diseases involving angiogenesis comprising agents inhibiting VEGF activity, agents blocking VEGF receptor, and agents reducing VEGF expression)

RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)



L17 ANSWER 16 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1237247 CAPLUS

DN 147:502360

TI Imidazoloxazole and imidazolothiazole compounds as RAF inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Lapierre, Jean-Marc; Namdev, Nivedita D.; Ashwell, Mark A.; France, Dennis S.; Wu, Hui; Hutchins, Patrick M.; Tandon, Manish; Liu, Yanbin; Link, Jeff S.; Ali, Syed M.; Brassard, Chris J.; Nicewonger, Robb B.; Filikov, Anton; Carazza, Rebecca J.

PA Argule Inc., USA

SO PCT Int. Appl., 195pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007123892	A2	20071101	WO 2007-US9348	20070416
	WO 2007123892	A3	20080131		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20070281955 A1 20071206 US 2007-785163 20070416 PRAI US 2006-792314P P 20060417 OS MARPAT 147:502360				

AB The invention provides imidazoloxazole and imidazolothiazole compds. of formula I and their synthesis. Compds. of formula I are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compds. are useful for the treatment of cell proliferative disorders such as cancer. Compds. of formula I wherein X is O, SOO-2; E and F are independently (CH2)1-3; Z is H, bond, CO, CONH and derivs., SO2, CONHSO2, etc.; R1 is (CH2)0-3-CONH2 and derivs., NHCONH2 and derivs., NHCSNH2 and derivs., etc.; R2 is H, (CH2)0-3-CONH2 and derivs., NHCONH2 and derivs., NHCSNH2 and derivs., etc.; R3 and R4 are independently H, (un)substituted lower alkyl, etc.; R12 is (un)substituted lower alkyl, (un)substituted (hetero)aryl, and (un)substituted heterocyclyl; R13 is H, C1-8 (fluoro)alkyl, C3-8 (fluoro), cycloalkyl, (halo)aryl and (halo)heteroaryl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All of the invention compds. were evaluated for their RAF inhibitory activity (some data given).

IT 815595-25-6P 815595-26-7P 815595-33-6P
 815595-34-7P 815595-49-4P 815595-53-0P
 815595-56-3P 815595-57-4P 815595-61-0P
 815595-62-1P 815595-63-2P 815595-64-3P
 815595-65-4P 815595-66-5P 815596-92-0P
 815596-93-1P 815596-94-2P 815596-95-3P


815596-96-4P 815597-01-4P 885046-43-5P
 885046-44-6P 885046-48-0P 885046-49-1P
 885046-54-8P 885046-56-0P 885046-58-2P
 885046-60-6P 885046-61-7P 885046-62-8P
 885046-63-9P 885046-64-0P 885046-65-1P
 885046-66-2P 885046-67-3P 885046-68-4P
 885046-69-5P 885046-70-8P 885046-71-9P
 885046-72-0P 885046-73-1P 885046-74-2P
 885046-75-3P 885046-76-4P 885046-77-5P
 885046-79-7P 885046-80-0P 885046-81-1P
 885046-82-2P 885046-83-3P 885046-84-4P
 885046-85-5P 885046-86-6P 885046-87-7P
 885046-88-8P 885046-89-9P 885046-90-2P
 885046-91-3P 885046-92-4P 885046-93-5P
 885046-94-6P 885047-07-4P 885047-08-5P
 885047-09-6P 885047-10-9P 885047-11-0P
 885047-24-5P 885047-25-6P 885047-26-7P
 885047-27-8P 885047-28-9P 885047-29-0P
 885047-30-3P 885047-34-7P 885047-35-8P
 885047-36-9P 885047-37-0P 885047-38-1P
 885047-39-2P 885047-40-5P 885047-41-6P
 885047-42-7P 885047-43-8P 885047-44-9P
 885047-45-0P 885047-46-1P 885047-47-2P
 885047-48-3P 885047-49-4P 885047-50-7P
 885047-51-8P 885047-52-9P 885047-53-0P
 885047-54-1P 885047-55-2P 885047-56-3P
 885047-57-4P 885047-59-6P 885047-60-9P
 885047-61-0P 885047-62-1P 885047-63-2P
 885047-64-3P 885047-65-4P 885047-66-5P
 885047-83-6P 885047-84-7P 885047-85-8P
 885047-95-0P 885048-01-1P 885048-02-2P
 885048-06-6P 885048-12-4P 885048-13-5P
 885048-15-7P 885048-32-8P 885048-34-0P
 885048-35-1P 885048-36-2P 885048-38-4P
 885048-41-9P 885048-43-1P 885048-44-2P
 885048-49-7P 885048-52-2P 885048-58-8P
 885048-64-6P 885048-69-1P 885048-71-5P
 885048-76-0P 885048-78-2P 885048-80-6P
 956025-01-7P 956026-67-8P 956026-68-9P
 956026-69-0P 956026-70-3P 956026-71-4P
 956026-72-5P 956026-73-6P 956026-74-7P
 956026-75-8P 956026-76-9P 956026-85-0P
 956026-88-3P 956026-89-4P 956026-90-7P
 956026-91-8P 956026-92-9P 956026-94-1P
 956026-95-2P 956026-96-3P 956026-97-4P
 956026-99-6P 956027-05-7P 956027-09-1P
 956027-10-4P 956027-11-5P 956027-12-6P
 956027-13-7P 956027-15-9P 956027-21-7P
 956027-22-8P 956027-23-9P 956027-24-0P
 956027-25-1P 956027-26-2P 956027-31-9P
 956027-54-6P 956027-60-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of imidazoloxazole and imidazolothiazole
 compds. as RAF kinase inhibitors useful in treatment of diseases)


RN 815595-25-6 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-26-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-33-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-34-7 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-49-4 CAPLUS
 CN Ethanone, 1-[4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-53-0 CAPLUS
 CN Ethanone, 1-[4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-56-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-57-4 CAPLUS
 CN Ethanone, 1-[4-[[4-(6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 815595-61-0 CAPLUS
 CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 815595-62-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-63-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 815595-64-3 CAPLUS

CN Ethanone, 1-[4-[[4-(6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-66-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815596-92-0 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-93-1 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-94-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815596-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815597-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidiny]- (CA INDEX NAME)




RN 885046-43-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(4-fluorophenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885046-44-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidiny]- (CA INDEX NAME)




RN 885046-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-49-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-54-8 CAPLUS

CN Methanone, [4-[[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-56-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]phenyl- (CA INDEX NAME)




RN 885046-58-2 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-60-6 CAPLUS


CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-8-quinolinyl- (CA INDEX NAME)




RN 885046-64-0 CAPLUS
 CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)



RN 885046-65-1 CAPLUS
 CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-furanyl- (CA INDEX NAME)




RN 885046-66-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-68-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 885046-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885046-70-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 885046-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 885046-72-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-73-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-74-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-(dimethylamino)phenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-75-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885046-76-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 885046-77-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-79-7 CAPLUS

CN Ethanone, 2-(4-fluorophenyl)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 885046-80-0 CAPLUS

CN 1-Butanone, 1-[4-[[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 885046-81-1 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-82-2 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885046-83-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-(cyclohexylmethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-84-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-(2-(4-fluorophenyl)ethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-85-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[5-methyl-2-(trifluoromethyl)-3-furanyl]- (CA INDEX NAME)




RN 885046-86-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-87-7 CAPLUS

CN 1-Propanone, 1-[4-[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-88-8 CAPLUS

CN 1-Propanone, 1-[4-[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-phenyl- (CA INDEX NAME)




RN 885046-89-9 CAPLUS

CN Ethanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 885046-90-2 CAPLUS

CN 1-Propanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methyl- (CA INDEX NAME)




RN 885046-91-3 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-(2S)-2-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.


yl]-2-pyrimidinyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885047-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidiny]- (CA INDEX NAME)




RN 885047-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(4-methylphenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885047-09-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-10-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-(1-methylethyl)phenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-25-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-(trifluoromethoxy)phenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-26-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-27-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-dichlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-28-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-29-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-bis(trifluoromethyl)phenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-30-3 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-34-7 CAPLUS
 CN Methanone, (4-amino-3,5,6-trichloro-2-pyridinyl) [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-35-8 CAPLUS
 CN Methanone, (2,6-dimethoxyphenyl) [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-36-9 CAPLUS
 CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 885047-37-0 CAPLUS
 CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 885047-38-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-39-2 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885047-40-5 CAPLUS
 CN Ethanone, 1-[4-[[4-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]-2-[(4-methyl-2-pyrimidinyl)thio]- (CA INDEX NAME)



RN 885047-41-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-(6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-42-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885047-43-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 885047-44-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-45-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-46-1 CAPLUS

CN Methanone, [4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl][4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-47-2 CAPLUS

CN Methanone, [4-(dimethylamino)phenyl][4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-48-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-49-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-50-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-51-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-52-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-53-0 CAPLUS

CN Acetamide, N-[5-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 885047-54-1 CAPLUS

CN Benzoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-55-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidiny]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885047-57-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 885047-59-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-60-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-furanylmethyl)-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-61-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-62-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,6-difluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-63-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-64-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-phenoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-66-5 CAPLUS

CN Benzonitrile, 4-[[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-83-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-84-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-85-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-95-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-naphthalenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-01-1 CAPLUS

CN Ethanone, 2-[4-(dimethylamino)phenyl]-1-[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885048-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-06-6 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-12-4 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885048-13-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-15-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1,1'-biphenyl)-4-ylimidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-32-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885048-34-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-35-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-36-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-(6-[1,1'-biphenyl]-4-ylimidazo[2,1-b]thiazol-5-yl)-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 885048-38-4 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-41-9 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-43-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidiny]-4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-44-2 CAPLUS

CN Benzoic acid, 4-[[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]- (CA INDEX NAME)




RN 885048-49-7 CAPLUS

CN Acetamide, N-[4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidiny]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)




RN 885048-52-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885048-58-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-64-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-69-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-71-5 CAPLUS

CN Phenol, 4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-76-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-78-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-80-6 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956025-01-7 CAPLUS


CN Phenol, 5-[5-[2-[[1-[(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]-2-fluoro- (CA INDEX NAME)



RN 956026-67-8 CAPLUS
 CN 2-Pyrimidinamine, N-(1-ethyl-4-piperidiny)-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956026-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-(1,1-dimethylethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-69-0 CAPLUS
 CN Butanoic acid, 4-amino-4-[[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]carbonyl]amino]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 956026-70-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-71-4 CAPLUS

CN Benzonitrile, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-72-5 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-73-6 CAPLUS

CN Benzonitrile, 3-[5-[2-(4-piperidinylamino)-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-74-7 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 956026-75-8 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-76-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(2-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956026-85-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956026-88-3 CAPLUS


CN Phenol, 3-[5-[2-[[1-(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-89-4 CAPLUS
 CN 1-Piperidineethanol, α -[4-(4-chlorophenoxy)methyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 956026-90-7 CAPLUS
 CN Benzonitrile, 4-[[4-[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinylsulfonyl]- (CA INDEX NAME)




RN 956026-91-8 CAPLUS
 CN 1-Piperidineethanol, α -[4-(4-cyanophenylsulfonyl)-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-92-9 CAPLUS

CN Benzamide, 4-[[4-[[[4-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-94-1 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956026-95-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956026-96-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-97-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-99-6 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956027-05-7 CAPLUS
 CN Phenol, 3-[5-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956027-09-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-10-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 956027-11-5 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(cyclopropylsulfonyl)-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 956027-12-6 CAPLUS
 CN Phenol, 3-[5-[2-[[1-(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956027-13-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956027-15-9 CAPLUS
 CN Phenol, 3-[5-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)



RN 956027-21-7 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(cyclopropylsulfonyl)-4-piperidinyl]-4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956027-22-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 956027-23-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 956027-24-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 956027-25-1 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclopentyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-26-2 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-31-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-54-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, propyl ester (CA INDEX NAME)



RN 956027-60-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



L17 ANSWER 17 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1092913 CAPLUS

DN 147:406847

TI Pyrimidine, quinazoline, pteridine and triazine derivatives as SST receptor modulators and their preparation

IN Binggeli, Alfred; Christ, Andreas; Maerki, Hans-Peter; Martin, Rainer Eugen

PA Switz.

SO U.S. Pat. Appl. Publ., 91pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070225271	A1	20070927	US 2007-724688	20070315
AU 2007229555	A1	20071004	AU 2007-229555	20070319
WO 2007110340	A2	20071004	WO 2007-EP52571	20070319
WO 2007110340	A3	20071115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2001867	A2	20081217	EP 2007-727049	20070319
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2008DN08153	A	20081121	IN 2008-DN8153	20080929
KR 2008104074	A	20081128	KR 2008-726236	20081027
FRAI EP 2006-111751	A	20060327		
WO 2007-EP52571	W	20070319		

OS CASREACT 147:406847; MARPAT 147:406847

AB This invention is concerned with compds. of formula I, and pharmaceutically acceptable salts thereof. Compds. of formula I wherein A is O and NH; R1 is H, C1-7 alkoxy, and halo; R2 is C2-7 alkyl, C2-7 alkenyl, C1-7 (halo)alkyl, etc.; R3 is H, C1-7 alkyl, OH, C1-7 alkoxy, C2-7 alkenyloxy, halo, etc.; R4 is H, OH, C1-7 alkoxy, amino, nitro, etc.; R5 is H, halo, C1-7 alkoxy, and C1-7 alkoxy-C1-7 alkoxy; G is (un)substituted pyrimidine, (un)substituted quinazoline, (un)substituted pteridine, (un)substituted triazine, etc.; and their pharmaceutically acceptable salts thereof, are claimed. The invention further relates to pharmaceutical compns. containing such compds., to a process for their preparation

and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their SST-5 modulatory activity (some data given).

IT 951000-57-0P 951000-72-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrimidine, quinazoline, pteridine and
triazine derivs. as SST receptor modulators)


RN 951000-57-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-ethoxy-4-methoxyphenyl)methyl]-4-piperidinyl]-4-
(2-thienyl)- (CA INDEX NAME)



RN 951000-72-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chloro-3-ethoxyphenyl)methyl]-4-piperidinyl]-4-
(2-thienyl)- (CA INDEX NAME)



L17 ANSWER 18 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1060802 CAPLUS

DN 147:385972

TI Pyrazole compounds as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of abnormal cell growth

IN Bennett, Michael John; Cho-Schultz, Sujin; Deal, Judith Gail; King, Stephen Joseph; Marrone, Tami Jo; Palmer, Cynthia Louise; Romines, William Henry, III; Rui, Eugene Yuanjin; Sutton, Scott Channing; Zhender, Luke Raymond

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 110pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007105058	A2	20070920	WO 2007-IB561	20070305
	WO 2007105058	A3	20071221		
	W:	AE, AG, AL, AM, AN, AO, AP, AR, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-782786P	P	20060316		
	US 2007-886561P	P	20070125		
OS	MARPAT 147:385972				

AB The invention is directed to compds. of formula I, and to salts and solvates thereof, their synthesis, and their use as Raf inhibitors. Compds. of formula I wherein R1 is H, OH, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, CN, NH2 and derivs., etc.; each R2 is independently H, halo, C1-6 alkyl, C2-6 alkenyl, C2-8 alkynyl; C2-8 alkoxy, and CN; R3 is H and NH(CH2)0-4R7; R4 is C1-6 alkylthio, C1-6 alkoxy, H, OH, C1-6 alkyl, C2-8 alkynyl, C2-8 alkenyl, CN, NH2 and derivs., etc.; R7 is H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, NH2 and derivs., etc.; m is 0, 1, 2 and 3; n is 0, 1, 2, 3 and 4; X is N and CH; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by addition of 4-picoline to Me 4-chloro-3-methylbenzoate; the resulting 1-(3-chloro-5-methoxyphenyl)-2-(pyridin-4-yl)ethanone underwent condensation with DMF di-Me acetal to give the corresponding dicarbonyl derivative, which underwent cyclization with hydrazine to give 4-[3-(3-chloro-5-methoxyphenyl)-1H-pyrazol-4-yl]pyridine, which underwent demethylation to give compound II. All the invention compds. were evaluated for their Raf kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values of 0.448 μ M against pMEK and 0.42 μ M against pERK. Compound II also exhibited a Ki value of 0.0147 μ M and 91 % inhibition at 1 μ M concentration of b-Raf.

IT 950524-86-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(drug candidate; preparation of pyrazoles as Raf inhibitors useful in the treatment of abnormal cell growth)

RN 950524-86-4 CAPLUS

CN Phenol, 3-chloro-5-[1-ethyl-4-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



L17 ANSWER 19 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:998153 CAPLUS
 DN 147:344090
 TI Preparation of multi-cyclic compounds useful in treatment of oncol.
 diseases related to kinase activity
 IN Cee, Victor J.; Deak, Holly L.; Geuns-Meyer, Stephanie D.; Hodous, Brian
 L.; Nguyen, Hanh Nho; Olivieri, Philip R.; Patel, Vinod F.; Romero, Karina
 PA Amgen Inc., USA
 SO PCT Int. Appl., 104pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007100646	A1	20070907	WO 2007-US4700	20070222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20070213325 A1 20070913 US 2007-709994 20070221 AU 2007221294 A1 20070907 AU 2007-221294 20070222 EP 1994030 A1 20081126 EP 2007-751460 20070222 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS PRAI US 2006-776507P P 20060224 US 2007-709994 A 20070221 WO 2007-US4700 W 20070222				

OS CASREACT 147:344090; MARPAT 147:344090

AB The title compds. I [A = (un)substituted benzimidazolyl, imidazolyl, triazolyl; B = phenylene, pyridylene, etc.; C1 = N or CR10; C2 = N or CH; D = (un)substituted pyrimidinyl, indazolyl, etc.; L1, L2 = NR3, O, S, C(O), S(O), SO2 or CR3R3; R3, R4 = H, halo, haloalkyl, etc.] which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases, were prepared Thus, reacting 4-[2-(4-aminophenoxy)pyridin-3-yl]pyrimidin-2-amine with 2-chloro-5-phenyl-1,3,4-thiadiazole afforded II. The compds. I are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, resp., to treat cancer and cancer-related diseases. For example, I was found to have IC50 of less than or equal to 5 μ M in the Aurora kinase A HTRF assay. The invention also includes pharmaceutical compns. comprising compds. I, and methods of treating disease states related to the activity of various protein kinases.

IT 948563-40-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of novel multicyclic compds. useful in treatment of oncol. diseases related to kinase activity)

RN 948563-40-4 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 20 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:874444 CAPLUS

DN 147:257789

TI 4-Aryl-2-aminopyrimidines or 4-aryl-2-aminoalkylpyrimidines as JAK-2 modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Mann, Grace; Aay, Naing; Arcalas, Arlyn; Brown, S. David; Chan, Wai Ki Vicky; Chen, Jeff; Du, Hongwang; Epshteyn, Sergey; Forsyth, Timothy; Galan, Adam A.; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Johnson, Henry William Beecroft; Kane, Brian; Kearney, Patrick; Kim, Byung Gyu; Koltun, Elena; Leahy, James William; Lee, Matthew Sangyup; Lewis, Gary L.; Meyr, Lisa E.; Noguchi, Robin Tammie; Pack, Michael; Ridgway, Brian Hugh; Shi, Xian; Woolfrey, John; Zhou, Peiwen

PA Exelixis, Inc., USA

SO PCT Int. Appl., 586 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089768	A2	20070809	WO 2007-US2515	20070130
WO 2007089768	A3	20070920		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007209928	A1	20070809	AU 2007-209928	20070130
CA 2640398	A1	20070809	CA 2007-2640398	20070130
EP 1979329	A2	20081015	EP 2007-717132	20070130
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRAI US 2006-763426P	P	20060130		
US 2006-785239P	P	20060323		
US 2006-840420P	P	20060825		
WO 2007-US2515	W	20070130		

OS MARPAT 147:257789


AB This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having formula I, pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof, and methods of use thereof. Compds. of formula I wherein D and E are independently H, halo, CF₃, heterocycloalkyl and alkyl; DE taken together to form 5- to 7-membered heteroaryl and 5- to 7-membered heterocycloalkyl; L is a bond, O and NH; Z is alkoxy, cycloalkyl, (un)substituted heteroaryl, aryl, (un)substituted heterocycloalkyl; Z-R25 taken together to form 5- to 6-membered (hetero)cycloalkyl, and 5- to 6-membered heteroaryl; n is 0, 1, 2, 3, and 4; R1 is H; R2 is (un)substituted (hetero)aryl, (un)substituted alkylaryl; R25 is alkyl, alkenyl, halo, haloalkyl, amino, etc.; and their

pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cross-coupling of 2,4-dichloropyrimidine with 4-(acetylamino)phenylboronic acid; the resulting N-[4-(2-chloropyrimidin-4-yl)phenyl]acetamide underwent amination with N-Boc-1,3-diaminobenzene to give compound II. All the invention compds. were evaluated for their JAK-2 inhibitory activity.


- IT 945754-01-8P 945754-03-0P 945755-25-9P
 945755-26-0P 945756-08-1P 945756-10-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aryl(amino)pyrimidines and aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment of diseases)
 RN 945754-01-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




- RN 945754-03-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




- RN 945755-25-9 CAPLUS
 CN Acetamide, N-[4-[2-(4-piperidinylamino)-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945755-26-0 CAPLUS
 CN Acetamide, N-[4-[2-[[1-(2,6-dichlorobenzoyl)-4-piperidinyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945756-08-1 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 945756-10-5 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



IT 945756-14-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aryl(amino)pyrimidines and aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment of diseases)
 RN 945756-14-9 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(5-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




IT 945756-45-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of aryl(amino)pyrimidines and aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment of diseases)

RN 945756-45-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thienyl)-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L17 ANSWER 21 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:640266 CAPLUS
 DN 147:52920
 TI Preparation of pyrimidine compounds as p38 MAP kinase inhibitors
 IN Kubo, Akira; Nakane, Akira; Nakajima, Tatsuo; Murakami, Takaaki; Miyoshi, Hidetaka; Ogasawara, Akito
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 60pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2007145819	A	20070614	JP 2006-290675	20061026
PRAI	JP 2005-313670	A	20051028		
OS	MARPAT 147:52920				


AB Title compds. I [R1 = H, halo, nitro, etc.; p = 1, 2; Z = -O-, -N(R2)-; R2 = H, alkyl, alkanoyl, ring A = O, etc.; R3 = (CH2)n-RA; RA = H, (un)substituted alkyl, (un)substituted alkoxyalkyl, etc.; n = 0-4; Q1 = H, halo, cyano, etc.; ring B = cycloalkane, saturated hetero-monocycle containing nitrogen atom; X = CH, N; Y = single bond, SO2, CO; ring C = aromatic hydrocarbon ring, (un)substituted heterocycle] and their pharmaceutically acceptable salts were prepared For example, reaction of compound II [R = NH2] with 2-chloroethylisocyanate afforded compound II [R = 2-oxo-1-imidazolidinyl]. In TNF α production-inhibition assays, compound II [R = 1,1-dioxo-2-isothiazolidinyl] showed 100% inhibitory activity.

IT 869220-92-8P 869221-34-1P 869221-35-2P
 869221-36-3P 869221-37-4P 869221-38-5P
 869221-39-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidine compds. as p38 MAP kinase inhibitors)
 RN 869220-92-8 CAPLUS
 CN 2H-imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 869221-34-1 CAPLUS
 CN 2H-imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-4-piperidinyl]amino]-4-


pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 869221-35-2 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 869221-36-3 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 869221-37-4 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-38-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-naphthalenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-39-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 775575-82-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrimidine compds. as p38 MAP kinase inhibitors)
 RN 775575-82-1 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



L17 ANSWER 22 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:602630 CAPLUS
 DN 147:211828
 TI Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors
 AU Alam, Mahbub; Beevers, Rebekah E.; Ceska, Tom; Davenport, Richard J.; Dickson, Karen M.; Fortunato, Mara; Gowers, Lewis; Haughan, Alan F.; James, Lynwen A.; Jones, Mark W.; Kinsella, Natasha; Lowe, Christopher; Meissner, Johannes W. G.; Nicolas, Anne-Lise; Perry, Benjamin G.; Phillips, David J.; Pitt, William R.; Platt, Adam; Ratcliffe, Andrew J.; Sharpe, Andrew; Tait, Laura J.
 CS UCB, Granta Park, Great Abington, Cambridge, CB21 6GS, UK
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(12), 3463-3467
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 147:211828
 AB The development of a series of aminopyrimidines, e.g., **1**, as inhibitors of c-Jun N-terminal kinases is described. The synthesis, in vitro inhibitory values for JNK1, JNK2 and CDK2, and the in vitro inhibitory value for a c-Jun cellular assay were discussed.
 IT 882563-01-1
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)
 RN 882563-01-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




IT 882563-40-8P 882565-39-1P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)
 RN 882563-40-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-39-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



IT 882562-75-6P 882562-82-5P 882562-91-6P

882562-98-3P 882563-10-2P 882563-12-4P

882563-14-6P 882564-23-0P 882564-31-0P

882564-35-4P 882564-39-8P 882565-41-5P

882566-85-0P 945016-58-0P 945016-59-1P


945016-60-4P 945016-61-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)


RN 882562-75-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 882562-82-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-91-6 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-10-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882563-12-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882563-14-6 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882564-23-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperazinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-31-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882564-35-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882564-39-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)- (CA INDEX NAME)




RN 882565-41-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-85-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 945016-58-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperidinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 945016-59-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 945016-60-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 945016-61-5 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




IT 882562-77-8P 882563-09-9P 882563-38-4P
 1004524-90-6P 1004526-40-2P 1004527-41-6P
 1004529-44-5P 1004529-53-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines
 with indole derivs. or (bromo)imidazopyridine followed by substitution
 with aminopiperidines, and their antiinflammatory activity as JNK
 inhibitor and SAR)
 RN 882562-77-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-
 pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-09-9 CAPLUS
 CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX
 NAME)




RN 882563-38-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1004524-90-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1004526-40-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-5-methyl-N-4-piperidinyl- (CA INDEX NAME)




RN 1004527-41-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 1004529-44-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1004529-53-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-1-yl)-N-4-piperidinyl- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 23 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:510085 CAPLUS

DN 146:501070

TI Pyrimidinyl-thiophenes as kinase modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases mediated by kinase activity

IN Arnold, William D.; Chen, Chixu; Gradl, Stefan N.; Hopkins, Stephanie A.; Steensma, Ruo W.; Tomimoto, Masaki; Wilson, Mark E.

PA SGX Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 144pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007053776	A1	20070510	WO 2006-US43047	20061102
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	CA 2628474	A1	20070510	CA 2006-2628474	20061102
	US 20070117800	A1	20070524	US 2006-556033	20061102
	EP 1948647	A1	20080730	EP 2006-836919	20061102
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRAI	US 2005-733585P	P	20051103		
	WO 2006-US43047	W	20061102		
OS	MARPAT 146:501070				


AB The invention provides pyrimidinyl-thiophene kinase modulators v of formula I which can be used to treat diseases mediated by kinase activity. Comps. of formula I wherein A is (un)substituted (hetero)aryl; R1 is H, F, Br, OH and derivs., (CH₂)_nNH₂ and derivs., CN, NO₂, CF₃, (un)substituted alkyl, etc.; R₂, R₃ and R₄ are independently H, halo, OH and derivs., NH₂ and derivs., CN, NO₂, CF₃, (un)substituted alkyl, etc.; n is 0 to 5; are claimed. Example compound II was prepared by amidation of 5-(2-methylsulfonylpyrimidin-4-yl)thiophene-2-sulfonyl chloride with dimethylamine; the resulting 5-(2-methylsulfonylpyrimidin-4-yl)thiophene-2-sulfonic acid dimethylamide underwent oxidation to 5-(2-methylsulfonylpyrimidin-4-yl)thiophene-2-sulfonic acid dimethylamide, which underwent nucleophilic aromatic substitution with 1-(3-aminophenyl)ethanol. All the invention compds. were evaluated for their kinase inhibitory activity (data given).

IT 936134-72-4P 936137-13-2P 936137-14-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrimidinylthiophenes as kinase modulators

useful in treatment of diseases - mediated by kinase activity)


RN 936134-72-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-piperidinylsulfonyl)-2-thienyl]-N-4-pyridinyl-
(CA INDEX NAME)



RN 936137-13-2 CAPLUS


CN 2-Thiophenecarboxamide, N-(2-cyanoethyl)-N-ethyl-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 936137-14-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[(1R)-1-phenylethyl]-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 24 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:259691 CAPLUS

DN 146:316944

TI Novel imidazo based heterocycles as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of inflammatory and proliferative diseases

IN Brienlinger, Eric C.; Calderwood, David J.; Frank, Kristine E.; Betschmann, Patrick; Hirst, Gavin C.; Morytko, Michael J.; Dixon, Richard W.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007028051	A2	20070308	WO 2006-US34275	20060901
	WO 2007028051	A3	20071101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	CA 2620223	A1	20070308	CA 2006-2620223	20060901
	US 20070099925	A1	20070503	US 2006-514626	20060901
	EP 1928237	A2	20080611	EP 2006-824879	20060901
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, MK, RS			
	MX 200802979	A	20080512	MX 2008-2979	20080229
	CN 101291582	A	20081022	CN 2006-80038658	20080417
PRAI	US 2005-714016P	P	20050902		
	US 2006-837560P	P	20060814		
	WO 2006-US34275	W	20060901		

OS MARPAT 146:316944

AB The invention is directed to imidazopyrazine and imidazopyrimidine compds. of formula I, wherein the variables are as defined herein. The compds. of formula I are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and

diseases and proliferative disorders and conditions, for example, cancers. Compds. of formula I wherein Z is (un)substituted (hetero)aryl; X and Y are independently N, CR4 and N-oxide, provided that X and Y cannot both be CR4 or both cannot be N-oxide; A is N, CR4 and N-oxide; R1, R4 and R10 are independently H, OH, F, Cl, Br, I, CF3, CN, NO2, NH2, (un)substituted aryloxy, etc.; Q is NH and derivs., O, S or a bond; L is a bond, C1-6 alkyl, CO, CO2, CONH, SO, or SO2; R3 is H, CONH2 and derivs., NHCHO and derivs., NHCO2H and derivs., CO2H and derivs., (un)substituted aryl, etc.; and their pharmaceutically acceptable salts, metabolites, isomers and

prodrugs thereof, are claimed. Example compound II was prepared by amination of 2-(4-fluorophenyl)-3-[2-(methanesulfonyl)pyrimidin-4-yl]imidazo[1,2-a]pyrazine with tert-Bu 4-aminopiperidine-1-carboxylate. All the invention compds. were evaluated for their kinase inhibitory activity.

IT 928315-08-6P 928316-07-8P 928316-23-8P


928316-51-2P 928318-77-8P 928318-80-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of imidazopyrimidine and imidazopyrazine derivs. as kinase inhibitors useful in the treatment of inflammatory and proliferative diseases)


RN 928315-08-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-07-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-23-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-51-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928318-77-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-80-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)



IT 928315-41-7P 928315-56-4P 928315-65-5P
 928315-68-8P 928316-09-0P 928316-12-5P
 928316-21-6P 928316-24-9P 928316-25-0P
 928316-35-2P 928316-40-9P 928316-44-3P
 928316-47-6P 928316-54-5P 928317-09-3P
 928318-78-9P 928318-81-4P 928318-86-9P
 928318-88-1P 928318-89-2P 928318-97-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of imidazopyrimidine and imidazopyrazine
 derivs. as kinase inhibitors useful in the treatment of inflammatory
 and proliferative diseases)
 RN 928315-41-7 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[2-(4-fluorophenyl)imidazo[1,2-
 a]pyrazin-3-yl]-2-pyrimidinyl]-8-methyl- (CA INDEX NAME)




RN 928315-56-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1-
 methyl-4-piperidinyl)- (CA INDEX NAME)




RN 928315-65-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 928315-68-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 928316-09-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)




RN 928316-12-5 CAPLUS

CN Ethanone, 1-[4-[[4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 928316-21-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidiny]-4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 928316-24-9 CAPLUS


CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidiny]-4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 928316-25-0 CAPLUS


CN Ethanone, 1-[4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-

pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 928316-35-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-[2-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 928316-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3-methylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-44-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-47-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-54-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]-8-methyl- (CA INDEX NAME)




RN 928317-09-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928318-78-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-81-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928318-88-1 CAPLUS

CN Ethanone, 1-[4-[[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-hydroxy- (CA INDEX NAME)




RN 928318-89-2 CAPLUS

CN Ethanone, 2-hydroxy-1-[4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 928318-97-2 CAPLUS

CN Ethanone, 1-[4-[[4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 25 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:61837 CAPLUS

DN 146:156236

TI Cellular cholesterol absorption modifiers, and their therapeutic use

IN Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.

PA Kalypsys, Inc., USA

SO PCT Int. Appl., 300pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008541	A2	20070118	WO 2006-US26242	20060705
	WO 2007008541	A3	20070726		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2005-697659P	P	20050708		
	US 2005-697686P	P	20050708		
	US 2005-697814P	P	20050708		
	US 2005-727646P	P	20051017		
	US 2006-782303P	P	20060313		
OS	MARPAT 146:156236				
AB	The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.				
IT	920527-98-6 920528-07-0 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cholesterol absorption modifiers and therapeutic use)				
RN	920527-98-6 CAPLUS				
CN	1-Piperidinecarboxylic acid, 4-[[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)				



RN 920528-07-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-difluorophenyl)-6-methyl-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 26 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1226019 CAPLUS
 DN 146:7975
 TI Preparation of pyrrolopyridines as protein kinase inhibitors
 IN Okram, Barun; Ren, Pingda; Gray, Nathanael S.
 PA IRM LLC, Bermuda; The Scripps Research Institute
 SO PCT Int. Appl., 51pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006124863	A2	20061123	WO 2006-US18868	20060515
WO 2006124863	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006247322 A1 20061123 AU 2006-247322 20060515 CA 2608333 A1 20061123 CA 2006-2608333 20060515 EP 1896470 A2 20080312 EP 2006-759904 20060515 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008540664 T 20081120 JP 2008-512430 20060515 MX 200714327 A 20080211 MX 2007-14327 20071115 KR 2008016643 A 20080221 KR 2007-729309 20071214 IN 2007DN09783 A 20080118 IN 2007-DN9783 20071217 CN 101218241 A 20080709 CN 2006-80025008 20080108 US 20080300267 A1 20081204 US 2008-914210 20080402 PRAI US 2005-681853P P 20050516 WO 2006-US18868 W 20060515				
OS MARPAT 146:7975				

AB The title compds. I-III [n = 0-2; R1 = halo, (halo)alkyl, (halo)alkoxy; R2 = (un)substituted arylalkyl or heteroaryl; X = CR7 or N (wherein R7 = H, alkyl)], useful in treating or preventing diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 and KDR kinases, were prepared E.g., a multi-step synthesis of IV, starting from 7-azaindole, was given. Compds. I-III showed IC50's in the range of 10 nM to 2 µM when tested in FGFR3 enzymic assay. Pharmaceutical compns. comprising compds. I-III are disclosed.

IT 915414-31-2P 915414-32-3P 915414-33-4P
 915414-35-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridines as novel protein kinase inhibitors useful

in treatment and prevention of diseases associated with abnormal or deregulated protein kinase activity)


RN 915414-31-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)




RN 915414-32-3 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)




RN 915414-33-4 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)



RN 915414-35-6 CAPLUS

CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)



L17 ANSWER 27 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:796732 CAPLUS

DN 145:211069

TI Preparation of phenyl-substituted pyrimidines as kinase inhibitors for treating an inflammatory disorder and/or cancer

IN Wrobelski, Stephen T.; Lin, Shuqun; Leftheris, Katerina; He, Liqi; Seitz, Steven, P.; Lin, Tai-An; Vaccaro, Wayne

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 216pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084017	A2	20060810	WO 2006-US3659	20060202
	WO 2006084017	A3	20061214		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20060178388	A1	20060810	US 2006-344881	20060201
	EP 1848714	A2	20071031	EP 2006-734200	20060202
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2008530012	T	20080807	JP 2007-554206	20060202
PRAI	US 2005-650077P	P	20050204		
	US 2006-344881	A	20060201		
	WO 2006-US3659	W	20060202		

OS MARPAT 145:211069

AB The title compds. I [two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is CR1; R1 = H, CN; n = 0-3; R2 = alkyl, cycloalkyl, alkenyl, etc.; G = (un)substituted monocyclic 5-6 membered heteroaryl; Z = H, alkyl, cycloalkyl, etc.; with provisos], useful for inhibiting p38 kinase, LIM kinase 1, and/or LIM kinase 2 (no specific data given), were prepared E.g., a multi-step synthesis of II, starting from n-propylthiourea, was given. Also disclosed are pharmaceutical compns. containing compds. I, and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.


IT 905296-27-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM kinases inhibitors for treating an inflammatory disorder and cancer)

RN 905296-27-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(2-chlorophenyl)-6-[2-(propylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 905296-26-6P 905296-37-9P 905296-51-7P
905296-76-6P 905299-23-2P 905299-60-7P
905299-61-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM kinases
inhibitors for treating an inflammatory disorder and cancer)


RN 905296-26-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-N-4-piperidinyl-6-[2-(propylamino)-5-
thiazolyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 905296-25-5

CMF C21 H25 Cl N6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 905296-37-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-fluorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 905296-51-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 905296-76-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 905299-23-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-fluorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-4-piperidiny- (CA INDEX NAME)




RN 905299-60-7 CAPLUS

CN Urea, N-ethyl-N'-[2-[6-[2-[(1-methylethyl)amino]-5-thiazolyl]-2-[[1-(1-methylethyl)-4-piperidiny]amino]-4-pyrimidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 905299-61-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[2-
 [[[(ethylamino) carbonyl] amino] methyl] phenyl]-6-[2-[(1-methylethyl) amino]-5-
 thiazolyl]-2-pyrimidinyl] amino]-, ethyl ester (CA INDEX NAME)



L17 ANSWER 28 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:655649 CAPLUS
 DN 145:124591
 TI Preparation of pyrimidine derivatives as protein kinase inhibitors
 IN Sun, Piaoyang; Lv, Aifeng; Yang, Baohai; Hu, Chunyong
 PA Peop. Rep. China
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA Chinese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006069525	A1	20060706	WO 2005-CN2308	20051226
	W: AE, AG, AL, AM, AT, AU, <u>AE</u> , BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CN 1939910	A	20070404	CN 2005-10107402	20050930
	CA 2602738	A1	20060706	CA 2005-2602738	20051226
	CN 1972917	A	20070530	CN 2005-80020883	20051226
	EP 1840122	A1	20071003	EP 2005-822296	20051226
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008526692	T	20080724	JP 2007-548675	20051226
	US 20080312251	A1	20081218	US 2008-794250	20080219
PRAI	CN 2004-10103077	A	20041231		
	CN 2005-10107402	A	20050930		
	WO 2005-CN2308	W	20051226		
OS	MARPAT 145:124591				
AB	The title pyrimidine derivs. I [wherein R1 = (un)substituted (hetero)aryl or heterocycle; R2 and R3 = independently H, halo, NH2, CN, etc.; R4 = H, halo, NH2, alkyl, etc.; R5 = H, halo, NO2, CN, alkoxy, etc.; R6 = H, (un)substituted (cyclo)alkyl, (hetero)aryl, heterocycle, etc.; Q and Z = independently (hetero)aryl or heterocycle; L = (un)substituted -NHC(=O)-, -CONH-, -NHSO2-, -NHC(=O)-, etc.; m and n = independently 0-3] or pharmaceutically acceptable salts thereof were prepared as protein kinase inhibitors. For example, II*CH3SO3H was prepared in a multi-step synthesis. II*CH3SO3H showed inhibitory activity with IC50 of 0.008 μM against K562 human cell. The title compds. are useful for treatment of proliferative disease (no data). Formulation of II*CH3SO3H as tablet was described.				
IT	895519-94-5P 895519-95-6P 895519-96-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of pyrimidine derivs. as protein kinase inhibitors)				
RN	895519-94-5 CAPLUS				

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[5-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-2-pyridinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 895519-95-6 CAPLUS

CN 2-Pyridinecarboxamide, 5-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 895519-96-7 CAPLUS

CN 2-Pyridinecarboxamide, 5-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 895520-02-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as protein kinase inhibitors)

RN 895520-02-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)

L17 ANSWER 29 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:627482 CAPLUS

DN 145:103701

TI Preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents

IN Hong, Fang-Tsao; Liao, Hongyu; Lopez, Patricia; Tadesse, Seifu; Tamayo, Nuria A.

PA Amgen Inc, USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006069258	A1	20060629	WO 2005-US46652	20051220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060161001	A1	20060720	US 2005-312292	20051219
AU 2005319137	A1	20060629	AU 2005-319137	20051220
CA 2591946	A1	20060629	CA 2005-2591946	20051220
EP 1833831	A1	20070919	EP 2005-855245	20051220
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI US 2004-637845P	P	20041220		
US 2005-312292	A	20051219		
WO 2005-US46652	W	20051220		

OS MARPAT 145:103701

AB Nitrogen-containing heterocycles such as I-III are prepared and used as prodrugs

in the treatment of inflammation disorders, as well as, but not limited to antiviral agents and therapeutic agents. Thus, I-III can be used to inhibit the production of TNF- α or IL-1- β , in glucagon binding assays, as COX-1 and/or COX-2 inhibitors, or in a Raf-kinase inhibition assay (no data). Finally, said compds. are also useful therapeutic prodrugs in the treatment of inflammation, acute or chronic myelogenous leukemia, type I and II diabetes, Alzheimer's disease, stroke, myocardial infarction, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus, influenza, adenovirus, and the herpes viruses.

IT 894791-80-1P 894791-81-2P 894791-82-3P


894792-73-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents)


RN 894791-80-1 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-[(1-methylethyl)amino]- (CA INDEX NAME)




RN 894791-81-2 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-(methylamino)- (CA INDEX NAME)




RN 894791-82-3 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-(ethylamino)- (CA INDEX NAME)



RN 894792-73-5 CAPLUS

CN Ethanone, 1-[4-[[4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




IT 894791-70-9P 894791-71-0P 894791-72-1P
 894791-78-7P 894791-79-8P 894791-91-4P
 894791-92-5P 894791-97-0P 894791-98-1P
 894791-99-2P 894792-21-3P 894792-28-0P
 894792-42-8P 894792-55-3P 894792-71-3P
 894792-72-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents)


RN 894791-70-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894791-71-0 CAPLUS

CN 2-Pyrimidinamine, 4-[(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-N-4-piperidinyl]- (CA INDEX NAME)




RN 894791-72-1 CAPLUS

CN Ethanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894791-78-7 CAPLUS

CN Ethanone, 2-amino-1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 894791-79-8 CAPLUS

CN 1-Propanone, 3-bromo-1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 894791-91-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894791-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-((3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-N-4-piperidinyl)- (CA INDEX NAME)




RN 894791-97-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-((3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-2-pyrimidinyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894791-98-1 CAPLUS

CN 2-Pyrimidinamine, 4-((3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-N-4-piperidinyl)- (CA INDEX NAME)




RN 894791-99-2 CAPLUS

CN Ethanone, 1-[[4-[(3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894792-21-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894792-28-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-1(2H)-yl)-6-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894792-42-8 CAPLUS
 CN 1,8-Naphthyridine-3-carboxylic acid,
 8-[2-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-4-
 pyrimidinyl]-5,6,7,8-tetrahydro-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 894792-55-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-
 1(2H)-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 894792-71-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-
 b][1,4]oxazin-8-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)



RN 894792-72-4 CAPLUS

CN 2-Pyrimidinamine, 4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-N-4-piperidinyl- (CA INDEX NAME)




IT 894791-93-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents)

RN 894791-93-6 CAPLUS

CN Ethanone, 1-[4-[(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 30 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:608560 CAPLUS

DN 145:83228

TI Preparation of pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases

IN Charrier, Jean-Damien; Durrant, Steven; Ramaya, Sharn; Jimenez, Juan-Miguel; Rutherford, Alistair

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065946	A1	20060622	WO 2005-US45336	20051215
	W: AE, AG, AL, AM, AN, AO, AP, AR, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HA, HE, HF, HG, HI, HM, HN, HP, HR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KI, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, PU, PY, QA, QZ, RE, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005316540	A1	20060622	AU 2005-316540	20051215
	CA 2591413	A1	20060622	CA 2005-2591413	20051215
	US 20060183911	A1	20060817	US 2005-304057	20051215
	EP 1831168	A1	20070912	EP 2005-854119	20051215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008524233	T	20080710	JP 2007-546878	20051215
	MX 200707330	A	20071004	MX 2007-7330	20070618
	IN 2007KN02260	A	20070817	IN 2007-KN2260	20070619
	NO 2007003628	A	20070716	NO 2007-3628	20070716
	KR 2007095952	A	20071001	KR 2007-716337	20070716
	CN 101111479	A	20080123	CN 2005-80047554	20070731
PRAI	US 2004-636754P	P	20041216		
	US 2005-673870P	P	20050422		
	WO 2005-US45336	W	20051215		

OS MARPAT 145:83228

AB The title compds. I [R3, R4 = H, halo or alkyl optionally substituted with halo, alkyl, OCH3, NO2, NH2, CN, NHCH3, SCH3, or N(CH)2; R2 = 3-8 membered saturated, partially unsatd., or fully unsatd. monocyclic ring having 0-3 heteroatoms independently selected from N, O, or S, or 8-12 membered saturated, partially unsatd., or fully unsatd. bicyclic ring system having 0-5 heteroatoms independently selected from N, O, or S; X1, X2 = C(O), NR, or SO2 (wherein one of X1 or X2 = NR and other of X1 or X2 = C(O) or SO2); R1 = TQ (T = a bond or alkylene wherein up tp 3 methylene units are optionally replaced by O, S, CS, etc.; Q = H, alkyl, 3-8 membered saturated, partially unsatd., or fully unsatd. monocyclic ring having 0-3 heteroatoms independently selected from N, O, or S, or 8-12 membered saturated, partially

unsatd., or fully unsatd. bicyclic ring system having 0-5 heteroatoms independently selected from N, O, or S] which are effective as inhibitors of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk) protein kinases, were prepared. Thus, reacting amrinone with 4-tert-butylbenzoyl chloride afforded 9% II which showed Ki between 0.1 μ M and 1 μ M against ITK.

The compds. I and their pharmaceutically acceptable compns. are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunol.-mediated disease.


IT 893436-12-9P 893436-30-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridones as inhibitors of Tec family protein kinases useful for treating and preventing inflammatory, proliferative, hyperproliferative, autoimmune or immunol.-mediated disease)


RN 893436-12-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5-[[4-(1,1-dimethylethyl)benzoyl]amino]-1,6-dihydro-6-oxo-3-pyridinyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 893436-30-1 CAPLUS


CN Benzamide, N-[1,2-dihydro-2-oxo-5-[2-(4-piperidinylamino)-4-pyrimidinyl]-3-pyridinyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 31 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:439442 CAPLUS
 DN 144:468188
 TI Preparation of pyrimidinyl-substituted fused pyrroles for treatment of
 kinase disorders
 IN Huang, Shenlin; Lin, Ronghui; Connolly, Peter J.; Emanuel, Stuart L.;
 Middleton, Steven A.
 PA Janssen Pharmaceutica, N.V., Belg.
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006050076	A1	20060511	WO 2005-US38905	20051028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20060183900	A1	20060817	US 2005-260986	20051028
PRAI	US 2004-623654P	P	20041029		
OS	CASREACT 144:468188; MARPAT 144:468188				
AB	Title compds. [I; A, B, C = CH, N; D = N, CR4; R1 = H, halo, OH, cyano, NO2, 1-3 of (substituted) alkyl, alkenyl, alkynyl, alkoxy, amino, sulfonylamino, alkylthio, carboxamide, etc.; R2 = (substituted) cycloalkyl, aryl, heteroaryl, heterocyclyl, alkyl; R3 = H, alkyl, alkoxyalkyl, haloalkyl hydroxyalkyl, CO2H, alkoxy carbonyl, CHO, CONH2, SO2NH2, etc.; R4 = H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, hydroxyalkoxy, CO3H, alkoxy carbonyl, etc.], were prepared Thus, 2-[4-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylaminophenyl]ethanol [preparation from 7-azaindole, 2,4-dichloropyrimidine, and 2-(4-aminophenyl)ethanol given] inhibited CDK1 with IC50 = 0.019 µM.				
IT	886547-58-6P 886547-63-3P 886547-65-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidinyl-substituted fused pyrroles for treatment of kinase disorders)				
RN	886547-58-6 CAPLUS				
CN	2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)- (CA INDEX NAME)				




RN 886547-63-3 CAPLUS

CN Ethanone, 1-[4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 886547-65-5 CAPLUS

CN 2-Pyrimidinamine, N-4-piperidinyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 32 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:380989 CAPLUS

DN 144:432824

TI Preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase

IN Ashwell, Mark; Tandon, Manish; Lapierre, Jean-Marc

PA Arqule, Inc., USA

SO PCT Int. Appl., 229 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006044869	A1	20060427	WO 2005-US37390	20051019
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2584368 A1 20060427 CA 2005-2584368 20051019 EP 1809636 A1 20070725 EP 2005-815645 20051019 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008517064 T 20080522 JP 2007-537967 20051019 PRAI US 2004-619876P P 20041019 WO 2005-US37390 W 20051019 OS CASREACT 144:432824; MARPAT 144:432824 AB The title compds. I [wherein X = O, S, SO, or SO ₂ ; Ar = 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzo[1,3]dioxol-5-yl, or (un)substituted aryl; R1 = H, CN, CO ₂ H, halo, alkyl, etc.; R2 = (un)substituted alkyl, cycloalkyl, heterocyclyl, or aryl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl, or heteroaryl] or pharmaceutically acceptable salts or prodrugs thereof are prepared as inhibitors of the p38 MAP kinase. For example, the compound II was prepared in a multi-step synthesis. I are useful for the treatment of inflammation and autoimmune disease (no data). IT 815595-31-4P 815595-32-5P 815595-35-8P 815595-36-9P 815595-59-6P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase) RN 815595-31-4 CAPLUS CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)				




RN 815595-32-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-36-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)


885047-59-6P 885047-60-9P 885047-61-0P
 885047-62-1P 885047-63-2P 885047-64-3P
 885047-65-4P 885047-66-5P 885047-83-6P
 885047-84-7P 885047-85-8P 885047-95-0P
 885048-01-1P 885048-02-2P 885048-06-6P
 885048-12-4P 885048-13-5P 885048-15-7P
 885048-32-8P 885048-34-0P 885048-35-1P
 885048-36-2P 885048-38-4P 885048-41-9P
 885048-43-1P 885048-44-2P 885048-45-3P
 885048-49-7P 885048-52-2P 885048-58-8P
 885048-64-6P 885048-69-1P 885048-71-5P
 885048-76-0P 885048-78-2P 885048-80-6P
 885048-86-2P 885048-87-3P 885048-88-4P
 885048-89-5P 885048-90-8P 885048-91-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase)

RN 815595-27-8 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 815595-44-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-45-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-58-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-60-9 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-43-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-44-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885046-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-49-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885046-54-8 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny](4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-56-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]phenyl- (CA INDEX NAME)




RN 885046-58-2 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-60-6 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-8-quinoliny- (CA INDEX NAME)




RN 885046-61-7 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)




RN 885046-62-8 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methoxy- (CA INDEX NAME)




RN 885046-63-9 CAPLUS

CN Methanone, cyclohexyl[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-64-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 885046-65-1 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-furanyl- (CA INDEX NAME)




RN 885046-66-2 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-68-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 885046-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885046-70-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 885046-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 885046-72-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-74-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885046-76-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 885046-77-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-79-7 CAPLUS
 CN Ethanone, 2-(4-fluorophenyl)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-80-0 CAPLUS
 CN 1-Butanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 885046-81-1 CAPLUS

CN Methanone, (4-fluorophenyl) 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-82-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885046-83-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(cyclohexylmethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-84-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-85-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[5-methyl-2-(trifluoromethyl)-3-furanyl]- (CA INDEX NAME)




RN 885046-86-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-(2-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-87-7 CAPLUS
 CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 885046-88-8 CAPLUS
 CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-phenyl- (CA INDEX NAME)




RN 885046-89-9 CAPLUS
 CN Ethanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 885046-90-2 CAPLUS


CN 1-Propanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 885046-91-3 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-(2S)-2-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885046-92-4 CAPLUS


CN 1-Piperidinecarboxamide, N-(3,4-difluorophenyl)-4-[[4-[6-(4-

fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-93-5 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 885046-94-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885046-95-7 CAPLUS


CN 1-Piperidinepentanoic acid, γ -amino-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885047-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 885047-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-09-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-10-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(1-methylethyl)phenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-(trifluoromethyl)phenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885047-25-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-(trifluoromethoxy)phenyl)sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 885047-26-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-piperidiny]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-27-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-dichlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-28-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-29-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-bis(trifluoromethyl)phenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-30-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-34-7 CAPLUS

CN Methanone, (4-amino-3,5,6-trichloro-2-pyridinyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-35-8 CAPLUS

CN Methanone, (2,6-dimethoxyphenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-36-9 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 885047-37-0 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 885047-38-1 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-39-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885047-40-5 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(4-methyl-2-pyrimidinyl)thio]- (CA INDEX NAME)




RN 885047-41-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-42-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-43-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 885047-44-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-45-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-46-1 CAPLUS

CN Methanone, [4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl][4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-47-2 CAPLUS

CN Methanone, [4-(dimethylamino)phenyl][4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-48-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-49-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-50-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-51-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-52-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-53-0 CAPLUS

CN Acetamide, N-[5-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 885047-54-1 CAPLUS

CN Benzoic acid, 4-[[[4-[[[4-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-55-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-56-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-57-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 885047-59-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-60-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-furanylmethyl)-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-61-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-62-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,6-difluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-63-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-64-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-phenoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-(trifluoromethyl)phenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-66-5 CAPLUS

CN Benzonitrile, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-83-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-84-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-85-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-95-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-naphthalenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-01-1 CAPLUS

CN Ethanone, 2-[4-(dimethylamino)phenyl]-1-[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885048-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-06-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-12-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885048-13-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-15-7 CAPLUS

CN 2-Pyrimidinamine, 4-(6-[1,1'-biphenyl]-4-ylimidazo[2,1-b]thiazol-5-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-32-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885048-34-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-35-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-36-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-[1,1'-biphenyl]-4-yl]imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885048-38-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-41-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-43-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[4-[6-(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-44-2 CAPLUS


CN Benzoic acid, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885048-45-3 CAPLUS
 CN Benzenepropanoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 885048-49-7 CAPLUS
 CN Acetamide, N-[4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)




RN 885048-52-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885048-58-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-64-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-69-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-71-5 CAPLUS

CN Phenol, 4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-76-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-78-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-80-6 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)



RN 885048-86-2 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HC1

RN 885048-87-3 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 885048-88-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 885048-89-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 885048-90-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 885048-91-9 CAPLUS
 CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HC1

IT 935431-17-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as
inhibitors of p38 MAP kinase)

RN 935431-17-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-
piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HC1

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 33 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:343042 CAPLUS

DN 144:390934

TI Preparation of aminopyrimidines as JNK inhibitors

IN Ratcliffe, Andrew James; Alam, Mahbub; Beevers, Rebekah Elisabeth;
 Davenport, Richard John; Davies, Natasha; Haughan, Alan Findlay; Jones,
 Mark William; Lowe, Christopher; Perry, Benjamin Garfield; Phillips, David
 Jonathan; Pitt, William Ross; Sharpe, Andrew

PA Celltech R & D Limited, UK

SO PCT Int. Appl., 153 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006038001	A1	20060413	WO 2005-GB3827	20051004
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2004-22284	A	20041006		
	GB 2005-9642	A	20050511		
OS	CASREACT 144:390934; MARPAT 144:390934				
AB	Title compds. I [A = pyrrole, pyrazole, imidazole or triazole ring; B = benzene, pyridine or pyrimidine ring; M = residue of an azetidine, pyrrolidine or piperidine ring; E = a covalent bond or (un)substituted straight or branched alkylene; Z = H, CHO, CONH2 and derivs., CO2H and derivs., (un)substituted Ph, heteroaryl, heterocycloalkyl, etc.; R1, R2 = independently H, halo, CN, NO2, OCF3, alkyl, alkoxy, etc.; R3 = H, alkyl, SO2H and derivs., etc.; R4 = H, alkoxy, oxo, CO2H and derivs., etc.; and their pharmaceutically acceptable salts, solvates or N-oxides] were prepared as JNK inhibitors. Thus, coupling 2,4,5-trichloropyrimidine with [1-(phenylsulfonyl)-1H-indol-3-yl]boronic acid, and amination of the 2-chloropyrimidine intermediate with Et 4-amino-1-piperidinecarboxylate gave aminopyrimidine I1•HCO2H. I possessed IC50 values for inhibition of human JNK1 and/or JNK2 and/or JNK3 enzyme activity of 5 µM or better. I are useful for treating autoimmune and inflammatory disorders, vascular, neurodegenerative, metabolic and ophthalmic disorders, neoplasm and pain.				
IT	882565-17-5P, 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-2-phenylacetamide RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (drug candidate; preparation of aminopyrimidines as JNK inhibitors)				
RN	882565-17-5 CAPLUS				
CN	1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-				

N-methyl- α -phenyl- (CA INDEX NAME)

IT 882566-86-1P 882566-87-2P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)

RN 882566-86-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-methyl- α -phenyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-87-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-methyl- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



IT 882562-76-7P 882562-81-4P,
 N-Ethyl-4-[[5-methyl-4-[1-(phenylsulfonyl)-1H-indol-3-yl]pyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-86-9P, tert-Butyl
 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-93-8P, tert-Butyl
 4-[[4-(1H-benzimidazol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-97-2P,
 4-(6-Fluoro-1H-indol-3-yl)-2-[(piperidin-4-yl)amino]pyrimidine-5-carbonitrile 882562-98-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-03-3P 882563-09-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine 882563-12-4P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N,N-dimethylpiperidine-1-carboxamide 882563-41-9P, tert-Butyl
 4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-54-4P 882563-56-6P, 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclopentanone 882563-60-2P,
 Methyl (3R)-4-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutanoate 882563-80-6P,
 N-[1-[(1,2,3-Benzotriazol-2-yl)ethanoyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-93-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(piperidin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-97-5P, tert-Butyl
 4-[[4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-99-7P 882564-05-8P
 882564-19-4P 882564-40-1P 882565-18-6P,
 [4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](tetrahydrofuran-3-yl)acetonitrile 882565-19-7P, tert-Butyl
 4-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](cyano)methyl]piperidine-1-carboxylate 882565-33-5P,
 tert-Butyl 4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxylate 882565-39-1P,
 4-[[5-Chloro-4-(1H-indol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-40-4P,
 2-[4-[[5-Chloro-4-(1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882562-76-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 882562-75-6

CMF C20 H22 Cl N5 O2



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882562-81-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[5-methyl-4-[1-(phenylsulfonyl)-1H-indol-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-86-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-93-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzimidazol-1-yl)-5-chloro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-97-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-(4-piperidinylamino)- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-03-3 CAPLUS

CN Glycine, N-[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl-, ethyl ester (CA INDEX NAME)




RN 882563-09-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 882563-12-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 882563-41-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-54-4 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 882563-56-6 CAPLUS


CN Cyclopentanone, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 882563-60-2 CAPLUS


CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-β-methyl-γ-oxo, methyl ester, (BR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-80-6 CAPLUS

CN Ethanone, 2-(2H-benzotriazol-2-yl)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-93-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)




RN 882563-97-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-99-7 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 882564-05-8 CAPLUS


CN 2-Pyrimidinamine, 5-chloro-4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 882564-19-4 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -oxo-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 882564-40-1 CAPLUS

CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-39-8

CMF C20 H23 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882565-18-6 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882565-19-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyanomethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-33-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-imidazo[1,2-a]pyridin-3-yl-5-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-39-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-40-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT 882562-77-8P, tert-Butyl 4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-82-5P, N-Ethyl-4-[[4-(1H-indol-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-83-6P, Ethyl 4-[[5-cyano-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-87-0P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethylacetamide 882562-88-1P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882562-89-2P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882562-90-5P, N-[2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]ethyl]acetamide 882562-91-6P, N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-92-7P, 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882562-94-9P, 4-[[4-(1H-Benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882562-95-0P, 2-[4-[[4-(1H-Benzimidazol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882562-98-3P, 4-[[5-Chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-01-1P, 4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-02-2P 882563-04-4P, 4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882563-05-5P, 4-(6-Fluoro-1H-indol-3-yl)-2-[[1-(1H-imidazol-2-yl)methyl]piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-06-6P, N-[[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]glycine 882563-07-7P,

4-(6-Fluoro-1H-indol-3-yl)-2-[[1-(propylsulfonyl)piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-08-8P,
 4-(6-Fluoro-1H-indol-3-yl)-2-[[1-(1H-imidazol-4-yl)methyl]piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-10-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882563-11-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-methoxypiperidine-1-carboxamide 882563-13-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(morpholin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-14-6P,
 N-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882563-15-7P,
 N-(1-Acetylpiperidin-4-yl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-16-8P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(methoxyacetyl)piperidin-4-yl]pyrimidin-2-amine 882563-17-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydrofuran-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-18-0P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-19-1P,
 5-Chloro-N-[1-(3-furanylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-20-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-isonicotinoylpiperidin-4-yl)pyrimidin-2-amine 882563-21-5P, N-[4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]phenyl]acetamide 882563-22-6P, 5-Chloro-N-[1-[[4-(dimethylamino)benzoyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-23-7P,
 882563-24-8P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-25-9P,
 5-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]imidazolidine-2,4-dione 882563-26-0P,
 N-[1-[(1-Acetylpiperidin-4-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-27-1P,
 [3-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-oxopropyl]urea 882563-28-2P,
 5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-29-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-30-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(3-methylisoxazol-5-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882563-31-7P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[3-(4-methylpiperazin-1-yl)propyl]piperidine-1-carboxamide 882563-33-9P
 882563-34-0P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-methoxy-N-methylpiperidine-1-carboxamide 882563-35-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylbutanamide 882563-36-2P,
 2-[4-[[5-Chloro-4-[1-[2-(methylamino)-2-oxoethyl]-1H-indol-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882563-37-3P, Ethyl (3R,4S)-4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxypiperidine-1-carboxylate 882563-38-4P, tert-Butyl 4-[[4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-39-5P, N-Ethyl-4-[[5-fluoro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882563-40-8P,
 4-[[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-42-0P,
 4-[[5-Chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]-N,N-dimethylpiperidine-1-carboxamide 882563-43-1P, tert-Butyl

[[4-[[5-chloro-4-[[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]sulfonyl]carbamate
 882563-44-2P, tert-Butyl 4-[[4-(1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-45-3P,
 4-[[4-(5-Chloro-1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-46-4P,
 4-[[4-(6-Chloro-1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-48-6P 882563-49-7P
 , 5-Chloro-N-[1-[(1H-imidazol-4-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-50-0P,
 N-[(S)-2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-1-[(1H-imidazol-4-yl)methyl]-2-oxoethyl]acetamide 882563-51-1P
 , 5-Chloro-N-[1-[(1H-imidazol-2-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-52-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-2-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882563-53-3P,
 (5R)-5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-55-5P 882563-57-7P
 , (5S)-5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-58-8P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclohexanol 882563-59-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(4-methoxycyclohexyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-61-3P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-1,3-oxazolidin-2-one 882563-62-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(3-thienyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-63-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(2-thienyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-64-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,3-thiazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-65-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(2-methyl-1,3-thiazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-66-8P,
 6-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-4,5-dihydropyridazin-3(2H)-one 882563-67-9P,
 5-Chloro-N-[1-(cyclopentylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-68-0P,
 N-(1-Benzoylpiperidin-4-yl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-69-1P, 5-Chloro-N-[1-(cyclopropylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-70-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-71-5P,
 N-[1-[3-(1H-Benzimidazol-2-yl)propanoyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-72-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-propionylpiperidin-4-yl)pyrimidin-2-amine 882563-73-7P, 5-Chloro-N-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-74-8P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,8-naphthyridin-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-75-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(2-methylbenzoyl)piperidin-4-yl]pyrimidin-2-amine 882563-76-0P, 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-4-oxobutanamide 882563-77-1P,
 5-Chloro-N-[1-(cinolin-4-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-78-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-isobutanoylpiperidin-4-yl)pyrimidin-2-amine 882563-79-3P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(3-

methylbenzoyl)piperidin-4-yl]pyrimidin-2-amine 882563-81-7P,
 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-5,6-dimethylpyridin-2(1H)-one 882563-82-8P,
 N-[1-[[1H-Benzimidazol-5-yl]carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-83-9P,
 N-[1-[[1H-Benzimidazol-2-yl]carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-84-0P 882563-85-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(2-phenylpropanoyl)piperidin-4-yl]pyrimidin-2-amine 882563-87-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(tetrahydrothiophene-3-ylacetyl)piperidin-4-yl]pyrimidin-2-amine 882563-88-4P,
 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclopentanol 882563-89-5P,
 (3R)-4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutanoic acid 882563-90-8P,
 (3R)-4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutan-1-ol 882563-92-0P 882563-94-2P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-N-ethylpiperidine-1-carboxamide 882563-95-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[1-(methylsulfonyl)piperidin-4-yl]carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-96-4P,
 2-[4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]piperidin-1-yl]-N-methylacetamide 882564-00-3P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-01-4P,
 (5S)-5-[[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882564-03-6P 882564-04-7P
 , 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydrofuran-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-06-9P,
 N-[2-[4-[[5-Chloro-4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882564-07-0P,
 5-Chloro-4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-08-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-2-yl)methyl]sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-10-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-4-yl)methyl]sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-11-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-12-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-13-8P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-14-9P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(methylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-15-0P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-16-1P,
 5-Chloro-4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-17-2P, Ethyl
 [4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](oxo)acetate 882564-18-3P, Methyl
 [4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](oxo)acetate 882564-20-7P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-2-(oxo)acetamide 882564-21-8P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethyl-2-(oxo)acetamide 882564-22-9P,

4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[2-(morpholin-4-yl)ethyl]piperidine-1-carboxamide 882564-23-0P,
5-Chloro-4-(1H-indol-3-yl)-N-[1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-24-1P,
4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[(pyridin-2-yl)methyl]piperidine-1-carboxamide 882564-25-2P
882564-27-4P 882564-29-6P,
4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-4-yl)piperidine-1-carboxamide 882564-30-9P,
4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-3-yl)piperidine-1-carboxamide 882564-32-1P 882564-33-2P,
5-Chloro-4-(1H-indol-3-yl)-N-[1-[(morpholin-4-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-34-3P 882564-36-5P
882564-38-7P 882564-41-2P,
5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-42-3P,
3-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-1,1-dimethylurea 882564-43-4P, Morpholine-4-carboxylic acid [2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amide 882564-44-5P,
5-Chloro-N-[1-[(1H-imidazol-1-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882564-45-6P,
N-[(3R)-1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-yl]acetamide 882564-46-7P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(4-hydroxycyclohexylamino)ethanone 882564-47-8P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[cyclohexyl(2-hydroxyethyl)amino]ethanone 882564-48-9P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxypropylamino)ethanone 882564-49-0P,
[1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-yl]methanol 882564-50-3P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethylcyclopentyl)amino]ethanone 882564-51-4P,
1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-ol 882564-52-5P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(4-hydroxybutylamino)ethanone 882564-53-6P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1-methylethylamino)ethanone 882564-54-7P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethyl-3-methylbutyl)amino]ethanone 882564-55-8P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[[1-(hydroxymethyl)propyl]amino]ethanone 882564-56-9P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1,1-dimethylethylamino)ethanone 882564-57-0P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethyl-2-methylpropyl)amino]ethanone 882564-58-1P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1-phenylethylamino)ethanone 882564-59-2P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxyethylamino)ethanone 882564-60-5P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[[1-(hydroxycyclohexyl)methyl]amino]ethanone 882564-62-7P,
1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(3-hydroxypropylamino)ethanone 882564-63-8P,
2-[1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-

yl]-2-oxoethyl]piperidin-2-yl]ethanol 882564-64-9P,
 2-[1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-4-yl]ethanol 882564-65-0P,
 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-4-ol 882564-66-1P,
 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidine-4-carboxamide 882564-67-2P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxybutylamino)ethanone 882564-68-3P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(3-hydroxy-2,2-dimethylpropylamino)ethanone 882564-69-4P
 882564-70-7P, (3R)-1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-ol 882564-71-8P,
 (3R)-1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-ol 882564-72-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(1H-indol-3-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-73-0P, 5-Chloro-N-[1-[[1,3-dimethylbutyl]amino]acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882564-74-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[pyrimidin-4-yl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-75-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyrrolidin-1-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-76-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(morpholin-4-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-77-4P, 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-N,N-diethylpiperidine-3-carboxamide 882564-78-5P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-methyl-2-(morpholin-4-yl)propyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-79-6P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[methyl(1-methyl-1H-imidazol-2-yl)methyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-80-9P, 3-[[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]benzenesulfonamide 882564-81-0P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(pyrrolidin-1-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-82-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-83-2P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[1,3-thiazol-2-yl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-84-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[2-(methylamino)propanoyl]piperidin-4-yl]pyrimidin-2-amine 882564-86-5P 882564-87-6P,
 [2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](methyl)carbamic acid tert-butyl ester 882564-88-7P,
 N-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-N-methylacetamide 882564-89-8P 882564-90-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,2,4-oxadiazol-3-yl)methyl]piperidin-4-yl]pyrimidin-2-amine 882564-91-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)methyl]piperidin-4-yl]pyrimidin-2-amine 882564-93-4P 882564-95-6P
 882564-97-8P
 882564-98-9P, 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetone 882564-99-0P, Methyl 2-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetate 882565-01-7P 882565-02-8P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(2-fluorophenyl)acetamide 882565-03-9P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-


(1H-indol-3-yl)ethylacetamide 882565-04-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(pyrimidin-4-yl)acetamide 882565-05-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(pyridin-3-yl)acetamide 882565-06-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[(pyridin-3-yl)methyl]acetamide 882565-07-3P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-(morpholin-4-yl)ethyl]acetamide 882565-08-4P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-(piperidin-1-yl)ethyl]acetamide 882565-09-5P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]acetamide 882565-10-8P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide 882565-11-9P
 , 5-Chloro-4-(1H-indol-3-yl)-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl]pyrimidin-2-amine 882565-12-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(cyclopropylmethyl)acetamide 882565-13-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(1,3-thiazol-2-yl)acetamide 882565-15-3P 882565-16-4P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylpropanamide 882565-20-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-phenylpropionitrile 882565-21-1P 882565-22-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(piperidin-4-yl)acetamide 882565-23-3P,
 3-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]dihydrofuran-2(3H)-one 882565-24-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(5-nitro-1,3-thiazol-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-25-5P,
 6-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]nicotinonitrile 882565-26-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyridin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-27-7P, N-[1-(5-Aminopyridin-2-yl)piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-28-8P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyrimidin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-29-9P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyrazin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-30-2P,
 2-[4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882565-31-3P, tert-Butyl
 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882565-32-4P,
 4-[[5-Chloro-4-(6-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-34-6P,
 N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxamide 882565-35-7P,
 4-[[5-Chloro-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-36-8P,
 4-[[5-Chloro-4-(imidazo[1,2-a]pyrimidin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-42-6P 882565-44-8P
 882565-45-9P, 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[[4-methylpiperazin-1-yl]carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-46-0P 882565-47-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methylpiperidin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-48-2P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-

methyl-4-oxobutanamide 882565-49-3P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-3-methyl-4-oxobutanamide 882565-50-6P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethyl-3-methyl-4-oxobutanamide 882565-51-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(3-methylbutanoyl)piperidin-4-yl]pyrimidin-2-amine 882565-52-8P 882565-53-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-54-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-phenylpropanamide 882565-55-1P,
 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-1,3,3-trimethylurea 882565-56-2P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(1-methylpiperidin-4-yl)piperidine-1-carboxamide 882565-57-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-isopropylpiperidine-1-carboxamide 882565-58-4P,
 N-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-1-(hydroxymethyl)-2-oxoethyl]acetamide 882565-59-5P
 882565-60-8P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(1-methylpiperidin-3-yl)piperidine-1-carboxamide 882565-61-9P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-cyclopropylpiperidine-1-carboxamide 882565-62-0P
 882565-63-1P, N-[1-[2-(Azetidin-1-yl)-2-oxoethyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-64-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydrofuran-3-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882565-65-3P,
 1-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-3-ol 882565-66-4P,
 3-[[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]dihydrofuran-2(3H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882562-77-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-82-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-83-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 882562-87-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882562-88-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-89-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882562-90-5 CAPLUS

CN Acetamide, N-[2-[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]ethyl]- (CA INDEX NAME)



RN 882562-91-6 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 882562-92-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)

pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)




RN 882562-94-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882562-95-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-01-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-02-2 CAPLUS

CN β -Alanine, N-[[4-[[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)


RN 882563-04-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882563-05-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-06-6 CAPLUS

CN Glycine, N-[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 882563-07-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[1-(propylsulfonyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-08-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[1-(1H-imidazol-5-ylmethyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-10-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882563-11-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methoxy- (CA INDEX NAME)




RN 882563-13-5 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)




RN 882563-14-6 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882563-15-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-16-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-methoxy- (CA INDEX NAME)




RN 882563-17-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882563-18-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 882563-19-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-furanyl- (CA INDEX NAME)




RN 882563-20-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 882563-21-5 CAPLUS

CN Acetamide, N-[4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 882563-22-6 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny] [4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 882563-23-7 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-γ-oxo-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 882563-24-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny] (1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 882563-25-9 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882563-26-0 CAPLUS

CN Ethanone, 1-[4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-27-1 CAPLUS

CN Urea, N-[3-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)




RN 882563-28-2 CAPLUS

CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 882563-29-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](5-methyl-2-pyrazinyl)- (CA INDEX NAME)




RN 882563-30-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 882563-31-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 882563-33-9 CAPLUS

CN Formic acid, compd. with 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]-1-piperidinecarboxamide (2:1) (CA INDEX NAME)

CM 1

CRN 882563-32-8

CMF C22 H28 Cl N7 O



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882563-34-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methoxy-N-methyl- (CA INDEX NAME)




RN 882563-35-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-α-ethyl-N-methyl- (CA INDEX NAME)



RN 882563-36-2 CAPLUS


CN 1H-Indole-1-acetamide, 3-[5-chloro-2-[[1-[2-(methylamino)-2-oxoethyl]-4-piperidinyl]amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)




RN 882563-37-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-3-methoxy-, ethyl ester, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 882563-38-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882563-39-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-ethyl-4-[[5-fluoro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 882563-40-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-42-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882563-43-1 CAPLUS

CN Carbamic acid, [[4-[[5-chloro-4-[[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 882563-44-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882563-45-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(5-chloro-1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882563-46-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(6-chloro-1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-48-6 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1,2,4-triazolo[4,3-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 882563-47-5

CMF C18 H21 Cl N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 882563-49-7 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1H-imidazol-5-yl- (CA INDEX NAME)



RN 882563-50-0 CAPLUS


CN Acetamide, N-[(1S)-2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(1H-imidazol-5-ylmethyl)-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-51-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1H-imidazol-2-yl- (CA INDEX NAME)



RN 882563-52-2 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2-pyridinyl)- (CA INDEX NAME)



RN 882563-53-3 CAPLUS

CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-55-5 CAPLUS

CN 2-Imidazolidinone, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-57-7 CAPLUS


CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-58-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](4-hydroxycyclohexyl)- (CA INDEX NAME)




RN 882563-59-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyloxy(4-methoxycyclohexyl)- (CA INDEX NAME)




RN 882563-61-3 CAPLUS

CN 2-Oxazolidinone, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyloxy]carbonyl]- (CA INDEX NAME)




RN 882563-62-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyloxy(3-thienyl)- (CA INDEX NAME)




RN 882563-63-5 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-thienyl- (CA INDEX NAME)




RN 882563-64-6 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-thiazolyl- (CA INDEX NAME)




RN 882563-65-7 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](2-methyl-4-thiazolyl)- (CA INDEX NAME)




RN 882563-66-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4,5-dihydro- (CA INDEX NAME)




RN 882563-67-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyclopentyl- (CA INDEX NAME)




RN 882563-68-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]phenyl- (CA INDEX NAME)




RN 882563-69-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyclopropyl- (CA INDEX NAME)




RN 882563-70-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-pyridinyl- (CA INDEX NAME)




RN 882563-71-5 CAPLUS

CN 1-Propanone, 3-(1H-benzimidazol-2-yl)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-72-6 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-73-7 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2,2-dimethyl- (CA INDEX NAME)




RN 882563-74-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1,8-naphthyridin-2-yl- (CA INDEX NAME)




RN 882563-75-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](2-methylphenyl)- (CA INDEX NAME)



RN 882563-76-0 CAPLUS


CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-γ-oxo- (CA INDEX NAME)



RN 882563-77-1 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-

piperidiny1]-4-cinnoliny1- (CA INDEX NAME)




RN 882563-78-2 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny1]-2-methyl- (CA INDEX NAME)




RN 882563-79-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny1](3-methylphenyl)- (CA INDEX NAME)




RN 882563-81-7 CAPLUS

CN 2(1H)-Pyridinone, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-5,6-dimethyl- (CA INDEX NAME)




RN 882563-82-8 CAPLUS

CN Methanone, 1H-benzimidazol-6-yl[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-83-9 CAPLUS

CN Methanone, 1H-benzimidazol-2-yl[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-84-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 882563-85-1 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-phenyl- (CA INDEX NAME)




RN 882563-87-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-3-thienyl)- (CA INDEX NAME)



RN 882563-88-4 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxycyclopentyl)- (CA INDEX NAME)



RN 882563-89-5 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-β-methyl-γ-oxo-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-90-8 CAPLUS

CN 1-Butanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 882563-92-0 CAPLUS


CN Formic acid, compd. with [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl][(2S)-4-hydroxy-2-pyrrolidinyl]methanone (1:1) (CA INDEX NAME)

CM 1

CRN 882563-91-9

CMF C22 H25 Cl N6 O2

Absolute stereochemistry.



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882563-94-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-ethyl- (CA INDEX NAME)




RN 882563-95-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl][1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882563-96-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 882564-00-3 CAPLUS


CN Methanone, [4-[[4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 882564-01-4 CAPLUS

CN 2-Pyrrolidinone, 5-[[4-[[4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882564-03-6 CAPLUS
 CN Acetamide, N-[2-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-oxoethyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 882564-02-5
 CMF C20 H23 N7 O2




CM 2

CRN 64-19-7
 CMF C2 H4 O2




RN 882564-04-7 CAPLUS
 CN Methanone, [4-[[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882564-06-9 CAPLUS

CN Acetamide, N-[2-[4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882564-07-0 CAPLUS

CN Methanone, [4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 882564-08-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(2-pyridinylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-10-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-pyridinylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-11-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-12-7 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-13-8 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-14-9 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882564-15-0 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-16-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-17-2 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-alpha-oxo-, ethyl ester (CA INDEX NAME)




RN 882564-18-3 CAPLUS


CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-alpha-oxo-, methyl ester (CA INDEX NAME)



RN 882564-20-7 CAPLUS


CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-methyl-α-oxo- (CA INDEX NAME)

RN 882564-21-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N,N-dimethyl-α-oxo- (CA INDEX NAME)


RN 882564-22-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 882564-23-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperazinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-24-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 882564-25-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)




RN 882564-27-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-, compd. with 4-nitrophenol (1:1) (CA INDEX NAME)

CM 1

CRN 882564-26-3


CMF C24 H30 Cl N7 O3 S



CM 2


CRN 100-02-7

CMF C6 H5 N O3




RN 882564-29-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-piperidinyl- (CA INDEX NAME)



RN 882564-30-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-3-piperidinyl- (CA INDEX NAME)




RN 882564-32-1 CAPLUS

CN Formic acid, compd. with N-ethyl-4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 882564-31-0

CMF C20 H24 N6 O



CM 2


CRN 64-18-6

CMF C H2 O2



RN 882564-33-2 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)



RN 882564-34-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-methyl-1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)

NAME)




● x HCl

RN 882564-36-5 CAPLUS
 CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-35-4
 CMF C21 H25 Cl N6 O



CM 2


CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 882564-38-7 CAPLUS
 CN Formic acid, compd. with 2-amino-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-37-6
 CMF C19 H21 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-41-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-pyridinylamino)- (CA INDEX NAME)




RN 882564-42-3 CAPLUS

CN Urea, N'-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N-dimethyl- (CA INDEX NAME)




RN 882564-43-4 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 882564-44-5 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 882564-45-6 CAPLUS

CN Acetamide, N-[(3R)-1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 882564-46-7 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-

piperidinyl]-2-[(4-hydroxycyclohexyl)amino]- (CA INDEX NAME)




RN 882564-47-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[cyclohexyl(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882564-48-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxypropyl)amino]- (CA INDEX NAME)




RN 882564-49-0 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[3-(hydroxymethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-50-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)cyclopentyl]amino]- (CA INDEX NAME)




RN 882564-51-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)




RN 882564-52-5 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[4-hydroxybutyl]amino]- (CA INDEX NAME)




RN 882564-53-6 CAPLUS
 CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1-methylethyl)amino]- (CA INDEX NAME)




RN 882564-54-7 CAPLUS
 CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1-(hydroxymethyl)-3-methylbutyl)amino]- (CA INDEX NAME)



RN 882564-55-8 CAPLUS
 CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1-(hydroxymethyl)propyl)amino]- (CA INDEX NAME)




RN 882564-56-9 CAPLUS
 CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1,1-dimethylethyl)amino]- (CA INDEX NAME)




RN 882564-57-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)-2-methylpropyl]amino]- (CA INDEX NAME)




RN 882564-58-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1-phenylethyl)amino]- (CA INDEX NAME)




RN 882564-59-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882564-60-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxycyclohexyl)methyl]amino]- (CA INDEX NAME)




RN 882564-62-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[3-(hydroxypropyl)amino]- (CA INDEX NAME)




RN 882564-63-8 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[2-(2-hydroxyethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-64-9 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[4-(2-hydroxyethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-65-0 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[(4-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 882564-66-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882564-67-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxybutyl)amino]- (CA INDEX NAME)



RN 882564-68-3 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3-hydroxy-2,2-dimethylpropyl)amino]- (CA INDEX NAME)



RN 882564-69-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882564-70-7 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[3-(3R)-3-

hydroxy-1-piperidiny]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 882564-71-8 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-[(3R)-3-hydroxy-1-pyrrolidiny]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882564-72-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-[(2-(1H-indol-3-yl)ethyl)amino]- (CA INDEX NAME)




RN 882564-73-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1,3-dimethylbutyl)amino]- (CA INDEX NAME)




RN 882564-74-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-pyrimidinylamino)- (CA INDEX NAME)




RN 882564-75-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 882564-76-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)




RN 882564-77-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N-diethyl- (CA INDEX NAME)




RN 882564-78-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-methyl-2-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 882564-79-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[methyl(1-methyl-1H-imidazol-2-yl)methyl]amino]- (CA INDEX NAME)




RN 882564-80-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]- (CA INDEX NAME)




RN 882564-81-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)




RN 882564-82-1 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)



RN 882564-83-2 CAPLUS
 CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2-thiazolylamino)- (CA INDEX NAME)




RN 882564-84-3 CAPLUS
 CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)- (CA INDEX NAME)



RN 882564-86-5 CAPLUS
 CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)-2-phenylethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-85-4
 CMF C26 H27 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-87-6 CAPLUS

CN Carbamic acid, [2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 882564-88-7 CAPLUS


CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N-methyl- (CA INDEX NAME)



RN 882564-89-8 CAPLUS


CN 2H-Pyran-4-carboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-1-piperidiny]-2-oxoethyl]tetrahydro- (CA INDEX NAME)




RN 882564-90-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(1,2,4-oxadiazol-3-ylmethyl)-4-piperidiny]- (CA INDEX NAME)



RN 882564-91-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(3-pyridinylmethyl)-4-piperidiny]- (CA INDEX NAME)




RN 882564-93-4 CAPLUS

CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyridinylmethyl)-4-piperidiny]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-92-3

CMF C23 H23 Cl N6



CM 2

CRN 64-18-6

CMF C H2 O2




RN 882564-95-6 CAPLUS

CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-94-5

CMF C23 H23 Cl N6



CM 2

CRN 64-18-6

CMF C H2 O2




RN 882564-97-8 CAPLUS

CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-96-7

CMF C22 H23 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-98-9 CAPLUS

CN 2-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882564-99-0 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 882565-01-7 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 882565-00-6

CMF C19 H20 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 882565-02-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(2-fluorophenyl)- (CA INDEX NAME)




RN 882565-03-9 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 882565-04-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-pyrimidinyl- (CA INDEX NAME)




RN 882565-05-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-3-pyridinyl- (CA INDEX NAME)




RN 882565-06-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 882565-07-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 882565-08-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 882565-09-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 882565-10-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 882565-11-9 CAPLUS

CN Ethanone, 2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 882565-12-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 882565-13-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-2-thiazolyl- (CA INDEX NAME)




RN 882565-15-3 CAPLUS
 CN Formic acid, compd. with 4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino-N-methyl-1-piperidineacetamide (1:1) (CA INDEX NAME)
 CM 1
 CRN 882565-14-2
 CMF C19 H22 Cl N7 O




CM 2
 CRN 64-18-6
 CMF C H2 O2




RN 882565-16-4 CAPLUS
 CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,α-dimethyl- (CA INDEX NAME)



RN 882565-20-0 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(phenylmethyl)- (CA INDEX NAME)

RN 882565-21-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(tetrahydro-3-furanyl)-, hydrochloride (1:2) (CA INDEX NAME)


● 2 HCl

RN 882565-22-2 CAPLUS

CN 1-Piperidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -4-piperidinyl]- (CA INDEX NAME)


RN 882565-23-3 CAPLUS

CN 2(3H)-Furanone, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]dihydro- (CA INDEX NAME)




RN 882565-24-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(5-nitro-2-thiazolyl)-4-piperidiny]- (CA INDEX NAME)




RN 882565-25-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 882565-26-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyridinyl)-4-piperidiny]- (CA INDEX NAME)




RN 882565-27-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-(5-amino-2-pyridinyl)-4-piperidiny]-5-chloro-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 882565-28-8 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882565-29-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyrazinyl)-4-piperidinyl]- (CA INDEX NAME)



RN 882565-30-2 CAPLUS


CN 1-Piperidineacetamide, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 882565-31-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-

pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-32-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(6-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882565-34-6 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methyl-2-pyrimidinyl)amino]- (CA INDEX NAME)




RN 882565-35-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-36-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(5-chloro-4-imidazo[1,2-a]pyrimidin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882565-42-6 CAPLUS

CN Formic acid, compd. with N-ethyl-4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 882565-41-5

CMF C20 H24 N6 O



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 882565-44-8 CAPLUS


CN Formic acid, compd. with 4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-

methyl-1-piperidineacetamide (1:1) (CA INDEX NAME)

CM 1

CRN 882565-43-7

CMF C20 H24 N6 O



CM 2


CRN 64-18-6

CMF C H2 O2

 $\text{O}=\text{CH}-\text{OH}$

RN 882565-45-9 CAPLUS

CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 882565-46-0 CAPLUS

CN Formic acid, compd. with [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](4-methyl-1-piperazinyl)methanone (1:1) (CA INDEX NAME)

CM 1

CRN 882565-45-9

CMF C22 H28 N8 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882565-47-1 CAPLUS

CN Methanone, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 882565-48-2 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-β-methyl-γ-oxo- (CA INDEX NAME)




RN 882565-49-3 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,β-dimethyl-γ-oxo- (CA INDEX NAME)




RN 882565-50-6 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N, β -trimethyl- γ -oxo- (CA INDEX NAME)


RN 882565-51-7 CAPLUS

CN 1-Butanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 882565-52-8 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]tetrahydro-N-methyl- (CA INDEX NAME)




RN 882565-53-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 882565-54-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
α-(phenylmethyl)- (CA INDEX NAME)


RN 882565-55-1 CAPLUS

CN Urea, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N',N'-trimethyl- (CA INDEX NAME)




RN 882565-56-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 882565-57-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 882565-58-4 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 882565-59-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)




RN 882565-60-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methyl-3-piperidinyl)- (CA INDEX NAME)



RN 882565-61-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 882565-62-0 CAPLUS


CN Ethanone, 1-[(2S)-2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-63-1 CAPLUS

CN Ethanone, 1-(1-azetidinyl)-2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882565-64-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(tetrahydro-3-furanyl)amino]- (CA INDEX NAME)




RN 882565-65-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)



RN 882565-66-4 CAPLUS

CN 2(3H)-Furanone, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]dihydro- (CA INDEX NAME)



IT 882565-67-5P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882565-68-6P, tert-Butyl 3-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidine-1-carboxylate
 882565-69-7P, N-[1-[(Azetidin-3-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-70-0P, tert-Butyl 3-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidine-1-carboxylate
 882565-71-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(isopropylamino)acetyl]piperidin-4-yl]pyrimidin-2-amine
 882565-72-2P, tert-Butyl 3-[[2-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]azetidine-1-carboxylate 882565-73-3P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(tetrahydro-2H-pyran-4-yl)piperidine-1-carboxamide 882565-74-4P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyrrolidin-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-75-5P 882565-76-6P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]butanoic acid 882565-77-7P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethanol 882565-78-8P, N-[2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethyl]acetamide 882565-79-9P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]-1-phenylethanol 882565-80-2P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]cyclohexanol 882565-81-3P, 4-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]butan-1-ol 882565-82-4P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethanol 882565-83-5P, 4-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]piperazin-2-one 882565-84-6P 882565-85-7P, 4-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]butan-2-ol 882565-86-8P, 2-[[tert-Butyl] [2-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethanol 882565-87-9P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]acetamide 882565-88-0P, 6-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]hexan-1-ol 882565-89-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882565-90-4P, 5-Chloro-N-[1-[[[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]amino]acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-91-5P, [1-[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-2-yl]methanol 882565-92-6P, 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]-3-methylpentan-1-ol 882565-93-7P, 1-[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-ol 882565-94-8P, N-[1-[(1-Acetylpyrrolidin-3-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-95-9P 882565-96-0P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[[methyl] (tetrahydro-2H-pyran-4-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882565-97-1P, N-[1-[(Azetidin-3-yl)amino]acetyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-

yl)pyrimidin-2-amine 882565-98-2P,
 1-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidin-3-ol 882565-99-3P,
 2-[3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidin-1-yl]-N-methylacetamide 882566-02-1P
 882566-03-2P, N-(Azetidin-3-yl)-4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882566-04-3P,
 tert-Butyl 3-[[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]amino]piperidine-1-carboxylate 882566-05-4P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1H-tetrazol-5-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-06-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(1-oxidopyridin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882566-07-6P,
 5-Chloro-N-[1-[(5,5-dimethylmorpholin-2-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882566-08-7P,
 5-Chloro-N-[1-[(1H-imidazol-5-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882566-18-9P,
 5-Chloro-4-(1-methyl-1H-indol-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine 882566-19-0P, 2-[4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-20-3P,
 4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-21-4P,
 5-Chloro-N-[1-[(dimethylamino)acetyl]piperidin-4-yl]-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine 882566-22-5P,
 4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-4-yl)piperidine-1-carboxamide 882566-23-6P,
 4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-24-7P 882566-25-8P
 , N-[2-[4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882566-26-9P,
 5-Chloro-4-(1H-indol-1-yl)-N-[1-[(methylamino)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-27-0P,
 5-Chloro-N-[1-[(dimethylamino)acetyl]piperidin-4-yl]-4-(1H-indol-1-yl)pyrimidin-2-amine 882566-28-1P, tert-Butyl
 4-[[4-(4-cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-29-2P, 2-[4-[[5-Chloro-4-(4-cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-30-5P,
 2-[4-[[4-(4-Cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-31-6P 882566-32-7P,
 2-[4-[[5-Chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-33-8P,
 tert-Butyl 4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-34-9P, tert-Butyl
 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-35-0P,
 N-Methyl-2-[4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882566-36-1P, tert-Butyl
 4-[[4-(4-amino-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-37-2P, tert-Butyl 4-[[4-(4-amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-38-3P
 , 4-[[4-(4-Amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-39-4P,
 4-[[4-(4-Amino-1H-indol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-40-7P,
 2-[4-[[4-(4-Amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-41-8P,
 2-[4-[[4-(4-Amino-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-

methylacetamide 882566-42-9P, tert-Butyl
 4-[[4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-43-0P,
 4-[[5-Chloro-4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]-N-
 ethylpiperidine-1-carboxamide 882566-44-1P,
 2-[4-[[5-Chloro-4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-
 1-yl]-N-methylacetamide 882566-45-2P,
 N-Ethyl-4-[[4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-
 carboxamide 882566-46-3P,
 2-[4-[[4-(4-Methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-
 methylacetamide 882566-47-4P, tert-Butyl
 4-[[5-chloro-4-[4-(dimethylamino)-1H-indol-1-yl]pyrimidin-2-
 yl]amino]piperidine-1-carboxylate 882566-48-5P, tert-Butyl
 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-49-6P,
 4-[[4-[4-(Dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]-N-
 ethylpiperidine-1-carboxamide 882566-50-9P,
 2-[4-[[4-[4-(Dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidin-1-
 yl]-N-methylacetamide 882566-51-0P, tert-Butyl
 4-[[4-[4-(aminocarbonyl)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-52-1P,
 1-[2-[[1-[2-(Methylamino)-2-oxoethyl]piperidin-4-yl]amino]pyrimidin-4-yl]-
 1H-indole-4-carboxamide 882566-53-2P,
 N-Methyl-2-[4-[[4-(1H-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-
 yl]amino]piperidin-1-yl]acetamide 882566-57-6P,
 N-[1-(3-Furanylcarbonyl)piperidin-4-yl]-4-(imidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-amine 882566-58-7P,
 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-
 N-methyl-2-phenylacetamide 882566-59-8P,
 6-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-
 yl]nicotinonitrile 882566-60-1P,
 4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-N-
 methoxypiperidine-1-carboxamide 882566-61-2P
 882566-62-3P, 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(morpholin-4-
 yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-63-4P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-
 yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882566-64-5P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(3-methylisoxazol-5-
 yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-65-6P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(3-methylbutanoyl)piperidin-4-
 yl]pyrimidin-2-amine 882566-66-7P,
 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-
 2-(piperidin-4-yl)acetamide 882566-67-8P,
 N-[1-[(Dimethylamino)acetyl]piperidin-4-yl]-4-(imidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-amine 882566-68-9P,
 4-(6-Bromoimidazo[1,2-a]pyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine
 882566-69-0P, 2-[4-[[4-(6-Bromoimidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide
 882566-70-3P, 2-[4-[[4-(8-Bromoimidazo[1,2-a]pyridin-2-
 yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide
 882566-71-4P, N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-
 methoxypyrimidin-2-yl]amino]piperidine-1-carboxamide 882566-72-5P
 , 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)-5-methoxypyrimidin-2-
 yl]amino]piperidin-1-yl]-N-methylacetamide 882566-85-0P
 882566-91-8P 882566-92-9P 882566-98-5P
 882566-99-6P 882567-00-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882565-67-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 882565-68-6 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882565-69-7 CAPLUS


CN Methanone, 3-azetidiny[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882565-70-0 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-1-piperidiny]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-71-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-[(1-methylethyl)amino]- (CA INDEX NAME)



RN 882565-72-2 CAPLUS


CN 1-Azetidinecarboxylic acid, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-oxoethyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882565-73-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 882565-74-4 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-3-pyrrolidiny- (CA INDEX NAME)



RN 882565-75-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-oxoethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-76-6 CAPLUS

CN Butanoic acid, 2-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]- (CA INDEX NAME)




RN 882565-77-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxyethyl)propylamino]- (CA INDEX NAME)




RN 882565-78-8 CAPLUS

CN Acetamide, N-[2-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]ethyl]- (CA INDEX NAME)




RN 882565-79-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-2-phenylethyl)amino]- (CA INDEX NAME)




RN 882565-80-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxycyclohexyl)amino]- (CA INDEX NAME)




RN 882565-81-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[ethyl(4-hydroxybutyl)amino]- (CA INDEX NAME)




RN 882565-82-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxyethyl)(2-methylbutyl)amino]- (CA INDEX NAME)



RN 882565-83-5 CAPLUS


CN 2-Piperazinone, 4-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 882565-84-6 CAPLUS


CN L-Serine, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-85-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3-hydroxybutyl)amino]- (CA INDEX NAME)




RN 882565-86-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1,1-dimethylethyl)(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882565-87-9 CAPLUS

CN Acetamide, 2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]methylamino]- (CA INDEX NAME)




RN 882565-88-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(6-hydroxyhexyl)amino]- (CA INDEX NAME)




RN 882565-92-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)-2-methylbutyl]amino]- (CA INDEX NAME)




RN 882565-93-7 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[(3-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 882565-94-8 CAPLUS


CN Ethanone, 1-[3-[[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 882565-95-9 CAPLUS


CN Ethanone, 1-[(2S)-2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4-hydroxy-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-96-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 882565-97-1 CAPLUS

CN Ethanone, 2-(3-azetidinylamino)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882565-98-2 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxy-1-azetidiny)- (CA INDEX NAME)



RN 882565-99-3 CAPLUS

CN 1-Azetidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl- (CA INDEX NAME)




RN 882566-02-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl-, (+)- (CA INDEX NAME)


NAME)

Rotation (+).




RN 882566-03-2 CAPLUS

CN 1-Piperidinecarboxamide, N-3-azetidinyl-4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-04-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-05-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 882566-06-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(1-oxido-2-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882566-07-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(5,5-dimethyl-2-morpholinyl)- (CA INDEX NAME)




RN 882566-08-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(1H-imidazol-5-yl)- (CA INDEX NAME)




RN 882566-18-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1-methyl-1H-indol-3-yl)-N-4-piperidinyl-
(CA INDEX NAME)


RN 882566-19-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-20-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-21-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882566-22-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-piperidinyl- (CA INDEX NAME)



RN 882566-23-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882566-24-7 CAPLUS


CN 1H-Indole-7-carbonitrile, 3-[5-chloro-2-[[1-[[[(2R)-5-oxo-2-pyrrolidinyl]carbonyl]-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882566-25-8 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-oxoethyl]- (CA INDEX NAME)




RN 882566-26-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)- (CA INDEX NAME)




RN 882566-27-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882566-28-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-29-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-30-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-31-6 CAPLUS

CN 1H-Indole-4-carbonitrile, 1-[2-[[1-[2-(dimethylamino)acetyl]-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 882566-32-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-33-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-34-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-35-0 CAPLUS

CN 1-Piperidineacetamide, N-methyl-4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-36-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-37-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-38-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-39-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-40-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-41-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-42-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-43-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-44-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-45-2 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-46-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-47-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-48-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-49-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-50-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-51-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(aminocarbonyl)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-52-1 CAPLUS

CN 1H-Indole-4-carboxamide, 1-[2-[[1-[2-(methylamino)-2-oxoethyl]-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 882566-53-2 CAPLUS

CN 1-Piperidineacetamide, N-methyl-4-[[4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-57-6 CAPLUS

CN Methanone, 3-furanyl[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882566-58-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl-α-phenyl- (CA INDEX NAME)




RN 882566-59-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882566-60-1 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-methoxy-1-piperidinyl]carbonyl]-, (4S)- (CA INDEX NAME)



RN 882566-61-2 CAPLUS


CN 2-Oxazolidinone, 4-[[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]carbonyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882566-62-3 CAPLUS

CN Ethanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 882566-63-4 CAPLUS

CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](1-methyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 882566-64-5 CAPLUS

CN Ethanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 882566-65-6 CAPLUS

CN 1-Butanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 882566-66-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-α-4-piperidinyl- (CA INDEX NAME)




RN 882566-67-8 CAPLUS

CN Ethanone, 2-(dimethylamino)-1-[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl- (CA INDEX NAME)




RN 882566-68-9 CAPLUS

CN 2-Pyrimidinamine, 4-(6-bromoimidazo[1,2-a]pyridin-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 882566-69-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(6-bromoimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-70-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(8-bromoimidazo[1,2-a]pyridin-2-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-71-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methoxy-2-pyrimidinyl)amino]- (CA INDEX NAME)




RN 882566-72-5 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methoxy-2-pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)



RN 882566-85-0 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-pyrazolo[1,5-a]pyridin-3-yl-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 882566-91-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-92-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 882566-98-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 882566-99-6 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
α-4-piperidinyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882567-00-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
α-4-piperidinyl-, (-)- (CA INDEX NAME)

Rotation (-).



IT 882566-89-4P 882566-90-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidines as JNK inhibitors)

RN 882566-89-4 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-90-7 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 34 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:74802 CAPLUS
 DN 144:171004
 TI Preparation of 4-(2- or 3-furyl)pyrimidine derivatives, and pharmaceutical compositions and antitumor agents containing them
 IN Miyazaki, Isao; Murakami, Koji
 PA Taiho Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006022073	A	20060126	JP 2004-203695	20040709
PRAI	JP 2004-203695		20040709		
OS	MARPAT 144:171004				


AB The derivs. I [X, Y = H, halo, lower alkyl, lower alkoxy, (un)substituted aryl, heteroaryl, NO₂, cyano, trihalomethyl, NR₁R₂, CO₂R₃, S(O)_nR₄, NHCOR₅, CONR₆R₇, COR₈, CH₂OR₉, CH:CHR₁₀, CH:CHCO₂R₁₁, CH:CHCONHR₁₂ [R₁-R₄, R₆, R₇, R₉ = H, lower alkyl, (un)substituted aryl, heteroaryl, (un)substituted aralkyl, heteroaralkyl; NR₆R₇ may be 4-7-membered heteroalicycyl; R₅ = lower alkyl, (un)substituted aryl; R₈ = H, lower alkyl; R₁₀, R₁₂ = (un)substituted aryl, heteroaryl; R₁₁ = H, lower alkyl; n = 0-2]; A = NZN (Z = C₂-10 linear, branched, or cyclic alkylene, wherein 1 or 2 N atoms may form 4-7-membered N-containing heteroalicycyl together with Z); B = CO, SO₂; C = (un)substituted aryl, heteroaryl, (α-lower alkyl)benzyl] or their salts are claimed. Also claimed are pharmaceutical compns. and antitumor agents containing I or their salts. Thus, IC₅₀ of 4-(2-furyl)-2-[1-[4-(2-methoxy-4-methylbenzenesulfonyl)piperazino]]pyrimidine (II), prepared from 4-(2-furyl)-2-piperazinopyrimidine and 2-methoxy-4-methylbenzenesulfonyl chloride, against proliferation of human hepatoma JHH-7 cells was 0.23 μM, vs. 0.99 μM of BAY 43-9006. IC₅₀ of I on proliferation of normal hepatic cell was ≥30 μM, vs. 3.46 μM of BAY 43-9006.

IT 874114-13-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of furylpyrimidine derivs. as antitumor agents)

RN 874114-13-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,4-difluorophenyl)sulfonyl]-4-piperidiny]-4-(2-furanyl)- (CA INDEX NAME)




L17 ANSWER 35 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1314210 CAPLUS
 DN 144:51578
 TI Preparation of mercaptoimidazoles as CCR2 receptor antagonists for the
 treatment of inflammatory disease
 IN Boeckx, Gustaaf Maria; Van Lommen, Guy Rosalia Eugene; Doyon, Julien
 Georges Pierre-Olivier; Coesemans, Erwin
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005118574	A1	20051215	WO 2005-EP52373	20050524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005250157	A1	20051215	AU 2005-250157	20050524
	CA 2565280	A1	20051215	CA 2005-2565280	20050524
	EP 1756089	A1	20070228	EP 2005-749653	20050524
	EP 1756089	B1	20081022		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1956976	A	20070502	CN 2005-80016545	20050524
	JP 2008500311	T	20080110	JP 2007-513923	20050524
	AT 411989	T	20081115	AT 2005-749653	20050524
	US 20070244138	A1	20071018	US 2006-569321	20061117
	IN 2006DN06982	A	20070713	IN 2006-DN6982	20061122
PRAI	WO 2004-EP50935	A	20040526		
	WO 2005-EP52373	W	20050524		

OS CASREACT 144:51578; MARPAT 144:51578

AB The invention relates to compds. I, N-oxides, pharmaceutically acceptable addition salts, quaternary amines, polymorphic forms or stereochem. isomeric forms thereof, wherein R1 = H, (un)substituted alkyl, cycloalkyl or (hetero)aryl; R2 independently = halo, alkyl(oxy/thio), etc.; R3 = H, cyano, etc.; R4 = H or alkyl; n = 1-5; Z = certain cycle ring. The invention also relates to processes for preparing I, their use as CCR2 antagonists and pharmaceutical compns. comprising them. For instance, II was synthesized in multiple steps from 1-(3,4-dichlorophenyl)-1-propanone. The CCR2 antagonistic activities of I were demonstrated by three assays, inhibition of MCP-1-induced Ca-flux in human THP-1 cells, 125I-MCP-1 binding assay and chemotactic response of cells in the presence of MCP-1. Therefore, I and their pharmaceutical compns. are useful for preventing or treating diseases mediated through activation of the CCR2 receptor, such as inflammation.

IT 871343-86-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of mercaptoimidazoles as CCR2 receptor antagonists for the
 treatment of inflammatory disease)
 RN 871343-86-1 CAPLUS
 CN 2H-Imidazole-2-thione, 1-[1-(3,4-dichlorophenyl)propyl]-1,3-dihydro-5-[2-
 (4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 36 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1289687 CAPLUS

DN 144:51568

TI Preparation of substituted 2-quinolyl-oxazoles and their heterocyclic analogs useful as pde4 inhibitors

IN Kuang, Rongze; Blythin, David; Shih, Neng-Yang; Shue, Ho-Jane; Chen, Xiao; Cao, Jianhua; Gu, Danlin; Huang, Ying; Schwerdt, John H.; Ting, Pauline C.; Wong, Shing-Chun; Xiao, Li

PA Schering Corporation, USA

SO PCT Int. Appl., 233 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116009	A1	20051208	WO 2005-US17134	20050516
	W:	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005247906	A1	20051208	AU 2005-247906	20050516
	CA 2565599	A1	20051208	CA 2005-2565599	20050516
	US 20060106062	A1	20060518	US 2005-130359	20050516
	EP 1758883	A1	20070307	EP 2005-750076	20050516
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	CN 1984901	A	20070620	CN 2005-80023666	20050516
	BR 2005011295	A	20071204	BR 2005-11295	20050516
	JP 2007537300	T	20071220	JP 2007-513471	20050516
	TW 286475	B	20070911	TW 2005-94115924	20050517
	MX 2006PA13414	A	20070123	MX 2006-PA13414	20061117
	KR 2007013306	A	20070130	KR 2006-724186	20061117
	IN 2006CN04254	A	20070629	IN 2006-CN4254	20061117
	NO 2006005830	A	20070216	NO 2006-5830	20061215
PRAI	US 2004-572266P	P	20040518		
	WO 2005-US17134	W	20050516		

OS CASREACT 144:51568; MARPAT 144:51568

AB Title compds. I [R1 = H, alkyl, cycloalkyl; R2, R3 and R5 independently = H or halo; R4 = H, halo, alkyl, etc.; A = substituted oxazolyl, imidazole, thiazole or pyrrole], and their pharmaceutically acceptable salts, are prepared and disclosed as pde4 inhibitors. Thus, e.g., II was prepared in a multistep synthesis from 2-trifluoromethyl-8-methoxyquinolin-5-yl carboxylic acid. In PDE4 assays, selected compds. possessed IC50 values ranging from 0.01-1.8 nM. Also claimed are pharmaceutical compns., the use of the compds. as PDE4 inhibitors, and combinations with other actives.

IT 871009-86-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinolyloxazoles and their heterocyclic analogs useful as PDE4 inhibitors)

RN 871009-86-8 CAPLUS

CN Methanone, [5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinolinyl]-4-oxazolyl][4-[[4-(2,6-difluorophenyl)-2-pyrimidinyl]amino]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 37 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1260610 CAPLUS

DN 144:22946

TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases

IN Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.

PA Amgen Inc., USA

SO PCT Int. Appl., 540 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113494	A2	20051201	WO 2005-US16346	20050509
	WO 2005113494	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005245386	A1	20051201	AU 2005-245386	20050509
	CA 2564355	A1	20051201	CA 2005-2564355	20050509
	US 20060009453	A1	20060112	US 2005-126000	20050509
	EP 1751136	A2	20070214	EP 2005-779977	20050509
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2007536280	T	20071213	JP 2007-511723	20050509
	MX 2006PA12613	A	20070131	MX 2006-PA12613	20061031
PRAI	US 2004-569193P	P	20040507		
	WO 2005-US16346	W	20050509		

OS MARPAT 144:22946

AB The present invention relates to nitrogen-heteroaryl-containing compounds. (shown as I; variables defined below; e.g.

4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]-N-[3-[(tetrahydrofuran-2-yl)methoxy]-5-trifluoromethylphenyl]benzamide (shown as II)) and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases. For I: A is N or CR10; B is N or CR11; D is N or CR12; E is N or


CH; G is NR13, O, S, C(O), S(O), SO2, CR13R13 or CR13R14; H1 is N or CR5; H2 is N or CR6; H3 is N or CR7; H4 is N or CR5; H5 is N or CR9; R1 is H, halo, haloalkyl, NO2, CN, NR13R13, OR13, SR13 (CH13)nR13, or R15; alternatively R1 taken together with R10 forms a partially or fully unsatd. 5- or 6-membered ring of C atoms optionally including 1-3 heteroatoms = O, N and S, and the ring (un)substituted; R2 is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; each of R3 and R4, independently, is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, prepns. and/or characterization data for >1200 examples of I and intermediates are included. For example, II was prepared in 2 steps starting with condensation of 4-(2-chloropyridin-3-yl)pyrimidine (preparation given) with 3-amino-4-fluorobenzoic acid in Et3N-TFA to give 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]benzoic acid, which was condensed with [3-[(trifluoromethyl)phenyl]amino]-5-trifluoromethylphenylamine using EDC and DMAP in DMF.

IT 870233-05-9P, N-[3-Methyl-4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-3-(trifluoromethyl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)

RN 870233-05-9 CAPLUS

CN Benzamide, N-[3-methyl-4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 38 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1193341 CAPLUS
 DN 143:460148
 TI Preparation of 4-[2-(cycloalkylamino)pyrimidin-4-yl]-3-phenylimidazolin-2-one derivatives as p38 MAP-kinase inhibitors for the treatment of inflammatory diseases
 IN Kubo, Akira; Nakane, Tetsu; Nakajima, Tatsuo; Murakami, Takanori; Miyoshi, Hidetaka; Ogasawara, Akihito
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105790	A1	20051110	WO 2005-JP8564	20050428
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005238390	A1	20051110	AU 2005-238390	20050428
	CA 2563042	A1	20051110	CA 2005-2563042	20050428
	EP 1740578	A1	20070110	EP 2005-738662	20050428
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	BR 2005010335	A	20071023	BR 2005-10335	20050428
	JP 2007535476	T	20071206	JP 2006-519531	20050428
	NO 2006004175	A	20061213	NO 2006-4175	20060915
	CN 101146797	A	20080319	CN 2005-80012938	20061024
	US 20070185326	A1	20070809	US 2006-587498	20061026
	MX 2006PA12512	A	20070208	MX 2006-PA12512	20061027
	KR 2006135965	A	20061229	KR 2006-724928	20061127
	KR 793479	B1	20080114		
PRAI	JP 2004-133204	A	20040428		
	US 2004-566089P	P	20040429		
	JP 2005-7832	A	20050114		
	WO 2005-JP8564	W	20050428		
OS	CASREACT 143:460148; MARPAT 143:460148				
AB	The invention provides novel heterocyclic compds. I [wherein: R1 is a halogen, nitro, alkyl, etc.; p is 1 or 2; A is 2-oxo-4-imidazolin-3,4-diyl, etc.; X is CH or N; Z is O, NR2; R2 is H, alkyl, etc.; B is cycloalkyl or monocyclic saturated heterocyclic group; Y is single bond, CO, SO2; and E is an aryl or heterocyclic group; or a pharmaceutically acceptable salt thereof], which are useful as p38 MAP kinase inhibitors. Approx. 135 compds. I were prepared, as well as some intermediates. For instance, reaction of sulfoxide II with the corresponding trans-isomeric cyclohexylamine derivative at 90° in dioxane for 5 days gave invention compound III, isolated as the				

monohydrochloride. In an in-vivo test for inhibition of LPS-induced TNF- α production in rats, invention compound IV.HCl gave 100% inhibition at 5 mg/kg orally.


IT 1044974-04-0 1044974-05-1 1044974-06-2
 1044974-07-3 1044974-08-4 1044974-09-5
 1044974-10-8 1044974-11-9 1044974-12-0
 1044974-13-1 1044974-14-2 1044974-15-3
 1044974-16-4 1044975-15-6 1044975-16-7
 1044975-17-8 1044975-18-9 1044975-19-0
 1044975-20-3 1044975-21-4 1044975-22-5
 1044975-23-6 1044975-24-7 1044975-25-8
 1044975-26-9 1044975-27-0 1044975-28-1
 1044996-99-7 1044997-00-3 1044997-01-4
 1044997-02-5 1044997-03-6 1044997-04-7
 1044997-05-8 1044997-06-9 1044997-07-0
 1044997-08-1 1044997-09-2 1044997-10-5
 1044997-11-6 1044997-12-7 1044997-13-8
 1044997-14-9 1044997-15-0 1044997-16-1
 1044997-17-2 1044997-18-3 1044997-19-4
 1044997-20-7 1044997-21-8 1044998-19-7
 1044998-20-0 1044998-21-1 1044998-22-2
 1044998-23-3 1044998-24-4 1044998-25-5
 1048020-53-6 1048022-13-4

RL: PRPH (Prophetic)

(Preparation of 4-[2-(cycloalkylamino)pyrimidin-4-yl]-3-phenylimidazolin-2-one derivatives as p38 MAP-kinase inhibitors for the treatment of inflammatory diseases)


RN 1044974-04-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-05-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-06-2 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044974-07-3 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(4-morpholinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044974-08-4 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-09-5 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-10-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1044974-11-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044974-12-0 CAPLUS
CN 2H-imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-13-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-4-[2-[[1-(2-thiazolyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1044974-14-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-15-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-16-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(4-morpholinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-15-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-16-7 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1044975-17-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044975-18-9 CAPLUS
CN 2H-Imidazol-2-one, 4-[2-[[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-19-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-20-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-4-[2-[[1-(2-thiazolyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1044975-21-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1044975-22-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044975-23-6 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[(1-(4-morpholinyl)-4-piperidinyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-24-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-25-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-26-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044975-27-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-28-1 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044996-99-7 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-([1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino)-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)



RN 1044997-00-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1044997-01-4 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-([1,1'-bipiperidin]-4-ylamino)-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-02-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-03-6 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-04-7 CAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-[(1-methyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1044997-05-8 CAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-06-9 CAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-07-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-oxazolyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-08-1 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-09-2 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1044997-10-5 CAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-oxo-1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-11-6 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-([1,1'-bipiperidin]-4-ylamino)-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-12-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-13-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-14-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-15-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-16-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-17-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-oxazolyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-18-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-19-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-20-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-oxo-1-pyrrolidinyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-21-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044998-19-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-20-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(phenylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-21-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-22-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044998-23-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-24-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044998-25-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1048020-53-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(1H-pyrazol-5-yl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 1048022-13-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1H-pyrazol-3-yl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




IT 869220-92-8P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-34-1P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,3,5-trimethylpyrazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-35-2P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,2-dimethylimidazol-5-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-36-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-37-4P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(phenylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-38-5P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(naphthalen-2-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-39-6P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(pyridin-2-yl)carbonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869222-25-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(cycloalkylamino)pyrimidinyl]phenylimidazolinone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)


RN 869220-92-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 869221-34-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-35-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-36-3 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]amino]-3-(4-fluorophenyl)-1,3-dihydro-1H-imidazol-2-one], hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-37-4 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1H-imidazol-2-one, 4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-38-5 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-naphthalenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-39-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 869222-25-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 775575-82-1, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of

[(cycloalkylamino)pyrimidinyl]phenylimidazolinone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)

RN 775575-82-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1154546 CAPLUS

DN 143:422365

TI Preparation of diarylpyridazines and -pyrimidines as inhibitors of serine/threonine kinase (Akt kinase) activity.

PA Merck & Co., Inc., USA; Bilodeau, Mark T.; Chua, Peter C.; Cosford, Nicholas D. P.; Hoffman, Jacob M.; Nagasawa, Johnny Yasuo

SO PCT Int. Appl., '72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100344	A1	20051027	WO 2005-US11687	20050405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, SZ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005233584	A1	20051027	AU 2005-233584	20050405
CA 2561311	A1	20051027	CA 2005-2561311	20050405
EP 1737843	A1	20070103	EP 2005-734336	20050405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1942465	A	20070404	CN 2005-80011976	20050405
JP 2007532558	T	20071115	JP 2007-507479	20050405
US 20080280889	A1	20081113	US 2006-547367	20060928
IN 2006DN06436	A	20070831	IN 2006-DN6436	20061101
PRAI US 2004-561167P	P	20040409		
WO 2005-US11687	W	20050405		

OS CASREACT 143:422365; MARPAT 143:422365

AB Title compds. [I; X = N, Y = CH, or X = CH, Y = N; n = 0-4; p = 0-5; R1, R2 = H, (substituted) alkyl, alkoxy, alkylcarbonyl, alkoxy carbonyl, alkynylalkoxy carbonyl, aryl, aryloxy, arylcarbonyl, aryloxy carbonyl, CO2H, cyano, halo, OH, amino, aminocarbonyl, O, perfluoroalkyl, perfluoroalkoxy, etc.], were prepared Thus, title compound (II) was prepared in 3 steps from 4-phenyl-3,6-dichloropyridazine, dimethylamine, 4-formylphenylboronic acid, and 2-(3-piperidine-4-yl-1H-pyrazol-5-yl)pyridine. Several I inhibited Akt1, Akt2, and/or Akt3 with IC50 ≤ 50 μM.

IT 868280-18-6P 868280-38-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyridazines and pyrimidines as inhibitors


of

serine/threonine kinase)

RN 868280-18-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-phenyl-4-[4-[[[4-(5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl)methyl]phenyl]-2-pyrimidinyl]amino]-,

ethyl ester (CA INDEX NAME)




RN 868280-38-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-phenyl-4-[[4-[[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-2-pyrimidinyl]amino]-, ethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 868280-18-6

CMF C37 H41 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 40 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1103779 CAPLUS

DN 143:387011

TI Preparation of azaindoles as inhibitors of JAK and other protein kinases

IN Salituro, Francesco; Farmer, Luc; Bethiel, Randy; Harrington, Edmund; Green, Jeremy; Court, John; Come, Jon; Lauffer, David; Aronov, Alex; Binch, Hayley; Boyall, Dean; Charrier, Jean-Damien; Everitt, Simon; Frayse, Damien; Mortimore, Michael; Pierard, Françoise; Robinson, Daniel

PA Vertex Pharmaceuticals Incorporated, USA; et al.

SO PCT Int. Appl., 432 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005095400	A1	20051013	WO 2005-US10846	20050330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005228904	A1	20051013	AU 2005-228904	20050330
	CA 2560454	A1	20051013	CA 2005-2560454	20050330
	EP 1730146	A1	20061213	EP 2005-756052	20050330
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	US 20070043063	A1	20070222	US 2005-93821	20050330
	CN 1938303	A	20070328	CN 2005-80010348	20050330
	BR 2005009369	A	20070911	BR 2005-9369	20050330
	JP 2007531760	T	20071108	JP 2007-506535	20050330
	MX 2006PA11327	A	20061215	MX 2006-PA11327	20061002
	IN 2006KN02852	A	20070608	IN 2006-KN2852	20061003
	NO 2006004852	A	20061024	NO 2006-4852	20061024
	KR 2007027542	A	20070309	KR 2006-722762	20061030
	JP 2008156370	A	20080710	JP 2008-60340	20080310
PRAI	US 2004-557503P	P	20040330		
	US 2004-625599P	P	20041105		
	JP 2007-506535	A3	20050330		
	WO 2005-US10846	W	20050330		


OS CASREACT 143:387011; MARPAT 143:387011

AB The title compds. I [R1 = TR', Si(R')3; R2-R4 = halo, CN, NO2, etc.; X1-X3 = N, CH (wherein the hydrogen atom of CH is optionally replaced by R5); x = 1-4; R5 = halo, CN, NO2, etc.; T = a bond, alkylidene, etc.; R' = H, alkyl, (hetero)cyclyl, etc.; with provisos] which are inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting with 7-azaindole, was given. The compds. I were tested against JAK2, JAK3, ROCK and Aurora kinases (data given). The invention also provides pharmaceutical compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 866545-69-9P 866545-70-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of azaindoles as inhibitors of JAK and other protein kinases)
 RN 866545-69-9 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(phenylmethyl)-4-piperidinyl]-4-(1H-pyrrolo[2,3-
 b]pyridin-3-yl)- (CA INDEX NAME)



RN 866545-70-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-
 pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 41 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1103772 CAPLUS

DN 143:386909

TI Substituted thiophene derivatives as anti-cancer agents, and their preparation, pharmaceutical compositions, and use as inhibitors of PKB/Akt, PKA, and CDC7.

IN Lin, Xiaodong; Rico, Alice; Zhou, Yasheen; Jefferson, Ann B.; Walter, Annette

PA Chiron Corporation, USA; Wang, Xiaojing Michael

SO PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005095386	A1	20051013	WO 2005-US10690	20050330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005228899	A1	20051013	AU 2005-228899	20050330
	CA 2561977	A1	20051013	CA 2005-2561977	20050330
	US 20050256121	A1	20051117	US 2005-95993	20050330
	EP 1732919	A1	20061220	EP 2005-760186	20050330
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1989131	A	20070627	CN 2005-80010575	20050330
	BR 2005008230	A	20070717	BR 2005-8230	20050330
	JP 2007531757	T	20071108	JP 2007-506511	20050330
	MX 2006PA10520	A	20070326	MX 2006-PA10520	20060914
	IN 2006KN02980	A	20070608	IN 2006-KN2980	20061016
	US 20080255120	A1	20081016	US 2008-129367	20080529
PRAI	US 2004-558342P	F	20040330		
	US 2005-95993	A3	20050330		
	WO 2005-US10690	W	20050330		

OS CASREACT 143:386909; MARPAT 143:386909

AB The invention relates to new substituted five-membered compds. I and their pharmaceutically acceptable salts, esters or prodrugs, compns. of the new compds. together with pharmaceutically acceptable carriers, and uses. In compds. I, A is N-containing heteroaryl with 5-6 ring atoms and 1-4 ring N atoms; n is 0-1; R is H, OH, (un)substituted (cyclo)alkyl, SO₂R⁷ (R⁷ is C1-C5 alkyl or substituted alkyl), alkoxy, CO₂H or esters, NO₂, (un)substituted (hetero)aryl or heterocyclyl, acylamino, or acyl; R¹ is (independently) halo, cyano, NO₂, OH, SH, (un)substituted: NH₂, alkoxy, (hetero)aryloxy, alkylthio, CONH₂, acylamino, (hetero)aryl, heterocyclyl, or alkyl; m is 0-2; R₂ and R₄ are independently H, (un)substituted: cycloalkyl, heterocyclyl, (hetero)aryl, alk(en/yn)yl, alkoxy, OH, (di)(alkyl)amino; with the proviso that one R₂ or R₄ is H under some

circumstances; R3 is H, alkyl, and (un)substituted (C1-5 alkylene)p-Z; Z is (un)substituted alkyl, alkylamino, (un)substituted alkoxy, cycloalkyl, (un)substituted heterocyclyl or (hetero)aryl; p is 0-1; Q is (un)substituted or thio-analogous CONH, CH2NH, NHCO, NHCO2, NHCONH, OCONH, CO2, CH:CH, C.tplbond.C, SO2NH, or SONH; where QR3 and R4 may form an (un)substituted heterocyclic ring; W is O, S, SO, or SO2; with provisos, and including pharmaceutically acceptable salts, esters and/or prodrugs. Over 370 compds. I were prepared, and these compds. are claimed individually. The compds. are inhibitors of Akt, PKA, and CDC7 protein kinases (no data), and are thus useful in the treatment of cancer. For example, 5-acetyl-2-thiophenecarboxylic acid was activated with CDI and amidated with 4-fluorophenethylamine to give the corresponding amide. The acetyl group of the amide was converted to a vinylogous enamine using DMF di-Me acetal, and this was condensed with methylguanidine HCl to give invention compound II.


IT 866522-78-3P, N-[2-(2,4-Dichlorophenyl)ethyl]-5-[2-(pyridin-4-ylamino)pyrimidin-4-yl]thiophene-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted thiophene derivs. as PKB/Akt, PKA, and CDC7 inhibitors for treatment of cancer)

RN 866522-78-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 42 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:902688 CAPLUS

DN 143:248403

TI Preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins

IN Hasegawa, Masaichi; Takada, Mio; Washio, Yoshiaki

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 85 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005076854	A2	20050825	WO 2005-US2972	20050203
	WO 2005076854	A3	20051222		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1713793	A2	20061025	EP 2005-712420	20050203
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
	JP 2007520558	T	20070726	JP 2006-552188	20050203
	US 20070117818	A1	20070524	US 2006-588527	20060804
PRAI	US 2004-542090P	P	20040204		
	WO 2005-US2972	W	20050203		
OS	CASREACT 143:248403; MARPAT 143:248403				
AB	The title compds. I [R1 = quinolinyl, benzodioxolanyl, benzimidazolyl, etc.; R2 = pyridyl, benzimidazolyl, indazolyl, etc.], useful for inhibiting hYAK3 proteins, were prepared E.g., a multi-step synthesis of I [R1 = quinolin-6-yl; R2 = (CH2)2NH2], starting from 2,4,6-trichloropyrimidine and 6-(4,4,5,5-tetramethyl-1,3,2)dioxaborolan-2-yl)quinoline, was given. The compds. I were tested for their ability to inhibit the hYAK3 kinase (specific data were given for representative compds. I). The pharmaceutical composition comprising the compound I and methods				
	for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins by administering an ED of compound I were disclosed.				
IT	863327-70-2P 863328-15-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins)				
RN	863327-70-2 CAPLUS				
CN	2-Thiophenecarboxamide, N-[6-[1,6-dihydro-6-oxo-2-(4-pyridinylamino)-4-pyrimidinyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)				



RN 863328-15-8 CAPLUS

CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



L17 ANSWER 43 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:451383 CAPLUS

DN 142:482041

TI A preparation of bicyclic pyrazolone derivatives, useful as cytokine inhibitors

IN Clark, Michael Philip; Laughlin, Steven Karl; Golebiowski, Adam; Brugel, Todd Andrew; Sabat, Mark

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., '75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047287	A2	20050526	WO 2004-US37264	20041109
	WO 2005047287	A3	20050728		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004289691	A1	20050526	AU 2004-289691	20041109
	CA 2545781	A1	20050526	CA 2004-2545781	20041109
	EP 1682551	A2	20060726	EP 2004-810572	20041109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
	CN 1878772	A	20061213	CN 2004-80032839	20041109
	JP 2007510739	T	20070426	JP 2006-539725	20041109
	BR 2004016358	A	20070508	BR 2004-16358	20041109
	SG 147476	A1	20081128	SG 2008-8004	20041109
	KR 2006086391	A	20060731	KR 2006-708849	20060508
	KR 835152	B1	20080609		
	IN 2006DN02569	A	20070810	IN 2006-DN2569	20060508
	MX 2006PA05209	A	20060720	MX 2006-PA5209	20060509
	NO 2006002639	A	20060608	NO 2006-2639	20060608
PRAI	US 2003-518886P	P	20031110		
	WO 2004-US37264	W	20041109		
OS	CASREACT 142:482041; MARPAT 142:482041				
AB	The invention relates to a preparation of 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-one derivs. of formula I [wherein: R is O(CH ₂)0-5-alkyl, NH ₂ , or is O(CH ₂)0-5-aryl, etc.; R1 is (hetero)aryl; L is (CH ₂)0-2, (CH ₂)0-2-NH-(CH ₂)0-2, or (CH ₂)0-2-O-(CH ₂)0-2, etc.; R2 is H, (CH ₂)0-5-O-(CH ₂)0-5H, (CH ₂)0-5-NH ₂ , or (CH ₂)0-5-CO ₂ H, etc.; Z is O, S, NH, or N(alkyl), etc.] which inhibit the extracellular release of inflammatory cytokines. For instance, pyrazolone derivative II [R3 = NHCH(Me)CH ₂ OMe] was prepared via heterocyclization of ketoester III with pyrazolidine dihydrochloride, S-oxidation of the obtained pyrazolopyrazolone derivative II (R3 = SMe), and subsequent amination of the obtained methanesulfonylpyrimidine derivative II (R3 = SO ₂ Me) by				

(S)-1-methoxy-2-propylamine (the yield of the heterocyclization step was 10%). The preferred invention compds. exhibited activities (IC50) at a level below 1 μ M.


IT 1044958-03-3 1044958-06-6 1044958-11-3
 1044958-16-8 1044958-19-1 1044958-24-8
 1044958-50-0 1044958-57-7 1044958-61-3
 1044958-67-9 1044958-69-1 1044958-96-4

RL: PRPH (Prophetic)

(A preparation of bicyclic pyrazolone derivatives, useful as cytokine inhibitors)

RN 1044958-03-3 CAPLUS


CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-(2-methylphenoxy)-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)



the hetero ring is not "aromatic"


RN 1044958-06-6 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-(2-methylphenoxy)-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-11-3 CAPLUS


CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(2-chlorophenoxy)-6,7-dihydro-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-16-8 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenoxy)-6,7-dihydro-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-19-1 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenoxy)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-24-8 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(2-chlorophenoxy)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-50-0 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-[(2-methylphenyl)methyl]-3-[2-(4-piperidinylamino)-4-
 pyrimidinyl]- (CA INDEX NAME)




RN 1044958-57-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044958-61-3 CAPLUS
CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-[(2-chlorophenyl)methyl]-6,7-dihydro-3-[2-(4-pyridinylamino)-4-
pyrimidinyl]- (CA INDEX NAME)




RN 1044958-67-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044958-69-1 CAPLUS
CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,

2-[(4-fluorophenyl)methyl]-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1044958-96-4 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
6,7-dihydro-2-[(2-methylphenyl)methyl]-3-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



L17 ANSWER 44 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:395300 CAPLUS
 DN 142:430277
 TI Novel imidazole derivatives, their preparation and use as anticancer agents
 IN Honold, Konrad; Scheiblich, Stefan; Von Hirschheydt, Thomas; Voss, Edgar
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040154	A1	20050506	WO 2004-EP11598	20041015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Y, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050113342	A1	20050526	US 2004-961907	20041012
	US 7169781	B2	20070130		
	AU 2004283845	A1	20050506	AU 2004-283845	20041015
	CA 2538134	A1	20050506	CA 2004-2538134	20041015
	EP 1678163	A1	20060712	EP 2004-765966	20041015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1867563	A	20061122	CN 2004-80030583	20041015
	BR 2004015525	A	20061226	BR 2004-15525	20041015
	JP 2007508344	T	20070405	JP 2006-534696	20041015
	MX 2006PA03698	A	20060605	MX 2006-PA3698	20060331
	KR 2006063985	A	20060612	KR 2006-707335	20060417
	KR 796971	B1	20080122		
	IN 2006CN01307	A	20070629	IN 2006-CN1307	20060417
PRAI	EP 2003-23677	A	20031017		
	WO 2004-EP11598	W	20041015		

OS CASREACT 142:430277; MARPAT 142:430277

AB The invention relates a group of novel imidazole derivs. I, which are inhibitors of tyrosine kinases. In compds. I, K and L are independently selected from H, halo, alkyl, OH, and alkoxy; X is H, OH, alkoxy, mercapto, alkylthio, etc.; Y is (un)substituted aryl or heteroaryl; Z is halo, OH, alkoxy, allyloxy, alkyl, methylthio, etc.; and n is 1 or 2. The invention also relates to the preparation of I, pharmaceutical compns. containing

one or more compds. I as active ingredients, as well as to the use of the compns. for the treatment of disorders mediated by c-met or src tyrosine kinases, such as cancer. II, formed by the substitution of the Weinreb-amide of 3-chlorobenzoyl chloride with lithiated 4-methyl-2-(methylthio)pyrimidine, was converted to the α -keto oxime with nitrite. The oxime underwent cyclization with III (prepared by silylation of 3,5-dichlorobenzyl alc. followed by formylation and

desilylation) in the presence of NH₄OAc to form N-hydroxyimidazole IV. IV was reduced to give the corresponding NH-imidazole and then oxidized to convert the methylthio group into a methylsulfonyl group, which then underwent substitution with 4-[2-(diethylamino)ethoxy]aniline to give imidazole V. The compds. of the invention are inhibitors of src and C-met tyrosine kinases, and compound V has IC₅₀ values of 0.5 nM and 4 nM, resp.


IT 850919-12-9P, 2-(2,6-Dichlorophenyl)-4-(4-chlorophenyl)-5-[2-(4-pyridinylamino)pyrimidin-4-yl]-imidazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole derivs. and their use as anticancer agents)

RN 850919-12-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)-1H-imidazol-5-yl]-N-4-pyridinyl- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 45 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:300435 CAPLUS

DN 142:373859

TI Preparation of pyrimidine and pyridine derivatives useful as HMG-CoA reductase inhibitors

IN Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030758	A1	20050407	WO 2004-US31212	20040922
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050085497	A1	20050421	US 2004-946055	20040921
	US 7371759	B2	20080513		
	EP 1667997	A1	20060614	EP 2004-784885	20040922
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRAI	US 2003-505893P	P	20030925		
	WO 2004-US31212	W	20040922		
OS	CASREACT 142:373859; MARPAT 142:373859				
AB	Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetonide derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis [no data].				
IT	849469-93-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine and pyridine derivs. useful as HMG-CoA reductase inhibitors)				
RN	849469-93-8 CAPLUS				
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-(4-pyridinylamino)-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)				


Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 46 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:130195 CAPLUS
 DN 142:373790
 TI One-pot synthesis of polysubstituted pyrimidines
 AU Kiselyov, Alexander S.
 CS Chemical Diversity, Small Molecule Drug Discovery, San Diego, CA, 92121, USA
 SO Tetrahedron Letters (2005), 46(10), 1663-1665
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 142:373790
 AB A series of polysubstituted pyrimidines, e.g., I, were synthesized from in situ generated α,β -unsatd. imines and the corresponding amidine or guanidine derivs. in a convenient one-pot procedure. The pyrimidines were obtained in good yields.
 IT 849589-54-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of polysubstituted pyrimidines via addition of alkylphosphates to arylcarbonitriles followed by olefination with arylaldehydes and heterocyclization with amidines or guanidines)
 RN 849589-54-4 CAPLUS
 CN 2-Pyrimidinamine, 4-phenyl-6-(3-pyridinyl)-N-4-pyridinyl- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 47 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:71173 CAPLUS

DN 142:176866

TI Preparation of biaryl piperazinyl-pyridine analogues as capsaicin receptor modulators

IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Chenard, Bertrand L.; De Lombaert, Stephane; Hodgetts, Kevin J.; Hutchison, Alan; Yoon, Taeyoung; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 381 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007648	A2	20050127	WO 2004-US23064	20040716
	WO 2005007648	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004257289	A1	20050127	AU 2004-257289	20040716
	CA 2531619	A1	20050127	CA 2004-2531619	20040716
	EP 1644358	A2	20060412	EP 2004-778532	20040716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1823057	A	20060823	CN 2004-80020350	20040716
	US 20070027155	A1	20070201	US 2004-893799	20040716
	JP 2007534624	T	20071129	JP 2006-520390	20040716
PRAI	US 2003-488564P	P	20030716		
	US 2003-516135P	P	20031031		
	WO 2004-US23064	W	20040716		
OS	CASREACT 142:176866; MARPAT 142:176866				
AB	The title compds. I [Ar2 = (un)substituted Ph, 6-membered aromatic heterocycle; X, Y, Z = CRx, N (at least one of X, Y and Z = N); K, J, F = N, CH or carbon substituted with R1; Rx = H, alkyl, NH2, CN, mono or dialkylamino; R1 = halo, OH, NH2, CN, etc.; R3 = H, halo, phenylalkyl, cycloalkylalkyl, etc.; R4 = H, alkyl, haloalkyl, oxol, useful for treating conditions related to capsaicin receptor activation, were prepared E.g., a 2-step synthesis of II, starting from 2,4,6-trichloropyrimidine and morpholine, was given. The compds. I were evaluated for agonist and antagonist capsaicin receptor activity (data given). Pharmaceutical compns. and methods for using compds. I to treat disorders related to capsaicin receptor activation (pain, asthma, etc.), are provided, as are methods for using such ligands, for receptor localization studies.				
IT	833468-31-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833468-31-8 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chloro-4-fluorophenyl)-N-methyl-N-(1-methyl-4-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (CA INDEX NAME)



L17 ANSWER 48 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:1127326 CAPLUS

DN 142:74593

TI Preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38

IN Ashwell, Mark; Ali, Syed; Liu, Jifeng; Liu, Yanbin; Lohse, Peter; Mekonnen, Belew; Selliah, Robert; Tandon, Manish; Wrona, Woj

PA Arqule, Inc., USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110990	A2	20041223	WO 2004-US15368	20040514
	WO 2004110990	A3	20050324		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004247626	A1	20041223	AU 2004-247626	20040514
	CA 2526285	A1	20041223	CA 2004-2526285	20040514
	EP 1633758	A2	20060315	EP 2004-752390	20040514
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1823072	A	20060823	CN 2004-80019855	20040514
	JP 2006528983	T	20061228	JP 2006-533130	20040514
	MX 2005PA12377	A	20060525	MX 2005-PA12377	20051115
	IN 2005DN05250	A	20071130	IN 2005-DN5250	20051116
	US 20070270418	A1	20071122	US 2007-556161	20070419
PRAI	US 2003-470735P	P	20030515		
	US 2003-512298P	P	20031017		
	WO 2004-US15368	W	20040514		

not prior
no 102(e) date

OS MARPAT 142:74593

AB In general, the present invention relates to compds. I [X = O, S(O)m; Y = OR4, NR4R5; m = 0-2; n = 1-2; R1 = H, CN, CO2H, halo, etc.; Ar = aryl; R3 = H, halo, NH2, etc.; R4, R5 = H, alkyl, aryl, etc.; or NR4R5 = heterocyclic ring; with the proviso] capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity. E.g., a multi-step synthesis of II, starting from cyanamide and 2-hydroxyacetaldehyde, was given. The compds. I were tested for their biol. activity in various tests. Thus, it was found that compds. I inhibit ATF2 phosphorylation by p38 MAP kinase in vitro (specific data were given for over 300 compds. I). Also, the compds. I inhibit the release of TNF α , IL-1 β or both in in vitro assay (data given). The compds. I were tested in the collagen-induced model of arthritis in rats and showed dose-dependent inhibition of clin. and histopathol. parameters of arthritis, including inflammation and bone damage (data

given for representative compds. I). The pharmaceutical composition comprising the compound I is disclosed.


IT 956026-85-0 1066555-66-5

RL: PRPH (Prophetic)

(Preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38)


RN 956026-85-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1066555-66-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 815594-66-2P 815595-25-6P 815595-26-7P

815595-27-8P 815595-29-0P 815595-31-4P

815595-32-5P 815595-33-6P 815595-34-7P

815595-35-8P 815595-36-9P 815595-44-9P

815595-45-0P 815595-49-4P 815595-53-0P

815595-54-1P 815595-56-3P 815595-57-4P

815595-58-5P 815595-59-6P 815595-60-9P

815595-61-0P 815595-62-1P 815595-63-2P

815595-64-3P 815595-65-4P 815595-66-5P

815595-67-6P 815596-58-8P 815596-73-7P

815596-92-0P 815596-93-1P 815596-94-2P

815596-95-3P 815596-96-4P 815597-01-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38)

RN 815594-66-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-

5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 815595-25-6 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-26-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 815595-27-8 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 815595-29-0 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 815595-31-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-32-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

NAME)




RN 815595-33-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-36-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-44-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-45-0 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 815595-49-4 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-53-0 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-54-1 CAPLUS

CN Ethanone, 1-[4-[[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 815595-57-4 CAPLUS


CN Ethanone, 1-[4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-58-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 815595-59-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815595-60-9 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.




RN 815595-61-0 CAPLUS
 CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)



RN 815595-62-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-63-2 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 815595-64-3 CAPLUS

CN Ethanone, 1-[4-[[4-(6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-66-5 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-67-6 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-{6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl}-2-pyrimidinyl]- (CA INDEX NAME)



RN 815596-58-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-{6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl}-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 815596-73-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-{6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl}-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815596-92-0 CAPLUS

CN Methanone, (4-fluorophenyl) 4-[[4-[[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-93-1 CAPLUS

CN Ethanone, 1-[[4-[[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-94-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815596-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815597-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 49 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:1059317 CAPLUS
 DN 142:23305
 TI Preparation of trisubstituted heteroaromatic compounds as calcium sensing
 receptor modulators
 IN Yang, Wu; Dickson, John K.; Cooper, Christopher B.; Dodd, Dharmpal S.;
 Ruan, Zheming; Schnur, Dora M.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004106296	A2	20041209	WO 2004-US16713	20040527
	WO 2004106296	A3	20051222		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050004151	A1	20050106	US 2004-854484	20040526
	US 7459460	B2	20081202		
PRAI	US 2003-473904P	P	20030528		
OS	CASREACT 142:23305; MARPAT 142:23305				
AB	Title compds. I [X = C, N; A, B = CH, N and A and B cannot both be CH; R1 = ArL; R2 = H, alkyl or R1 and R2 can be joined to form a cycloheteroalkyl ring; Ar = (hetero)aryl; L = linking group; R3, R4, R6 = H, alkyl, cycloalkyl, etc.; R4 = alkyl, cycloalkyl, alkenyl, alkynyl, etc.; R7 = alkyl, cycloalkyl, etc.; R8 = H, alkyl or R7 and R8 can be joined together to form a 4-7 membered cycloheteroalkyl ring] are prepared For instance, II is prepared in 5 steps from pyrazole-1-carboxyimidine and benzylmethylamine. I are calcium-sensing receptor modulators; they are useful for the treatment of diseases associated with abnormal bone or mineral homeostasis.				
IT	802915-97-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of trisubstituted heteroarom. compds. as calcium sensing receptor modulators)				
RN	802915-97-5 CAPLUS				
CN	1-Piperidinecarboxylic acid, 4-[[5-[(2-phenoxyethyl)amino]carbonyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)				



L17 ANSWER 50 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:878380 CAPLUS

DN 141:379931

TI Preparation of aminopyrimidines as IKK inhibitors for treating autoimmune diseases and inflammations

IN Bollback, Birgit; Denholm, Alastair; Eder, Joerg; Hersperger, Rene; Janser, Philipp; Revesz, Laszlo; Schlapbach, Achim; Waelchli, Rudolf

PA Novartis Ag, Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 217 pp.

CODEN: PIXXD2

Applicant's

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004089913	A1	20041021	WO 2004-EP3819	20040408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004228352	A1	20041021	AU 2004-228352	20040408
AU 2004228352	B2	20080306		
CA 2521340	A1	20041021	CA 2004-2521340	20040408
EP 1615898	A1	20060118	EP 2004-726485	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009314	A	20060425	BR 2004-9314	20040408
CN 1802357	A	20060712	CN 2004-80016050	20040408
JP 2006522768	T	20061005	JP 2006-505087	20040408
US 20070043048	A1	20070222	US 2005-552317	20051007
IN 2005CN02563	A	20070831	IN 2005-CN2563	20051007
GB 2003-8466	A	20030411		
WO 2004-EP3819	W	20040408		

OS MARPAT 141:379931

AB Title compds. I [wherein R1 = H, (un)substituted lower alkyl, aryl, heterocycloalkyl, etc.; R2 = (un)substituted aryl, wherein aryl is not 4-(4-fluorophenyl)-1(1-methylpiperidin-4-yl)imidazole; each R3, R4 = independently H, CN, halo, OH, lower alkoxy, (un)substituted lower alkyl; X = CR6R7; Y = CR8R9; Z = CR10R11; W = CR12R13; each R6 to R13 = independently H, (un)substituted lower alkyl, lower alkoxy, CH2O-NH2, etc.; wherein at least one of R6 to R13 is not equal to H; any pair of R6 to R13 are joined together to form an (un)substituted C1 to C4 bridge in which one or more of the bridge atoms is optionally replaced by O, S, NH and derivs.; their pharmaceutically acceptable salts, esters or prodrugs] were prepared as inhibitors of IKK protein kinase (IKK) and production of tumor necrosis factor- α (TNF- α). For e.g., a 3-step synthesis of II was given. I showed IC50 values range of 20 to 1,000 nM in the IkB kinase activity assay. I, at 30 mg/kg p.o., i.v. or s.c., inhibited TNF- α production to the extent of up to about 50% or more in LPS stimulated mice. I are useful as immunosuppressants and antiinflammatory

agents.

IT 778643-81-5P, [4-[5-(3-Amino-3-methylbut-1-ynyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine

778644-21-6P, 1-[5'-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl][2,2']bithiophenyl-5-yl]ethanone

778644-27-2P, 1-[4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone O-methyloxime

778644-31-8P, 4-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester

778644-36-3P, [4-[5-[1-[2-(Piperidin-1-yl)ethyl]amino]methyl]thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-44-3P,

N-[5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methylmethanesulfonamide 778644-54-5P,

[4-[5-(1-Aminocyclohexylethynyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-62-5P,

3-[1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-71-6P,

[4-[5-(2-Aminoethyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-72-7P,

[4-(4,5,6,7-Tetrahydrobenzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-79-4P,

1-[4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone 778644-81-8P,

[4-(5-Chlorothiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-82-9P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester

778644-88-5P, 1-[5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]ethanone

778644-90-9P, [5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanol 778644-92-1P,

4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778644-95-4P,

3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzonitrile 778645-08-2P,

[4-[5-(Aminomethyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-09-3P,

[4-[5-(4-Aminomethylphenyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-16-2P,

3-[3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionic acid methyl ester 778645-20-8P,

1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-one 778645-21-9P,

1-Phenyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-one 778645-25-3P,

[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl] (1-benzylpiperidin-4-yl)amine 778645-26-4P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl] (piperidin-4-yl)amine 778645-27-5P,

3-[4-[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidin-1-yl]propionitrile 778645-28-6P,

[4-(6-Methoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-29-7P,

2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-ol 778645-32-2P,

[4-(6-(Oxiranylmethoxy)benzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-34-4P,


[4-(6-Methoxybenzo[b]thiophen-2-yl)-5-methylpyrimidin-2-yl] (2,2,6,6-

tetramethylpiperidin-4-yl)amine 778645-61-7P,
 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionic acid methyl ester 778645-65-1P,
 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-1-ol 778645-68-4P,
 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butyronitrile 778645-70-8P,
 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-one 778645-84-4P,
 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-3-carbonitrile 778645-86-6P,
 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-4-carbonitrile 778645-95-7P,
 [4-(6-Methoxy-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-97-9P, [4-(7-Methoxy-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-16-5P,
 [4-(7-Nitro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-30-3P, (E)-4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]-2-methylbut-3-en-2-ol 778646-31-4P, (E)-3-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]acrylonitrile 778646-32-5P,
 (E)-4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-methylbut-3-en-2-ol 778646-33-6P,
 (E)-3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]acrylonitrile 778646-34-7P,
 [4-(6-[(E)-2-(Imidazol-1-yl)ethenyl]-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-35-8P,
 (E)-3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acrylonitrile 778646-36-9P,
 (E)-N,N-Dimethyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-propenamide 778647-25-9P,
 [3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778643-81-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methyl-1-butyn-1-yl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-21-6 CAPLUS

CN Ethanone, 1-[5'-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2-bithiophen]-5-yl]- (CA INDEX NAME)




RN 778644-27-2 CAPLUS

CN Ethanone, 1-[4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]phenyl]-, O-methyl oxime (CA INDEX NAME)




RN 778644-31-8 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[5-bromo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-36-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[[[2-(1-piperidinyl)ethyl]amino]methyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-44-3 CAPLUS

CN Methanesulfonamide, N-[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]methyl]- (CA INDEX NAME)




RN 778644-54-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(1-aminocyclohexyl)ethynyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-62-5 CAPLUS

CN Propanenitrile, 3-[[[5-[2-(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)




RN 778644-71-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-aminoethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-72-7 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-79-4 CAPLUS

CN Ethanone, 1-[4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778644-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-chloro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-82-9 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-88-5 CAPLUS

CN Ethanone, 1-[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]- (CA INDEX NAME)




RN 778644-90-9 CAPLUS

CN 2-Thiophenemethanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-92-1 CAPLUS

CN 2-Thiophenebutanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-95-4 CAPLUS

CN Benzonitrile, 3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-08-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(aminomethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-09-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(aminomethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-16-2 CAPLUS

CN 2-Thiophenepropanoic acid, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-20-8 CAPLUS

CN 3-Pentanone, 1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-21-9 CAPLUS

CN 1-Propanone, 1-phenyl-3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-25-3 CAPLUS


CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-[1-(phenylmethyl)-4-piperidinyl]-
(CA INDEX NAME)

RN 778645-26-4 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-4-piperidinyl- (CA INDEX NAME)




RN 778645-27-5 CAPLUS

CN 1-Piperidinepropanenitrile, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-
(CA INDEX NAME)


RN 778645-28-6 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-29-7 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-32-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-oxiranylmethoxy)benzo[b]thien-2-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-34-4 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxybenzo[b]thien-2-yl)-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-61-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-65-1 CAPLUS

CN Benzenepropanol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-68-4 CAPLUS

CN Benzenebutanenitrile, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-70-8 CAPLUS

CN 2-Butanone, 4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778645-84-4 CAPLUS

CN 1H-Indole-3-carbonitrile, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-86-6 CAPLUS

CN 1H-Indole-4-carbonitrile, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-95-7 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxy-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-97-9 CAPLUS

CN 2-Pyrimidinamine, 4-(7-methoxy-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-16-5 CAPLUS


CN 2-Pyrimidinamine, 4-(7-nitro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-30-3 CAPLUS

CN 3-Buten-2-ol, 4-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-indol-6-yl]-2-methyl-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-31-4 CAPLUS

CN 2-Propenenitrile, 3-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-indol-6-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-32-5 CAPLUS

CN 3-Buten-2-ol, 4-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-2-methyl-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-33-6 CAPLUS

CN 2-Propenenitrile, 3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-6-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[(1E)-2-(1H-imidazol-1-yl)ethenyl]-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-35-8 CAPLUS

CN 2-Propenenitrile, 3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-36-9 CAPLUS


CN 2-Propenamide, N,N-dimethyl-3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 778647-25-9 CAPLUS

CN 1H-Indol-7-amine, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 778643-77-9P, 2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778643-78-0P, 4-[5-[5-Methoxy-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-2-methylbutan-2-ol 778643-79-1P, [4-[5-(4-Methoxybutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine hydrochloride 778643-80-4P, (E)-4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]but-3-en-2-ol 778643-82-6P, (E)-2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-1-but-3-en-2-ol 778643-83-7P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pyrrolidin-2-one 778643-84-8P, 4-[5-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778643-85-9P, 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-2-ol 778643-86-0P, 2,2-Dimethyl-N-methyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778643-87-1P, 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]pyrrol-1-yl]butan-2-ol 778643-88-2P, 2-[2-[(5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl)methyl]cyclopropyl]propan-2-ol 778643-89-3P, 2-[(1R,2R)-2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]cyclopropyl]propan-2-ol 778643-90-6P, 2-Ethoxy-2-methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-one 778643-91-7P, [4-[5-(3-Methoxypropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-92-8P, 2'-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]bicyclopropyl-1-ol 778643-93-9P, 4-[3-Methoxy-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-2-methylbutan-2-ol 778643-94-0P, [4-[5-(2-Amino-2-methylpropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-95-1P, 2,2-Difluoro-3-methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butane-1,3-diol 778643-96-2P, 2,3,3-Trimethyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778643-97-3P, [4-(5-Benzyloxythiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-98-4P, [4-[5-(Butyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-99-5P, [4-(5-Propoxythiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-00-1P, [4-[5-(2-Methoxyethoxy)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-01-2P, [4-[5-(Pyridin-4-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-02-3P, 1-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-

yl]thiophen-2-yl]piperidin-4-ol 778644-03-4P,
 [4-[5-(Pyridin-3-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-04-5P,
 [4-[5-(Pyridin-2-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-05-6P,
 [4-[5-(Piperazin-4-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-06-7P,
 4-[5-[2-[(8-Azabicyclo[3.2.1]oct-3-yl)exo-amino]pyrimidin-4-yl]thiophen-2-yl]-1-methylpiperidin-4-ol 778644-07-8P,
 8-Azabicyclo[3.2.1]oct-3-yl[4-[5-(piperazin-1-yl)thiophen-2-yl]pyrimidin-2-yl]exo-amine 778644-08-9P,
 [4-[5-(E)-3-Amino-3-methylbut-1-enyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-09-0P,
 [4-[5-(3-Amino-3-methylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-10-3P,
 2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-3-butyn-2-ol 778644-11-4P,
 [4-[5-(3-Methylpiperazin-1-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-12-5P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-sulfonamide 778644-13-6P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid N-[(S)-1-carbamoyl-2-phenylethyl]amide 778644-14-7P, (S)-3-Phenyl-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]aminopropionic acid methyl ester 778644-15-8P,
 (R)-3-Phenyl-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]aminopropionic acid methyl ester 778644-16-9P, 2-Benzyl-1-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]piperidin-4-one 778644-17-0P, 1-[[[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]piperidine-4-carboxylic acid isopropylamide 778644-18-1P,
 2-(Biphenyl-4-yl)-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]amino]acetic acid methyl ester 778644-19-2P, (2S,4R)-4-Hydroxy-1-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]pyrrolidine-2-carboxylic acid benzyl ester 778644-20-5P, [4-[[2,2']Bithiophenyl-5-yl]-5-methylpyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-22-7P
 778644-23-8P, [5-Bromo-4-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-24-9P, N-[2-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]acetamide 778644-25-0P,
 [4-[5-(2-Aminoethyl)thiophen-2-yl]-5-bromopyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-26-1P,
 [5-Bromo-4-[5-(2-dimethylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-28-3P,
 [4-[5-[4-((Z)-1-Methyl-1-propenyl)phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-29-4P,
 [4-[5-[4-(1-Aminoethyl)phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-30-7P,
 [5-Bromo-4-[5-chlorothiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-32-9P,
 4-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778644-33-0P,
 [4-[5'-(1-Aminoethyl)[2,2']bithiophenyl-5-yl]pyrimidin-2-yl](2,2,6,6-

tetramethylpiperidin-4-yl)amine 778644-34-1P,
 [4-[5-(3-Aminomethylphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-35-2P,
 [4-[5-[4-[(Dimethylamino)methyl]phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-37-4P,
 [4-[5-[Methyl[2-(piperidin-1-yl)ethyl]amino]methyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-38-5P,
 2-Methyl-5-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-2-ol 778644-39-6P,
 [4-[5-(2-Isopropylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-40-9P,
 N-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]methanesulfonamide 778644-41-0P,
 [2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]urea 778644-42-1P,
 [5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methylurea 778644-43-2P,
 N-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]methanesulfonamide 778644-45-4P,
 [4-[5'-[(Dimethylamino)methyl]-[2,2']bithiophenyl-5-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-46-5P,
 [5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methylurea 778644-47-6P,
 2-Methoxy-N-[5'-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methyl]acetamide 778644-48-7P,
 3-[3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778644-49-8P,
 [4-[5-(3-Amino-3-ethylpentyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-50-1P,
 [4-[5-(2-Methylsulfinyloxyethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-51-2P,
 [4-[5-(3-Methylsulfanyloxypropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-52-3P,
 [4-[5-(4-Methylsulfonylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-53-4P,
 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-ol 778644-55-6P,
 [4-[5-[2-(1-Aminocyclohexyl)ethyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-56-7P,
 Phenyl[4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyryl]amino]acetic acid methyl ester 778644-57-8P,
 [4-[5-(5-Phenylpentyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-58-9P,
 [N-Benzyl[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]acetic acid ethyl ester 778644-59-0P,
 778644-60-3P, 1-Phenyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778644-61-4P,
 3-Ethyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-ol 778644-63-6P,
 3-[Benzyl[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-64-7P,
 3-[Methyl-[5-[2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-65-8P,
 N-(2-Cyanoethyl)-N-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]acetamide 778644-66-9P,
 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethanone 778644-67-0P,

[4-[5-(4-Chlorophenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-68-1P,
 3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carbonitrile 778644-69-2P,
 [4-[(2,2')Bithiophenyl-5-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-70-5P 778644-73-8P,
 4-Chloro-2-[(E)-2-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethenyl]benzonitrile 778644-74-9P, 2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-4,5,6,7-tetrahydrobenzo[b]thiophen-4-ol 778644-75-0P, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(thieno[3,2-c]pyridin-2-yl)pyrimidin-2-yl]amine 778644-76-1P, (4-Chlorophenyl)[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanol 778644-77-2P,
 N-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]acetamide 778644-78-3P,
 [4-[5-(2-Dimethylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-80-7P,
 3-Methyl-5-[2-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidin-4-yl]thiophene-2-carboxylic acid methyl ester 778644-83-0P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid 778644-84-1P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid benzylamide 778644-85-2P,
 [4-(5-Nitrothiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-86-3P, [4-[5-(4-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-87-4P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenol 778644-89-6P,
 [4-[5-(2-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-91-0P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid (2-aminoethyl)amide 778644-93-2P,
 [4-[5-(3-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-94-3P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzenesulfonamide 778644-96-5P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzoic acid methyl ester 778644-97-6P,
 [4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]methanol 778644-98-7P,
 [3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]methanol 778644-99-8P,
 N-[3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]acetamide 778645-00-4P,
 [4-[5-(3-Aminophenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-01-5P,
 1-[3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone 778645-02-6P,
 5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-sulfonamide 778645-03-7P,
 [4-[5-(1-Aminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-04-8P,
 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778645-05-9P,
 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionic acid methyl ester 778645-06-0P,

[4-[5-(4-Aminobutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-07-1P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carbonitrile 778645-10-6P,
 [5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl][2,2']bithiophenyl-5-yl]methanol 778645-11-7P,
 2-Methyl-1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778645-12-8P,
 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778645-13-9P,
 [4-[5-(3-Aminopropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-14-0P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778645-15-1P,
 [4-(5'-Aminomethyl-[2,2']bithiophenyl-5-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-17-3P, Acetic acid
 2-methyl-2-nitro-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propyl ester 778645-18-4P,
 6-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]hexanenitrile 778645-19-5P,
 [4-[5-(6-Aminohexyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-22-0P,
 4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylic acid ethyl ester 778645-23-1P,
 4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]-2,2,6,6-tetramethylpiperidin-1-ol 778645-24-2P,
 [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](1,2,2,6,6-pentamethylpiperidin-4-yl)amine 778645-30-0P, [4-(6-Ethoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-31-1P, [4-(6-Allyloxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-33-3P,
 1-Isopropylamino-3-[[2-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-yl]oxy]propan-2-ol 778645-35-5P, 1-Isopropylamino-3-[[2-[5-methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-yl]oxy]propan-2-ol 778645-36-6P,
 [1-(3-Aminopropyl)piperidin-4-yl][4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]amine 778645-37-7P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6-trimethylpiperidin-4-yl)amine 778645-38-8P,
 [4-(3-Methylbenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-39-9P,
 [4-(5-Methylbenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-40-2P,
 [4-(7-Methoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-41-3P,
 [4-(Benzo[b]thiophen-5-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-42-4P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-43-5P,
 2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophene-7-carboxylic acid (2-diethylaminoethyl)amide 778645-44-6P, 8-Azabicyclo[3.2.1]oct-3-yl[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]endo-amine 778645-45-7P,
 (2R,4R)-4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidine-2-carboxylic acid methyl ester 778645-47-9P,
 [4-(Benzo[b]thiophen-2-yl)-5-methylpyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-48-0P,
 [4-[4-(Pyridin-4-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-

yl)amine 778645-49-1P, 1-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]piperidin-4-ol 778645-50-4P, [4-[4-(Pyridin-3-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-51-5P, [4-[4-(Pyridin-2-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-52-6P, [4-[4-(4-Methylpiperazin-1-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-53-7P, [4-[6-(3-Amino-3-methylbutyl)pyridin-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-54-8P, [4-(4-Methylsulfonylphenyl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-55-9P, [4-(Naphthalen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-57-1P, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(4-vinylphenyl)pyrimidin-2-yl]amine 778645-58-2P, 4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzenesulfonamide 778645-59-3P, N-(2-Hydroxyethyl)-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzenesulfonamide 778645-60-6P, [4-[4-(3-Amino-3-methylbutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-62-8P, 2-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-ol 778645-63-9P, 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionamide 778645-64-0P, [4-[4-(2-Aminoethyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-66-2P, [4-[4-(3-Aminopropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-67-3P, [4-[4-(3-Methoxypropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-69-5P, [4-[4-(4-Aminobutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-71-9P, 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-ol 778645-72-0P, [4-[4-(3-Aminobutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-73-1P, 2-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butyronitrile 778645-74-2P, [4-[4-(2-Aminopropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-75-3P, 2-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]methyl]benzonitrile 778645-76-4P, [4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]acetoneitrile 778645-77-5P, [4-[4-[2-(1-imidazol-1-yl)ethoxy]phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-78-6P, 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]butyronitrile 778645-79-7P, [4-[4-(Pyridin-4-ylmethoxy)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-80-0P, [4-[Indol-1-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-81-1P, [4-(4-Methoxyindol-1-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-82-2P, 1-[1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-3-yl]ethanone 778645-83-3P, [4-(5-Methoxyindol-1-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-85-5P, 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-3-carboxamide 778645-87-7P, 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-4-carboxamide 778645-88-8P, [4-[1-Methylindol-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-


yl)amine 778645-89-9P, [4-(1H-Indol-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-90-2P, [4-(1H-Indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-91-3P, [4-(1-Methylindol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-92-4P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-5-carbonitrile 778645-93-5P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-6-carbonitrile 778645-94-6P, [4-(5H-[1,3]Dioxolo[4,5-f]indol-7-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-96-8P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-ol hydrobromide 778645-98-0P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-ol 778645-99-1P, [4-[6-(2-Aminopropyl)-1H-indol-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-00-7P, [6-Methoxy-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]indol-1-yl]acetonitrile 778646-01-8P, [4-(7-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-02-9P, [4-(6-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-03-0P, [4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-04-1P, [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-05-2P, [4-(6-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-06-3P, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(6-trifluoromethyl-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-07-4P, [4-(7-Methyl-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-08-5P, 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]butan-2-ol 778646-09-6P, [4-(6,7-Difluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-10-9P, 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]butan-2-ol 778646-11-0P, [4-(5,7-Difluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-12-1P, [4-[6-[(Morpholin-4-yl)sulfonyl]-1H-indol-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-13-2P, [4-(5-Fluoro-7-methyl-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-14-3P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-6-sulfonic acid dimethylamide 778646-15-4P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-7-carbonitrile 778646-17-6P, (Morpholin-4-yl)[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]methanone 778646-18-7P, 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-7-sulfonic acid methylamide 778646-19-8P, (5-Azaspiro[3.5]non-8-yl)[4-(7-chloro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-20-1P, [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2-dimethylpiperidin-4-yl)amine 778646-21-2P, [4-(7-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2-dimethylpiperidin-4-yl)amine 778646-22-3P, (1-Azaspiro[5.5]undecan-4-yl)[4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-23-4P, (trans-2,6-Dimethylpiperidin-4-yl)[4-(1H-indol-3-yl)pyrimidin-2-yl]amine 778646-24-5P, [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](trans-2,6-

dimethylpiperidin-4-yl)amine 778646-25-6P,
 (trans-2,6-Dimethylpiperidin-4-yl) [4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-26-7P, [4-(5-Fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-27-8P,
 [4-(6-Chloro-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-28-9P,
 [4-(7-Chloro-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-29-0P,
 [4-(6-Chloro-7-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-37-0P,
 (E)-2-Methyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acrylonitrile 778646-38-1P,
 4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]-2-methylbutan-2-ol 778646-39-2P,
 3-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-40-5P,
 3-[7-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-41-6P,
 4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-methylbutan-2-ol 778646-42-7P,
 3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-43-8P,
 [4-(6-[2-(Imidazol-1-yl)ethyl]-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-44-9P,
 3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionitrile 778646-45-0P,
 N,N-Dimethyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionamide 778646-46-1P,
 2-Methyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778643-77-9 CAPLUS

CN 2-Thiophenepropanol, α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-78-0 CAPLUS

CN 2-Thiophenepropanol, 5-[5-methoxy-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- α,α -dimethyl- (CA INDEX NAME)



RN 778643-79-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-methoxybutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 778643-80-4 CAPLUS

CN 3-Buten-2-ol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778643-82-6 CAPLUS


CN 3-Buten-2-ol, 2-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778643-83-7 CAPLUS

CN 2-Pyrrolidinone, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-84-8 CAPLUS

CN 2-Thiophenebutanol, 5-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-85-9 CAPLUS

CN 2-Thiopheneethanol, alpha-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-86-0 CAPLUS

CN 2-Thiophenepropanamide, N, α , α -trimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-87-1 CAPLUS

CN 1H-Pyrrole-1-propanol, α , α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778643-88-2 CAPLUS


CN Cyclopropanemethanol, α , α -dimethyl-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl)methyl]- (CA INDEX NAME)



RN 778643-89-3 CAPLUS


CN Cyclopropanemethanol, α , α -dimethyl-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778643-90-6 CAPLUS

CN 1-Propanone, 2-ethoxy-2-methyl-1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-91-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methoxypropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-92-8 CAPLUS

CN [1,1'-Bicyclopropyl]-1-ol, 2'-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-93-9 CAPLUS

CN 2-Thiophenepropanol, 3-methoxy- α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-94-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-amino-2-methylpropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-95-1 CAPLUS

CN 1,3-Butanediol, 2,2-difluoro-3-methyl-1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-96-2 CAPLUS

CN 2-Thiophenepropanol, $\alpha,\alpha,\beta,\beta$ -tetramethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-97-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(phenylmethoxy)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-98-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-butyl-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-99-5 CAPLUS

CN 2-Pyrimidinamine, 4-(5-propoxy-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-00-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-methoxyethoxy)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-01-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-02-3 CAPLUS

CN 4-Piperidinol, 1-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-03-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-04-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-05-6 CAPLUS


CN 2-Pyrimidinamine, 4-[5-(1-piperazinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-06-7 CAPLUS

CN 4-Piperidinol, 4-[5-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-4-pyrimidinyl]-2-thienyl]-1-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 778644-07-8 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[5-(1-piperazinyl)-2-thienyl]-2-pyrimidinyl]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.




RN 778644-08-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methyl-1-buten-1-yl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-09-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methylbutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-10-3 CAPLUS

CN 3-Butyn-2-ol, 2-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-11-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methyl-1-piperazinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-12-5 CAPLUS


CN 2-Thiophenesulfonamide, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778644-13-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 778644-14-7 CAPLUS

CN L-Phenylalanine, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 778644-15-8 CAPLUS


CN D-Phenylalanine, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 778644-16-9 CAPLUS

CN 4-Piperidinone, 2-(phenylmethyl)-1-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]- (CA INDEX NAME)




RN 778644-17-0 CAPLUS

CN 4-Piperidinecarboxamide, N-(1-methylethyl)-1-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]- (CA INDEX NAME)



RN 778644-18-1 CAPLUS


CN [1,1'-Biphenyl]-4-acetic acid, alpha-[[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 778644-19-2 CAPLUS


CN L-Proline, 4-hydroxy-1-[(5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl)carbonyl]-, phenylmethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778644-20-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2,2'-bithiophen]-5-yl-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-22-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-(1-aminoethyl)[2,2'-bithiophen]-5-yl]-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-23-8 CAPLUS

CN 2-Pyrimidinamine, 5-bromo-4-((4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl))- (CA INDEX NAME)




RN 778644-24-9 CAPLUS

CN Acetamide, N-[2-[5-[5-bromo-2-((2,2,6,6-tetramethyl-4-piperidinyl)amino)]-4-pyrimidinyl]-2-thienyl]ethyl)- (CA INDEX NAME)




RN 778644-25-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-aminoethyl)-2-thienyl]-5-bromo-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-26-1 CAPLUS


CN 2-Pyrimidinamine, 5-bromo-4-[5-[2-(dimethylamino)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-28-3 CAPLUS


CN 2-Pyrimidinamine, 4-[5-[4-[(1Z)-1-methyl-1-propen-1-yl]phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778644-29-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(1-aminoethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-30-7 CAPLUS


CN 2-Pyrimidinamine, 5-bromo-4-(5-chloro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-32-9 CAPLUS
 CN 2-Thiophenebutanol, 5-[5-bromo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-33-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[5'-(1-aminoethyl)[2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-34-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-[3-(aminomethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-35-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-[4-[(dimethylamino)methyl]phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-37-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-[1-methyl[2-(1-piperidinyl)ethyl]amino]methyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-38-5 CAPLUS

CN 2-Thiophenebutanol, α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778644-39-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-[(1-methylethyl)amino]ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-40-9 CAPLUS

CN Methanesulfonamide, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-41-0 CAPLUS

CN Urea, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-42-1 CAPLUS

CN Urea, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)




RN 778644-43-2 CAPLUS

CN Methanesulfonamide, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)




RN 778644-45-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-[(dimethylamino)methyl][2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-46-5 CAPLUS

CN Urea, N-[[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]methyl]- (CA INDEX NAME)




RN 778644-47-6 CAPLUS

CN Acetamide, 2-methoxy-N-[(5'-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl)methyl]- (CA INDEX NAME)




RN 778644-48-7 CAPLUS

CN 2-Thiophenepropanamide, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-49-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-ethylpentyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny]- (CA INDEX NAME)




RN 778644-50-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(methylsulfinyl)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny]- (CA INDEX NAME)




RN 778644-51-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[3-(methylthio)propyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)- (CA INDEX NAME)




RN 778644-52-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylsulfonyl)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)- (CA INDEX NAME)




RN 778644-53-4 CAPLUS

CN 2-Thiophenepropanol, alpha-ethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-55-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(1-aminocyclohexyl)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)- (CA INDEX NAME)




RN 778644-56-7 CAPLUS

CN Benzeneacetic acid, α -[[1-oxo-4-{5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]butyl}amino]-, methyl ester
(CA INDEX NAME)




RN 778644-57-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(5-phenylpentyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-58-9 CAPLUS

CN Glycine, N-(phenylmethyl)-N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 778644-59-0 CAPLUS


CN 2-Propanol, 2-methyl-1-[(phenylmethyl)[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)



RN 778644-60-3 CAPLUS


CN 2-Thiophenepropanol, α -phenyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778644-61-4 CAPLUS

CN 2-Thiophenepropanol, α, α -diethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778644-63-6 CAPLUS

CN Propanenitrile, 3-[(phenylmethyl)[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl)methyl]amino]- (CA INDEX NAME)




RN 778644-64-7 CAPLUS

CN Propanenitrile, 3-[methyl[5-[2-[(1,2,2,6,6-pentamethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl)methyl]amino]- (CA INDEX NAME)




RN 778644-65-8 CAPLUS

CN Acetamide, N-(2-cyanoethyl)-N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl)methyl]- (CA INDEX NAME)




RN 778644-66-9 CAPLUS

CN Ethanone, 1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-67-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-68-1 CAPLUS

CN 2-Thiophenecarbonitrile, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-69-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2,2'-bithiophen]-5-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-70-5 CAPLUS


CN 2-Pyrimidinamine, 4-[5-(1-methylethenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-73-8 CAPLUS


CN Benzonitrile, 4-chloro-2-[(1E)-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 778644-74-9 CAPLUS

CN Benzo[b]thiophene-4-ol, 4,5,6,7-tetrahydro-2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,2,6,6-tetramethyl-4-piperidinyl)-4-thieno[3,2-c]pyridin-2-yl- (CA INDEX NAME)




RN 778644-76-1 CAPLUS

CN 2-Thiophenemethanol, α-(4-chlorophenyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-77-2 CAPLUS

CN Acetamide, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-78-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-80-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-83-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-84-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(phenylmethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-85-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-nitro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-86-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-87-4 CAPLUS

CN Phenol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-89-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-91-0 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-aminoethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-93-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-94-3 CAPLUS

CN Benzenesulfonamide, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-96-5 CAPLUS

CN Benzoic acid, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino)-4-pyrimidinyl]-2-thienyl]-, methyl ester (CA INDEX NAME)




RN 778644-97-6 CAPLUS

CN Benzenemethanol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino)-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-98-7 CAPLUS

CN Benzenemethanol, 3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino)-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-99-8 CAPLUS

CN Acetamide, N-[3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino)-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778645-00-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-aminophenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-01-5 CAPLUS

CN Ethanone, 1-[3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778645-02-6 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-03-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-aminoethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-04-8 CAPLUS

CN 2-Thiophenepropanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-05-9 CAPLUS

CN 2-Thiophenepropanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-06-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(4-aminobutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)]- (CA INDEX NAME)




RN 778645-07-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-10-6 CAPLUS

CN [2,2'-Bithiophene]-5-methanol, 5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-11-7 CAPLUS

CN 2-Thiophenemethanol, α-(1-methylethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-12-8 CAPLUS

CN 2-Thiophenepropanamide, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-13-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-aminopropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-14-0 CAPLUS


CN 2-Thiophenepropanol, α -methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778645-15-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-(aminomethyl)[2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-17-3 CAPLUS

CN 2-Thiophenemethanol, α -(1-methyl-1-nitroethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-, 2-acetate (CA INDEX NAME)


RN 778645-18-4 CAPLUS

CN 2-Thiophenehexanenitrile, 5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-19-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(6-aminohexyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-22-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 778645-23-1 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-24-2 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-30-0 CAPLUS

CN 2-Pyrimidinamine, 4-[(6-ethoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)]- (CA INDEX NAME)




RN 778645-31-1 CAPLUS

CN 2-Pyrimidinamine, 4-[(2-propen-1-yloxy)benzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)]- (CA INDEX NAME)




RN 778645-33-3 CAPLUS

CN 2-Propanol, 1-[(1-methylethylamino)-3-[[2-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]benzo[b]thien-6-yl]oxy]]- (CA INDEX NAME)




RN 778645-35-5 CAPLUS


CN 2-Propanol, 1-[(1-methylethylamino)-3-[[2-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]benzo[b]thien-6-yl]oxy]]- (CA INDEX NAME)




RN 778645-36-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-(3-aminopropyl)-4-piperidiny]-4-benzo[b]thien-2-yl-
(CA INDEX NAME)

RN 778645-37-7 CAPLUS


CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(2,2,6-trimethyl-4-piperidiny)-
(CA INDEX NAME)

RN 778645-38-8 CAPLUS

CN 2-Pyrimidinamine, 4-(3-methylbenzo[b]thien-2-yl)-N-(2,2,6-tetramethyl-4-piperidiny)-
(CA INDEX NAME)


RN 778645-39-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methylbenzo[b]thien-2-yl)-N-(2,2,6-tetramethyl-4-piperidiny)-
(CA INDEX NAME)




RN 778645-40-2 CAPLUS

CN 2-Pyrimidinamine, 4-(7-methoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-41-3 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-5-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-42-4 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-43-5 CAPLUS


CN Benzo[b]thiophene-7-carboxamide, N-[2-(diethylamino)ethyl]-2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778645-44-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 778645-45-7 CAPLUS


CN 2-Piperidinecarboxylic acid, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-, methyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778645-47-9 CAPLUS

RN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-48-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-49-1 CAPLUS

CN 4-Piperidinol, 1-methyl-4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778645-50-4 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(3-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-51-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(2-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-

piperidiny)- (CA INDEX NAME)




RN 778645-52-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-methyl-1-piperazinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-53-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-amino-3-methylbutyl)-3-pyridinyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-54-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methylthio)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-naphthalenyl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-57-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-ethenylphenyl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-58-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-59-3 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-60-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-amino-3-methylbutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-62-8 CAPLUS

CN Benzenepropanol, α,α -dimethyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778645-63-9 CAPLUS

CN Benzenepropanamide, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-64-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(2-aminoethyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-66-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-aminopropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-67-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-methoxypropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-69-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-aminobutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-71-9 CAPLUS

CN Benzenepropanol, α-methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-aminobutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-73-1 CAPLUS

CN Benzenebutanenitrile, α-methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-74-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(2-aminopropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-75-3 CAPLUS

CN Benzonitrile, 2-[[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenoxy]methyl]- (CA INDEX NAME)




RN 778645-76-4 CAPLUS

CN Acetonitrile, 2-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenoxy]- (CA INDEX NAME)




RN 778645-77-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-78-6 CAPLUS

CN Butanenitrile, 4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]phenoxy]- (CA INDEX NAME)




RN 778645-79-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[2-(4-pyridinylmethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-80-0 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-81-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-methoxy-1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-82-2 CAPLUS

CN Ethanone, 1-[1-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 778645-83-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methoxy-1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-85-5 CAPLUS

CN 1H-Indole-3-carboxamide, 1-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-87-7 CAPLUS

CN 1H-Indole-4-carboxamide, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-88-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1-methyl-1H-indol-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-89-9 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-90-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-91-3 CAPLUS

CN 2-Pyrimidinamine, 4-(1-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-92-4 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-93-5 CAPLUS

CN 1H-Indole-6-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-94-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5H-1,3-dioxolo[4,5-f]indol-7-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-96-8 CAPLUS


CN 1H-Indol-6-ol, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, hydrobromide (1:?) (CA INDEX NAME)




● x HBr

RN 778645-98-0 CAPLUS

CN 1H-Indol-7-ol, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-99-1 CAPLUS

CN 1H-Indole-6-ethanamine, α -methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778646-00-7 CAPLUS

CN 1H-Indole-1-acetonitrile, 6-methoxy-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-01-8 CAPLUS

CN 2-Pyrimidinamine, 4-(7-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-02-9 CAPLUS

CN 2-Pyrimidinamine, 4-(6-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-03-0 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-04-1 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-05-2 CAPLUS

CN 2-Pyrimidinamine, 4-(6-chloro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-06-3 CAPLUS

CN 2-Pyrimidinamine, N-(2,2,6,6-tetramethyl-4-piperidinyl)-4-[6-(trifluoromethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 778646-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-(7-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-08-5 CAPLUS

CN 1H-Indole-6-propanol, α, α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-09-6 CAPLUS

CN 2-Pyrimidinamine, 4-(6,7-difluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-10-9 CAPLUS

CN 1H-Indole-7-propanol, α, α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778646-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5,7-difluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-12-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-morpholinylsulfonyl)-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-13-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-fluoro-7-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778646-14-3 CAPLUS

CN 1H-Indole-6-sulfonamide, N,N-dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-15-4 CAPLUS

CN 1H-Indole-7-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-17-6 CAPLUS

CN Methanone, 4-morpholinyl[3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 778646-18-7 CAPLUS

CN 1H-Indole-7-sulfonamide, N-methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-19-8 CAPLUS

CN 5-Azaspiro[3.5]nonan-8-amine, N-[4-(7-chloro-1H-indol-3-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 778646-20-1 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-(2,2-dimethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-21-2 CAPLUS

CN 2-Pyrimidinamine, N-(2,2-dimethyl-4-piperidiny1)-4-(7-fluoro-1H-indol-3-yl)- (CA INDEX NAME)



RN 778646-22-3 CAPLUS


CN 1-Azaspiro[5.5]undecan-4-amine, N-[4-(7-fluoro-1H-indol-3-yl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 778646-23-4 CAPLUS

CN 2-Pyrimidinamine, N-[(2R,6R)-2,6-dimethyl-4-piperidiny1]-4-(1H-indol-3-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 778646-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-[(2R,6R)-2,6-dimethyl-4-piperidiny]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 778646-25-6 CAPLUS


CN 2-Pyrimidinamine, N-[(2R,6R)-2,6-dimethyl-4-piperidiny]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778646-26-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778646-27-8 CAPLUS

CN 2-Pyrimidinamine, 4-(6-chloro-5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-29-0 CAPLUS


CN 2-Pyrimidinamine, 4-(6-chloro-7-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-37-0 CAPLUS

CN 2-Propenenitrile, 2-methyl-3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-38-1 CAPLUS


CN 1H-Indole-6-propanol, 5-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778646-39-2 CAPLUS

CN 1H-Indole-6-propanenitrile, 5-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778646-40-5 CAPLUS

CN 1H-Indole-6-propanenitrile, 7-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-41-6 CAPLUS

CN 1H-Indole-7-propanol, 5-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-42-7 CAPLUS

CN 1H-Indole-6-propanenitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-43-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[2-(1H-imidazol-1-yl)ethyl]-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-44-9 CAPLUS

CN 1H-Indole-7-propanenitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-45-0 CAPLUS

CN 1H-Indole-7-propanamide, N,N-dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-46-1 CAPLUS

CN 1H-Indole-7-propanenitrile, alpha-methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 778646-65-4P, 2-Methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-2-ol 778646-69-8P, 2,3,3-Trimethyl-5-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-2-ol 778646-71-2P, 2-[(1S,2S)-2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]cyclopropyl]propan-2-ol 778646-74-5P, [4-(5-[2-(2-Dimethylaminoethoxy)thiophen-2-yl]pyrimidin-2-yl)](2,2,6,6-tetramethylpiperidin-4-yl)amine dihydrochloride 778646-82-5P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid phenethylamide 778646-83-6P, [4-(1H-Indol-3-yl)piperidin-1-yl][5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanone 778646-88-1P, 1-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]cyclobutanol 778646-90-5P, (5-Azaspiro[3.5]nonan-8-yl)[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]amine 778646-93-8P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](trans-2,6-

dimethylpiperidin-4-yl)amine 778647-26-0P,
 N-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acetamide 778647-27-1P,
 [4-(7-Bromo-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-28-2P, [4-(1H-Pyrrolo[3,2-h]quinolin-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine
 780767-19-3P, 8-Azabicyclo[3.2.1]oct-3-yl[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]-exo-amine 780767-20-6P 780767-21-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778646-65-4 CAPLUS

CN 2-Thiopheneethanol, α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-69-8 CAPLUS


CN 2-Thiophenebutanol, $\alpha,\alpha,\beta,\beta$ -tetramethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-71-2 CAPLUS


CN Cyclopropanemethanol, α,α -dimethyl-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 778646-74-5 CAPLUS


CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethoxy]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 778646-82-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-phenylethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-83-6 CAPLUS

CN Methanone, [4-(1H-indol-3-yl)-1-piperidiny][5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778646-88-1 CAPLUS

CN Cyclobutanol, 1-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)



RN 778646-90-5 CAPLUS


CN 5-Azaspiro[3.5]nonan-8-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)- (CA INDEX NAME)



RN 778646-93-8 CAPLUS


CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-[(2R,6R)-2,6-dimethyl-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778647-26-0 CAPLUS

CN Acetamide, N-[3-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-indol-7-yl]- (CA INDEX NAME)




RN 778647-27-1 CAPLUS

CN 2-Pyrimidinamine, 4-(7-bromo-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 778647-28-2 CAPLUS


CN 2-Pyrimidinamine, 4-(1H-pyrrolo[3,2-h]quinolin-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 780767-19-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)-, (3-exo)- (CA INDEX NAME)


Relative stereochemistry.



RN 780767-20-6 CAPLUS

CN 2-Pyrimidinamine, N-[(2R,6S)-2,6-dimethyl-4-piperidinyl]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 780767-21-7 CAPLUS

CN 2-Pyrimidinamine, N-[(2R,6S)-2,6-dimethyl-4-piperidinyl]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 778645-56-0P, [4-(4-Bromophenyl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate, IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778645-56-0 CAPLUS

CN 2-Pyrimidinamine, 4-(4-bromophenyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-

(CA INDEX NAME)




IT 778646-58-5P, [4-(5-Bromothiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-64-3P, 4-[5-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester 778646-76-7P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]piperazine-1-carboxylic acid ethyl ester 778646-78-9P, (8-Azabicyclo[3.2.1]oct-3-yl)[4-[5-[4-(ethoxycarbonyl)piperazin-1-yl]thiophen-2-yl]pyrimidin-2-yl]exo-amine 778646-80-3P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid ethyl ester 778646-81-4P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid 778646-84-7P, 1-[5'-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]ethanone O-methyloxime 778646-85-8P, Toluene-4-sulfonic acid 4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyl ester 778646-86-9P, [4-[5-(4-Methylsulfonylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-87-0P, [4-[5-(4-Methylsulfinylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-01-1P, [4-[6-(3-Amino-3-methylbut-1-ynyl)pyridin-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-02-2P, (4-Phenylpyrimidin-2-yl)(2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-03-3P, [4-[4-(3-Amino-3-methylbut-1-ynyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-04-4P, 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionic acid 778647-05-5P, Toluene-4-sulfonic acid 3-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propyl ester 778647-07-7P, Toluene-4-sulfonic acid 1-methyl-3-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propyl ester 778647-09-9P, 1-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-2-one 778647-10-2P, 1-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-2-ol 778647-11-3P, Toluene-4-sulfonic acid 1-methyl-2-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]ethyl ester 778647-13-5P, 4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)
 RN 778646-58-5 CAPLUS
 CN 2-Pyrimidinamine, 4-(5-bromo-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-64-3 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 778646-76-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, ethyl ester (CA INDEX NAME)



RN 778646-78-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-4-pyrimidinyl]-2-thienyl]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 778646-80-3 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)




RN 778646-81-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-84-7 CAPLUS

CN Ethanone, 1-[5'-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]-, O-methyloxime (CA INDEX NAME)




RN 778646-85-8 CAPLUS

CN 2-Thiophenebutanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 2-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778646-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylthio)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-87-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylsulfinyl)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778647-01-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-amino-3-methyl-1-butyn-1-yl)-3-pyridinyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778647-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-phenyl-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778647-03-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-amino-3-methyl-1-butyn-1-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778647-04-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778647-05-5 CAPLUS

CN Benzenepropanol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778647-07-7 CAPLUS

CN Benzenepropanol, α-methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778647-09-9 CAPLUS


CN 2-Propanone, 1-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778647-10-2 CAPLUS


CN Benzeneethanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778647-11-3 CAPLUS

CN Benzeneethanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)

RN 778647-13-5 CAPLUS

CN Phenol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 778646-77-8, 5-Bromo-2-[[[(8-azabicyclo[3.2.1]oct-3-yl)exo-amino]pyrimidin-4-yl]thiophene


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)

RN 778646-77-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-(5-bromo-2-thienyl)-2-pyrimidinyl]-
, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 51 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:857595 CAPLUS

DN 141:350190

TI Preparation of thiazoles as inhibitors of protein kinases

IN Brencley, Guy; Farmer, Luc J.; Harrington, Edmund Martin; Knegtel, Ronald; O'Donnell, Michael; Salituro, Francesco G.; Studley, John R.; Wang, Jian

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087699	A2	20041014	WO 2004-US9166	20040325
	WO 2004087699	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225977	A1	20041014	AU 2004-225977	20040325
	CA 2523126	A1	20041014	CA 2004-2523126	20040325
	US 20050004150	A1	20050106	US 2004-809946	20040325
	US 7276502	B2	20071002		
	EP 1605946	A2	20051221	EP 2004-758338	20040325
	EP 1605946	B1	20080528		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
	JP 2006522125	T	20060928	JP 2006-509290	20040325
	AT 396731	T	20080615	AT 2004-758338	20040325
PRAI	US 2003-457468P	P	20030325		
	WO 2004-US9166	W	20040325		
OS	MARPAT 141:350190				
AB	The title compds. [I; R1, R2 = R, halo, CN, NO2, etc.; R = H, (un)substituted alkyl; Ar1 = (un)substituted aryl, heteroaryl, etc.; R3, R4 = ZR7; or R3 and R4 are taken together to form (un)substituted (un)saturated 3-8 membered ring having 0-3 heteroatoms; Z = a bond, alkylidene, etc.; R7 = halo, CN, NO2, etc.], useful of inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting from benzothiazole, was given. The compds. I were tested against SYK and ZAP-70 kinases (data given for representative compds. I). The invention also provides pharmaceutically acceptable compns. comprising said compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders.				
IT	774229-12-8P 774229-32-2P 774229-55-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of thiazoles as inhibitors of protein kinases)				


RN 774229-12-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 774229-32-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-piperidinyl- (CA INDEX NAME)



RN 774229-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-pyridinyl- (CA INDEX NAME)



L17 ANSWER 52 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:857175 CAPLUS
 DN 141:350167
 TI Preparation of imidazolin-2-one derivatives as p38 MAP kinase inhibitors
 IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;
 Ogasawara, Akihito; Hiramatsu, Hajime; Nakajima, Tatsuo; Nakane, Tetsu
 PA Japan
 SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of Appl. No. PCT/JP02/10937.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040204426	A1	20041014	US 2004-827294	20040420
	WO 2003035638	A1	20030501	WO 2002-JP10937	20021022
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004201666	A1	20040513	AU 2004-201666	20040421
	WO 2004094404	A1	20041104	WO 2004-JP5716	20040421
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2004339210	A	20041202	JP 2004-125060	20040421
	EP 1628968	A1	20060301	EP 2004-728708	20040421
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	JP 2001-324029	A	20011022		
	JP 2002-263680	A	20020910		
	WO 2002-JP10937	A2	20021022		
	JP 2003-116076	A	20030421		
	AU 2002-363108	A3	20021022		
	WO 2004-JP5716	W	20040421		
OS	MARPAT 141:350167				
AB	The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonfyl, (un)substituted				

alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl), PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts were prepared as p38 mitogen activation proteins (MAP) kinase inhibitors. Thus, reacting 2,2-diethoxy-2-(pyridin-4-yl)ethylamine (preparation given) with 4-fluorophenyl isocyanate afforded the imidazolinone II. The representative compds. I significantly reduced the production of TNF- α in mice in vivo.


IT 521090-46-0P 521090-47-1P 521090-48-2P
521090-50-6P 521090-51-7P 521090-60-8P
521091-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MAP kinase inhibitor; preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 521090-47-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[(1-phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (CA INDEX NAME)




RN 521090-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 521090-50-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 521090-51-7 CAPLUS
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 521090-60-8 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 521091-47-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


IT 1070144-05-6 1070144-08-9 1070144-10-3
 1070144-11-4 1070144-13-6 1070144-15-8
 1070144-18-1 1070144-24-9 1070144-25-0
 1070144-29-4 1070144-30-7 1070144-35-2
 1070144-36-3 1070144-40-9 1070144-41-0
 1070144-42-1 1070144-48-7 1070144-53-4
 1070144-56-7 1070144-57-8 1070144-59-0
 1070144-62-5 1070144-65-8 1070144-68-1
 1070144-71-6 1070144-73-8 1070144-76-1
 1070144-78-3 1070144-79-4 1070144-81-8

RL: PRPH (Prophetic)

(Preparation of imidazolin-2-one derivatives as p38 MAP kinase inhibitors)


RN 1070144-05-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1070144-08-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1070144-10-3 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1070144-11-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1070144-13-6 CAPLUS
 CN 2H-imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-15-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 1070144-18-1 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylpropyl)- (CA INDEX NAME)




RN 1070144-24-9 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-25-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-29-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-30-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-35-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 1070144-36-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1070144-40-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1070144-41-0 CAPLUS
CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(1-methylpropyl)]- (CA INDEX NAME)




RN 1070144-42-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(1-methylpropyl)-
(CA INDEX NAME)




RN 1070144-48-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-1-(1-methylpropyl)-
(CA INDEX NAME)




RN 1070144-53-4 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1070144-56-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-57-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-59-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-62-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 1070144-65-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1070144-68-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1070144-71-6 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-(3-chlorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)


RN 1070144-73-8 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-76-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1070144-78-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1070144-79-4 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)]- (CA INDEX NAME)



RN 1070144-81-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-((1-methylpropyl)-4-[[2-
[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

IT 774579-33-8P 774579-49-6P 774579-50-9P
 774579-76-9P 774579-77-0P 774579-78-1P
 774579-79-2P 774579-80-5P 774579-81-6P
 774579-82-7P 774579-83-8P 774579-84-9P
 774579-85-0P 774579-86-1P 774579-87-2P
 774579-88-3P 774579-89-4P 774579-90-7P
 774579-91-8P 774579-92-9P 774579-93-0P
 774579-96-3P 774579-99-6P 774580-00-6P
 774580-01-7P 774580-03-9P 774580-04-0P
 774580-05-1P 774580-06-2P 774580-07-3P
 774580-08-4P 774580-09-5P 774580-10-8P
 774580-11-9P 774580-16-4P 774580-17-5P
 774580-18-6P 774580-19-7P 774580-23-3P
 774580-24-4P 774580-25-5P 774580-48-2P
 774580-49-3P 774580-50-6P 774580-59-5P
 774580-60-8P 774580-61-9P 774580-71-1P
 774580-72-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 774579-33-8 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 774579-49-6 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-50-9 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-76-9 CAPLUS
 CN 2H-imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-77-0 CAPLUS
 CN 2H-imidazol-2-one, 1-(1-acetyl-4-piperidinyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-78-1 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-79-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 774579-80-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 774579-81-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-82-7 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(butylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-83-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 2-methylpropyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-84-9 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(1-oxobutyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774579-85-0 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-86-1 CAPLUS
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774579-87-2 CAPLUS
 CN 2H-Imidazol-2-one, 1-ethyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774579-88-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-90-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-91-8 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-92-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-93-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-96-3 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-99-6 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-00-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-01-7 CAPLUS
 CN 2H-Imidazol-2-one, 1-(cyclopropylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-03-9 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-04-0 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-methylethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-05-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-06-2 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-oxopropyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-07-3 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-[(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-08-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-[(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-09-5 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-10-8 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[[1-(1-methylethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-11-9 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-16-4 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-17-5 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclobutyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-18-6 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-19-7 CAPLUS
 CN 1-Piperidinesulfonamide, 4-[[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-23-3 CAPLUS
 CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(methoxymethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-24-4 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-25-5 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-48-2 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclopentyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-49-3 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-50-6 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 774580-59-5 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclohexyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-3-(4-fluorophenyl)-1,3-dihydro-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-60-8 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-61-9 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-71-1 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-72-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L17 ANSWER 53 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:372883 CAPLUS

DN 140:375182

TI Preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia

IN Clark, Michael Philip; Laufersweiler, Matthew John; De, Biswanath; Janusz, Michael John

PA The Procter & Gamble Company, USA

SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 246,214.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040087639	A1	20040506	US 2003-689388	20031020
	US 7087615	B2	20060808		
	US 20030134867	A1	20030717	US 2002-246214	20020918
	US 6730668	B2	20040504		
	CN 1681819	A	20051012	CN 2003-821850	20030318
	CN 1315834	C	20070516		
	ZA 2005001590	A	20060222	ZA 2005-1590	20050223
	KR 2007051374	A	20070517	KR 2007-710029	20070502
	KR 842191	B1	20080630		
	KR 2007087684	A	20070828	KR 2007-716926	20070723
PRAI	US 2001-323625P	P	20010920		
	US 2002-246214	A2	20020918		
	WO 2003-US8477	W	20030318		
	KR 2005-704666	A3	20050318		
	KR 2007-710029	A3	20070502		

OS MARPAT 140:375182

AB The present invention relates to compds. which are capable of preventing the extracellular release of inflammatory cytokines, said compds., including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, have the formula (I) $[R = O(CH_2)_kR_3]$, (un)substituted NH_2 (wherein $k = 0-5$; $R_3 =$ (un)substituted alkyl, hydrocarbyl, heterocyclyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl); $R_1 =$ (un)substituted (hetero)aryl; $R_2 = H$, $(CH_2)_jO(CH_2)_nR_8$, $(CH_2)_jNR_9aR_9b$, $(CH_2)_jCO_2R_{10}$, $(CH_2)_jOCO_2R_{10}$, $(CH_2)_jCON(R_{10})_2$, $(CH_2)_jCON(R_{10})_2$; or two R_2 units can be taken together to form a CO unit (wherein R_8 , R_9a , R_9b , $R_{10} = H$, alkyl; or R_9a and R_9b are taken together to form carbocyclic or heterocyclic ring; $j, n = 0-5$); $Z = O, S, NR_{11}, NOR_{11}$ ($R_{11} = H$, alkyl)]. Interleukin-1 (IL-1) and tumor necrosis factor- α (TNF- α) are among the important biol. substances known collectively as cytokines and understood to mediate the inflammatory response associated with the immunol. recognition of infectious agents. These pro-inflammatory cytokines are suggested as an important mediators in many disease states or syndromes, inter alia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (IBS), septic shock, cardiopulmonary dysfunction, acute respiratory disease, cachexia, and therefore responsible for the progression and manifestation of human disease states. The compds. I can provide pain relief, and reduce psoriasis in humans or higher mammal (data provided for one of the compds. I). Thus, 6.0 g Me 4-fluorophenylacetate was added to a cold (-78°) solution of lithium diisopropylamide (2M, 21.4 mL in THF and stirred at -78° for 1 h at -78°, followed by adding dropwise a solution of 6.0 g 2-methylsulfanylpurimidine-4-carboxaldehyde (preparation

given) in 30 mL THF and the resulting mixture was stirred for 45 min at -78° to give, after workup and silica gel chromatog., 8.7 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-hydroxypropionic acid Me ester (II) (76 %). To a suspension of CrO3 in CH2Cl2 (300 mL) was added pyridine and stirred vigorously for 1 h at room temperature, followed by adding a solution of the crude II prepared above in 50 mL CH2Cl2 dropwise, and the reaction mixture was stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 3.7 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-oxopropionic acid Me ester (III) (43% yield) as a yellow solid. To a solution of 7.8 g pyrazolidine in 100 mL pyridine was added 11.5 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-oxopropionic acid Me ester and heated to 90° for 16 h to give, after silica gel chromatog., 3.9 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one (37%) which (1.3 g) was dissolved in a 1:1 mixture of THF and MeOH (56 mL), treated dropwise with 9.34 g Oxone in 42 mL H2O, and stirred at room temperature for 1 h to give 2-(4-fluorophenyl)-3-(2-methanesulfonylpyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one. The pharmaceutical comps. comprising the compound I are claimed.


IT 503072-98-8P, 2-(4-Fluorophenyl)-3-[2-[[1-(propanesulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (pyrimidinyl)dihydro-5H-pyrazolo[1,2-a]pyrazolones which provide analgesia)

RN 503072-98-8 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 54 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:162457 CAPLUS
 DN 140:199322
 TI Preparation of 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for the
 prevention of extracellular release of inflammatory cytokines
 IN Clark, Michael Philip; Laufersweiler, Matthew John; Golebiowski, Adam;
 Sabat, Mark; Brugel, Todd Andrew
 PA The Procter & Gamble Company, USA
 SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 246,214.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040038971	A1	20040226	US 2003-390216	20030317
	US 6849627	B2	20050201		
	US 20030134867	A1	20030717	US 2002-246214	20020918
	US 6730668	B2	20040504		
	CN 1681819	A	20051012	CN 2003-821850	20030318
	CN 1315834	C	20070516		
	ZA 2005001590	A	20060222	ZA 2005-1590	20050223
	KR 2007051374	A	20070517	KR 2007-710029	20070502
	KR 842191	B1	20080630		
	KR 2007087684	A	20070828	KR 2007-716926	20070723
PRAI	US 2001-323625P	P	20010920		
	US 2002-246214	A2	20020918		
	WO 2003-US8477	W	20030318		
	KR 2005-704666	A3	20050318		
	KR 2007-710029	A3	20070502		
OS	MARPAT 140:199322				
AB	Title comps. I [R1 = (un)substituted aryl, heteroaryl; R2 = H, (CH2)jO(CH2)nR8, (CH2)jCO2R10, etc.; R8, R10 = H, alkyl; j, n = 0-5; Z = O, S, NR11, etc.; R11 = H, alkyl; R3 = (un)substituted aryl, heteroaryl] and their pharmaceutically acceptable salts were prepared For example, condensation of sulfone II, e.g., prepared from pyruvic aldehyde di-Me acetal in 4-steps, and (S)-methylbenzylamine afforded pyrazolopyrazolone III. In cell based interleukin-1, cyclooxygenase-2 and tumor necrosis factor assays, comps. I exhibited IC50 values below 1.0 µM (sic).				
IT	503072-98-8 1055722-42-3 RL: PRPH (Prophetic) (Preparation of 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for the prevention of extracellular release of inflammatory cytokines)				
RN	503072-98-8 CAPLUS				
CN	1H,5H-Pyrazolo[1,2-a]pyrazol-1-one, 2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)				



RN 1055722-42-3 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-2-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 660857-85-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrazolo[1,2-a]pyrazolones for the
prevention of extracellular release of inflammatory cytokines)

RN 660857-85-2 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-(4-fluorophenyl)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
(CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 55 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:143155 CAPLUS

DN 140:199339

TI Preparation of 6-aminopurines and related compounds as selective
phosphodiesterase-4 inhibitors for treatment of psychosis and inflammation

IN Liu, Ruiping; Hopper, Allen T.; Tehim, Ashok; Hess, Hans-Jurgen E.; Rong,
Yajing

PA Memory Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014913	A2	20040219	WO 2003-US24914	20030808
	WO 2004014913	A3	20040729		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2494028	A1	20040219	CA 2003-2494028	20030808
	AU 2003264017	A1	20040225	AU 2003-264017	20030808
	EP 1529049	A2	20050511	EP 2003-785075	20030808
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1688580	A	20051026	CN 2003-823977	20030808
	JP 2005538134	T	20051215	JP 2004-527913	20030808
	US 20070093510	A1	20070426	US 2003-636979	20030808
	US 7332486	B2	20080219		
	US 20080139583	A1	20080612	US 2008-26198	20080205
PRAI	US 2002-401765P	P	20020808		
	US 2003-636979	A1	20030808		
	WO 2003-US24914	W	20030808		
OS	MARPAT 140:199339				
AB	Title compds. I [X = NHR1; R1 = H, (un)substituted alkyl, cycloalkyl, etc.; R2 = (un)substituted aryl, heteroaryl, heteroarylalkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, electrophilic substitution of aminocyclopropane with compound I [X = Cl; R2 = 2-fluorobenzyl], e.g., prepared from 5-aminoimidazole-4-carboxamide hydrochloride in 3-steps, followed by acid work-up furnished compound I [R1 = cyclopropyl; R2 = 2-fluorobenzyl] methanesulfonate in 80.3% overall yield. In human PDE-4 inhibition assays, compds. I showed indicative (sic.) inhibition of PDE-4 activity (no data provided). Compds. I are claimed useful for the treatment of psychosis, Alzheimer's disease, allergy, inflammation, etc.				
IT	660867-32-3P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 6-aminopurines and related compds. as selective PDE-4				

inhibitors for treatment of psychosis and inflammation)

RN 660867-32-3 CAPLUS

CN 9H-Purin-6-amine, N-cyclopropyl-9-[2-(4-pyridinylamino)-4-pyrimidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 56 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:991504 CAPLUS

DN 140:42177

TI Preparation of pyrazoles as p38 α kinase, TNF and/or cyclooxygenase-2 inhibitors

IN Benson, Alan G.; Fraher, Thomas Phillip; Hepperle, Michael E.; Jerome, Kevin D.; Naing, Win; Seiness, Shaun Raj; Walker, John K.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 341 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003104223	A1	20031218	WO 2003-US17906	20030605
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2488402	A1	20031218	CA 2003-2488402	20030605
	AU 2003237446	A1	20031222	AU 2003-237446	20030605
	US 20040082551	A1	20040429	US 2003-456933	20030605
	BR 2003011619	A	20050308	BR 2003-11619	20030605
	EP 1511743	A1	20050309	EP 2003-736898	20030605
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005538958	T	20051222	JP 2004-511293	20030605
	MX 2004PA11638	A	20050307	MX 2004-PA11638	20041123
PRAI	US 2002-386415P	P	20020605		
	WO 2003-US17906	W	20030605		
OS	MARPAT 140:42177				

AB This invention is directed generally to pyrazoles (shown as I; variables defined below; most examples of I are 4-pyrimidinylpyrazoles, e.g. II) that, inter alia, inhibit p38 α kinase (data included), TNF (no data), and/or cyclooxygenase-2 (no data) activity. The pyrazoles further include tautomers of such compds., as well as salts of such compds. and tautomers. This invention also is directed to compns. of such pyrazoles, intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (particularly pathol. conditions) associated with p38 kinase, TNF, and/or cyclooxygenase-2 activity. For I: L1 = a bond, O, S, S(O), S(O)2, N(Ra), C(O), C(O)N(Ra), N(Ra)C(O), C(O)O, OC(O), OC(O)O, C(H):C(H), C.tplbond.C, N:N, N(Ra)N(Ra), N(Ra)C(O)N(Ra), C(S)N(Ra), N(Ra)C(S), CH2, OCH2, CH2O, SCH2, and CH2S; and L2 = O, S, S(O), S(O)2, N(Ra), C(O), C(O)N(Ra), N(Ra)C(O), C(O)O, OC(O), OC(O)O, C(H):C(H), C.tplbond.C, N:N, N(Ra)N(Ra), N(Ra)C(O)N(Ra), C(S)N(Ra), N(Ra)C(S), CH2, OCH2, CH2O, SCH2, and CH2S. X1 = N and C bonded to H, except that X1 is C bonded to H if any of X2, X3, X5, or X6 is NH or O; and X2 = CH2, NH, and O, except that X2 is CH2 if X3 is O or NH; and X3 = CH2, NH, and O, except that X3 is CH2 if X2 is O or NH; and X4 = N and C bonded to H; and X5 = CH2 and NH, except that X5 is

CH2 if X3 is O or X6 is NH; and X6 = CH2 and NH, except that X6 is CH2 if X2 is O or X5 is NH. R1 = H, hydroxyalkyl, carboxyalkyl, aminoalkyl, aminocarbonylalkyl, and aminocarbonylaminoalkyl; R3A and R3B = halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl; and R3c = H, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl; R4 = pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, and the sulfone of thiomorpholinyl; R5 = H, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxyalkoxyalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, and heterocyclylalkyl; addnl. details are given in the claims. Although the methods of preparation are not claimed, 28 example preps. and characterization data for an addnl. 114 examples of I are included. For example, II was prepared from 4-[3-(4-chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-5-yl]cyclohexanone and ((R)-(+)- α -methylbenzyl)amine followed by sodium triacetoxycborohydride.

IT 635726-14-6P 635726-15-7P 635726-16-8P


635726-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazoles as p38 α kinase, TNF and/or cyclooxygenase-2 inhibitors)


RN 635726-14-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 635726-15-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 635726-16-8 CAPLUS

CN Ethanone, 1-[4-[5-(4-chlorophenyl)-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-1-piperidinyl]-2-hydroxy- (CA INDEX NAME)



RN 635726-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-5-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 57 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:376852 CAPLUS
 DN 138:385443
 TI Preparation of amino imidazolyl pyrimidinecarboxaldehyde
 thiosemicarbazones, pyridine analogs and related compounds as inhibitors
 of Ikb kinases
 IN Hawley, Ronald Charles; Labadie, Sharada Shenvi; Sjogren, Eric Brian;
 Talamas, Francisco Xavier
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040131	A1	20030515	WO 2002-EP12164	20021031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2465711	A1	20030515	CA 2002-2465711	20021031
	AU 2002350657	A1	20030519	AU 2002-350657	20021031
	EP 1444223	A1	20040811	EP 2002-785344	20021031
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013899	A	20040831	BR 2002-13899	20021031
	CN 1582284	A	20050216	CN 2002-822194	20021031
	JP 2005511608	T	20050428	JP 2003-542177	20021031
	RU 2308455	C2	20071020	RU 2004-117545	20021031
	US 20030144303	A1	20030731	US 2002-288968	20021106
	US 6846828	B2	20050125		
	MX 2004PA04166	A	20040708	MX 2004-PA4166	20040430
	US 20050107403	A1	20050519	US 2004-967430	20041018
	US 7157580	B2	20070102		
PRAI	US 2001-338312P	P	20011107		
	WO 2002-EP12164	W	20021031		
	US 2002-288968	A3	20021106		
OS	MARPAT 138:385443				

AB The present invention relates to aminopyrimidine and aminopyridine derivs. (shown as I; variables defined below; e.g. 2-butylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone (I)) and methods for their preparation. The compds. are useful as inhibitors of Ikb kinases and, therefore, may be used for the treatment of inflammatory, metabolic or malignant conditions (e.g. rheumatoid arthritis, inflammatory bowel disease, psoriasis, cancer, diabetes and septic shock). IC50 values for inhibition of IKKβ enzyme activity are reported for 3 examples of I; e.g. 0.314 μM for 1. Eleven example preps. of intermediates and I and characterization data for .apprx.150 I are included. For example, 2-isopropylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde

2-methylthiosemicarbazone was prepared in 7 steps starting from Et diethoxyacetate, thiourea and benzyl bromide giving 2-benzylsulfanyl-6-diethoxymethylpyrimidin-4-ol as the 1st intermediate (50%); this intermediate was sequentially converted to the chloride (74%), pyrimidine imidazole, sulfone (31% for 2 steps), amino pyrimidine acetal (66%), aldehyde (64%) and finally the aldehyde thiosemicarbazone (71%). For I: one of either V or X is N and the other is CRa, or both V and X are CRa (Ra = H, (C1-C6)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C6)alkyl); Y is O, S or NR (R is H, CN, NO₂, (C1-C10)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C10)alkenyl or (C2-C10)alkynyl). Z is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or N(R2)(R3); R1 is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl(C1-C6)alkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4) heteroalkyl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl, C(O)R11 or (C1-C6)alkylene-C(O)R11; R4 is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)alkynyl; A is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, halo (C1-C6) alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl(C1-C6) alkyl, heterosubstituted (C3-C7)cycloalkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4)heteroalkyl, heteroaryl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl or RaRbNC(:X) (Ra and Rb = H, (C1-C4)alkyl or aryl). X is O or S; B is a (un)substituted five- or six-membered aromatic ring containing at least 1 N and 0-3 addnl. heteroatoms,

wherein the B ring substituents = halogen, CF₃, CF₃O, (C1-C6)alkyl, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, cyano, nitro, sulfonamido, acyl, acylamino and carboxamido; U is -NR₅-, -O- or -S-; addnl. details are given in the claims.


IT 525559-27-7P, 2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
2-(3-hydroxy-3-methylbutyl)thiosemicarbazone 525559-33-5P,
2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-(tetrahydropyran-4-ylmethyl)thiosemicarbazone 525559-42-6P,
2-((1-Benzylpiperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525559-64-2P,
2-((1-(Ethoxycarbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525559-69-7P, 2-((1-Acetylpiperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525559-74-4P, 2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525560-00-3P,
2-((1-(Dimethylamino)carbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525560-07-0P, 2-((1-(Dimethylamino)sulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525560-08-1P,
2-((1-(Ethylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525560-11-6P, 2-((1-(Isopropylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525560-12-7P,
2-((1-(2-Acylethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-

yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-13-8P, 2-((1-(Aminocarbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-16-1P,
 2-((1-(Acetylmethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-19-4P, 2-((1-(Aminocarbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-20-7P,
 2-((1-(Methylamino)carbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-21-8P, 2-((1-(Dimethylamino)carbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-22-9P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-25-2P, 2-((1-(Methylamino)carbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-29-6P,
 2-((1-(2-(Methylsulfonyl)ethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-30-9P, 2-((1-(Cyanomethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-35-4P, 2-((1-(2-Cyanoethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-43-4P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-((tetrahydropyran-4-yl)methyl)thiosemicarbazone 525560-44-5P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-butylthiosemicarbazone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyridine analogs and related compds. as inhibitors of IkB kinases)


RN 525559-27-7 CAPLUS

CN Hydrazinecarbothioamide, 1-(3-hydroxy-3-methylbutyl)-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525559-33-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]methylene]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 525559-42-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(phenylmethyl)-4-piperidiny]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525559-64-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 525559-69-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[(1-acetyl-4-piperidyl)amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525559-74-4 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-00-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 525560-07-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-[(dimethylamino)sulfonyl]-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-08-1 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-11-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-12-7 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(3-oxobutyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-13-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 525560-16-1 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(2-oxopropyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-19-4 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 525560-20-7 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 525560-21-8 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 525560-22-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-25-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 525560-29-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-30-9 CAPLUS

CN Hydrazonecarbothioamide, 2-[[2-[[1-(cyanomethyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-35-4 CAPLUS

CN Hydrazonecarbothioamide, 2-[[2-[[1-(2-cyanoethyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-43-4 CAPLUS

CN Hydrazonecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)



RN 525560-44-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-butyl- (CA INDEX NAME)




IT 525559-28-8, 2-(1-Methanesulfonylpiperidin-4-ylamino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyridine analogs and related compds. as inhibitors of Ikb kinases)

RN 525559-28-8 CAPLUS

CN 4-Pyrimidinecarboxaldehyde, 6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 58 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:335096 CAPLUS
 DN 138:353990
 TI Preparation of 4-imidazolin-2-one derivatives as MAP kinase inhibitors
 IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;
 Ogasawara, Akihito; Hiramatsu, Hajime
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035638	A1	20030501	WO 2002-JP10937	20021022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461100	A1	20030501	CA 2002-2461100	20021022
	AU 2002363108	A1	20030506	AU 2002-363108	20021022
	EP 1439174	A1	20040721	EP 2002-802049	20021022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013465	A	20041109	BR 2002-13465	20021022
	CN 1571781	A	20050126	CN 2002-820837	20021022
	CN 100402521	C	20080716		
	HU 2004001949	A2	20050128	HU 2004-1949	20021022
	US 20040204426	A1	20041014	US 2004-827294	20040420
	MX 2004PA03729	A	20040723	MX 2004-PA3729	20040421
	KR 742058	B1	20070723	KR 2004-705911	20040421
	NO 2004002010	A	20040709	NO 2004-2010	20040514
PRAI	JP 2001-324029	A	20011022		
	JP 2002-263680	A	20020910		
	WO 2002-JP10937	W	20021022		
	JP 2003-116076	A	20030421		
OS	MARPAT 138:353990				
AB	The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, Naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, or alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonyl, (un)substituted alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl), PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts are prepared as mitogen activation proteins (MAP) kinase inhibitors. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl showed 69% inhibitory activity against TNF-α in rat in the amount of 1 mg/kg after 90 min.				
IT	521090-46-0P 521090-47-1P 521090-48-2P				

521090-50-6P 521090-51-7P 521090-60-8P


521091-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(MAP kinase inhibitor; preparation of imidazolinone derivs. as MAP kinase
inhibitors)

RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methyl-4-
piperidinyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 521090-47-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[[1-
(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-imidazol-1-
yl]methyl]- (CA INDEX NAME)




RN 521090-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 521090-50-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 521090-51-7 CAPLUS
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 521090-60-8 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 521091-47-4 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RE.CNT 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 59 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:326011 CAPLUS
 DN 139:230704
 TI 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors
 AU Manley, Peter J.; Balitza, Adrienne E.; Bilodeau, Mark T.; Coll, Kathleen E.; Hartman, George D.; McFall, Rosemary C.; Rickert, Keith W.; Rodman, Leonard D.; Thomas, Kenneth A.
 CS Departments of Medicinal Chemistry and Cancer Research, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(10), 1673-1677
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:230704
 AB 2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound I (R = H) (KDR IC50=105 nM, Cell IC50=8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative I (R = Me) (KDR IC50=6 nM, cell IC50=19 nM).
 IT 496795-25-6P 496795-34-7P 496795-35-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 2,4-disubstituted pyrimidines as a novel class of KDR kinase inhibitors)
 RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)




RN 496795-34-7 CAPLUS
 CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 496795-35-8 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dimethyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 60 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:242338 CAPLUS

DN 138:271694

TI Preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for control of inflammatory cytokines

IN Clark, Michael Phillip; Lauferweiler, Matthew John; Djung, Jane Far-Jine; Natchus, Michael George; De, Biswanath

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024971	A1	20030327	WO 2002-US30135	20020920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 6566357	B1	20030520	US 2002-246499	20020918
	US 20030105084	A1	20030605	US 2002-245927	20020918
	US 6821971	B2	20041123		
	CA 2461073	A1	20030327	CA 2002-2461073	20020920
	AU 2002327690	A1	20030401	AU 2002-327690	20020920
	AU 2002327690	B2	20060720		
	EP 1427728	A1	20040616	EP 2002-763693	20020920
	EP 1427728	B1	20070307		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012716	A	20040803	BR 2002-12716	20020920
	CN 1555375	A	20041215	CN 2002-818228	20020920
	CN 1257905	C	20060531		
	CN 1555379	A	20041215	CN 2002-818229	20020920
	CN 1250551	C	20060412		
	CN 1556811	A	20041222	CN 2002-818380	20020920
	CN 1249066	C	20060405		
	JP 2005504082	T	20050210	JP 2003-528818	20020920
	PT 1427727	T	20050630	PT 2002-763692	20020920
	ES 2237691	T3	20050801	ES 2002-763692	20020920
	HU 2005000752	A2	20060130	HU 2005-752	20020920
	AT 332901	T	20060815	AT 2002-799017	20020920
	AT 356126	T	20070315	AT 2002-763693	20020920
	ES 2268154	T3	20070316	ES 2002-799017	20020920
	RU 2299885	C2	20070527	RU 2004-111803	20020920
	NZ 531063	A	20070831	NZ 2002-531063	20020920
	ES 2282459	T3	20071016	ES 2002-763693	20020920
	ZA 2004001260	A	20040830	ZA 2004-1260	20040217
	ZA 2004001402	A	20040827	ZA 2004-1402	20040220
	ZA 2004001403	A	20040830	ZA 2004-1403	20040220
	MX 2004PA02574	A	20040618	MX 2004-PA2574	20040318

	NO 2004001605	A	20040621	NO 2004-1605	20040420
	HK 1071565	A1	20070126	HK 2005-104374	20050524
PRAI	US 2001-323625P	P	20010920		
	WO 2002-US30135	W	20020920		

OS MARPAT 138:271694

AB The present invention relates to compds. which are capable of preventing the extracellular release of inflammatory cytokines, said compds., including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, have the formula (I) $[R = O(CH_2)kR_3, (un)substituted NH_2; \text{wherein } k = \text{an integer of } 0-5; R_3 = \text{each } (un)substituted C1-C4 \text{ alkyl, hydrocarbyl, heterocyclyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl; } R1 = \text{each } (un)substituted \text{ aryl or heteroaryl; } R_2 = H, (CH_2)jO(CH_2)nR_8, (CH_2)jNR_9aR_9b, (CH_2)jCO_2R_{10}, (CH_2)jOCO_2R_{10}, (CH_2)jCON(R_{10})_2, (CH_2)jOCON(R_{10})_2; \text{ or two } R_2 \text{ units can be taken together to form a CO unit; wherein } R_8, R_9a, R_9b, R_{10} = H, C1-4 \text{ alkyl; or } R_9a \text{ and } R_9b \text{ are taken together to form a } C3-7 \text{ carbocyclic or heterocyclic ring; } j, n = \text{an integer of } 0-5; Z = O, S, NR_{11}, NOR_{11}; \text{ wherein } R_{11} = H, C1-4 \text{ alkyl}].$ Interleukin-1 (IL-1) and tumor necrosis factor- α (TNF- α) are among the important biol. substances known collectively as cytokines and understood to mediate the inflammatory response associated with the immunol. recognition of infectious agents. These pro-inflammatory cytokines are suggested as an important mediators in many disease states or syndromes, inter alia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (IBS), septic shock, cardiopulmonary dysfunction, acute respiratory disease, cachexia, and therefore responsible for the progression and manifestation of human disease states. The compds. I can block, abate, control, mitigate, or prevent the release of cytokines from cells which produce them (no data). Thus, 6.0 g Me 4-fluorophenylacetate was added to a cold (-78°) solution of lithium diisopropylamide (2 M, 21.4 mL) in THF and stirred at -78° for 1 h at -78°, followed by adding dropwise a solution of 6.0 g 2-methylsulfonylpyrimidine-4-carboxaldehyde (preparation given) in 30 mL THF and the resulting mixture was stirred for 45 min at -78° to give, after workup and silica gel chromatog., 8.7 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-hydroxypropionic acid Me ester (II) (76 %). To a suspension of CrO₃ in CH₂Cl₂ (300 mL) was added pyridine and stirred vigorously for 1 h at room temperature, followed by adding a solution of the crude II prepared above in 50 mL CH₂Cl₂ dropwise, and the reaction mixture was stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 3.7 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-oxopropionic acid Me ester (III) (43% yield) as a yellow solid. To a solution of 7.8 g pyrazolidine in 100 mL pyridine was added 11.5 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-3-oxopropionic acid Me ester and heated to 90° for 16 h to give, after silica gel chromatog., 3.9 g 2-(4-fluorophenyl)-3-(2-methylsulfonylpyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one (37%) which (1.3 g) was dissolved in a 1:1 mixture of THF and MeOH (56 mL), treated dropwise with 9.34 g Oxone in 42 mL H₂O, and stirred at room temperature for 1 h to give 2-(4-fluorophenyl)-3-(2-methanesulfonylpyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one.


IT 503072-98-8P, 2-(4-Fluorophenyl)-3-[2-[[1-(propanesulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for control of extracellular release inflammatory cytokines)

RN 503072-98-8 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 61 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:154244 CAPLUS

DN 138:187786

TI Preparation of pyrimidinylthiazoles as antiinflammatories.

IN Love, Christopher John; Van Wauwe, Jean Pierre Frans; De Brabander, Marc J.; Moses, Roger Clive; Goncharenko, Mykhalyo; Cooymans, Ludwig Paul; Vandermaesen, Nele; Diels, Gaston Stanislas Marcella; Sibley, Anthony William; Noulia, Caterina

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015776	A1	20030227	WO 2002-EP8956	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451981	A1	20030227	CA 2002-2451981	20020809
	AU 2002331227	A1	20030303	AU 2002-331227	20020809
	AU 2002331227	B2	20080124		
	EP 1418911	A1	20040519	EP 2002-767360	20020809
	EP 1418911	B1	20060510		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	HU 2004001160	A2	20040928	HU 2004-1160	20020809
	HU 2004001160	A3	20080128		
	BR 2002011910	A	20041019	BR 2002-11910	20020809
	JP 2005504767	T	20050217	JP 2003-520735	20020809
	CN 1633294	A	20050629	CN 2002-815776	20020809
	NZ 530772	A	20060331	NZ 2002-530772	20020809
	AT 325608	T	20060615	AT 2002-767360	20020809
	ES 2264734	T3	20070116	ES 2002-767360	20020809
	IN 2004DN00272	A	20050401	IN 2004-DN272	20040206
	US 20040254192	A1	20041216	US 2004-486820	20040211
	US 7138403	B2	20061121		
	NO 2004000631	A	20040312	NO 2004-631	20040212
	ZA 2004001164	A	20050512	ZA 2004-1164	20040212
	MX 2004PA01400	A	20040527	MX 2004-PA1400	20040213
PRAI	EP 2001-203088	A	20010813		
	WO 2002-EP8956	W	20020809		

OS MARPAT 138:187786


AB Use of title compds. [I; Z = halo, alkyl; hydroxyalkyl, carboxyalkyl, cyanoalkyl, aminoalkyl, aminoalkyl, aminocarbonylalkyl, alkoxyalkyl, polyhaloalkyl, alkoxy, cyano, amino, aminocarbonyl, aminocarbonyl, alkyloxy, carbonyl, alkylcarbonyloxy, etc.; Q = (substituted) cycloalkyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzoxazolyl,

benzimidazolyl, indazolyl, imidazopyridyl, etc.; L = substituted Ph, (substituted) monocyclic 5-6 membered partially saturated or aromatic heterocycle, bicyclic partially saturated or aromatic heterocycle] for the manufacture of a medicament for the prevention or the treatment of diseases mediated through tumor necrosis factor- α (TNF- α) and/or interleukin-12 (IL-12), is claimed. Thus, Me 3-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]-3-oxopropanoate was added to a mixture prepared from NaOMe and diguanidine carbonate in EtOCH₂CH₂OH followed by 3 h reflux to give 76% 5- (2-aminopyrimidin-4-yl)-4-methyl-2-(4-trifluoromethylphenyl)thiazole. The latter at 10-8 M gave 92% inhibition of IL-12p70.

IT 499796-65-5P 499796-66-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidinylthiazoles as antiinflammatories)


RN 499796-65-5 CAPLUS

CN 2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]- (CA INDEX NAME)



RN 499796-66-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 62 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:117808 CAPLUS

DN 138:170248

TI Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors

IN Fraley, Mark E.; Hoffman, William F.; Hartman, George D.

FA Merck & Co., Inc., USA

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011838	A1	20030213	WO 2002-US23882	20020727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002326466	A1	20030217	AU 2002-326466	20020727
	US 20040181066	A1	20040916	US 2004-485291	20040129
FRAI	US 2001-309407P	P	20010801		
	WO 2002-US23882	W	20020727		

OS MARPAT 138:170248

AB The present invention relates to title compds. I [wherein R_{1a} = H, (un)substituted alkyl, OR₈, or N(R₈)₂; R₁ and R₂ = independently H, halo, CF₃, (CH₂)₂tR₉COR₈, COR₉, (CH₂)₂tOR₈, CN, (CH₂)₂tNR₇R₈, (CH₂)₂CONR₇R₈, CO₂R₈, (CH₂)₂SO₂-2(CH₂)₂tNR₇R₈, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R₃ = H, CN, halo, N(R₈)₂, OR₈, or (un)substituted (ar)alkyl or aryl; R₇ = H or (un)substituted (ar)alkyl; R₈ = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR₇R₈ = (un)substituted heterocyclyl; R₉ = independently (un)substituted alkyl, heterocyclyl, or aryl; W = aryl or heterocyclyl; m = 0-2; n = independently 0-6; p = 0-4; t = independently 0-6; or pharmaceutically acceptable salts, hydrates, or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, cyclization of 2-bromo-1-[2-(methylthio)pyrimidin-4-yl]ethanone (3-step preparation given) with thiourea in EtOH gave 5-bromo-4-[2-(methylthio)pyrimidin-4-yl]-1,3-thiazol-2-amine-#Br. Oxidation to the methylsulfinyl derivative using oxone followed by substitution with 3,5-dimethylaniline afforded II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC values between 0.01 M and 5.0 M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).

II 1055062-70-8 1055062-71-9 1055062-75-3
 1055062-76-4 1055062-80-0 1055062-98-0
 1055062-99-1 1055063-00-7 1055063-13-2


1055063-14-3 1055063-15-4 1055063-16-5

RL: PRPH (Prophetic)

(Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors)


RN 1055062-70-8 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-chloro-4-pyridinyl]amino]-4-pyrimidinyl]-2-amino- (CA INDEX NAME)




RN 1055062-71-9 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-chloro-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-75-3 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-chloro-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-76-4 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-methyl-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-80-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-[[4-(2-amino-5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-chloro-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055062-98-0 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-methyl-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-99-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-[[4-(5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-methyl-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055063-00-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[6-chloro-4-[[4-(5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055063-13-2 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-methyl-4-pyridinyl]amino]-4-pyrimidinyl]-2-amino- (CA INDEX NAME)




RN 1055063-14-3 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[[2-methyl-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055063-15-4 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[[2-chloro-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1055063-16-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[[4-(2-amino-5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-methyl-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 63 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:117807 CAPLUS
 DN 138:153548
 TI Preparation of 4-(pyrazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Fraley, Mark E.; Peckham, Jennifer P.; Arrington, Kenneth L.; Hoffman, William F.; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011837	A1	20030213	WO 2002-US23879	20020726
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002355733	A1	20030217	AU 2002-355733	20020726
	US 20040235875	A1	20041125	US 2004-485296	20040129
	US 7109204	B2	20060919		
PRAI	US 2001-309399P	P	20010801		
	WO 2002-US23879	W	20020726		
OS	MARPAT 138:153548				

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)tCONR7R8, CO2R8, (CH2)tSOO-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = independently H, CN, halo, N(R3)2, (CH2)tOR8, or (un)substituted (ar)alkyl or aryl; R7 = independently H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted heterocyclyl, alkyl, or aryl; V = a bond, aryl, or heterocyclyl; W = aryl or heterocyclyl; m = 0-2; n = 0-6; p = 0-4; t = independently 0-6; and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, 2-(methylthio)pyrimidine-4-carboxylic acid was amidated with dimethylhydroxylamine-HCl in the presence of EDC and TEA, and the product treated with MeMgBr in Et2O to give 1-[2-(methylthio)pyrimidin-4-yl]ethanone. Coupling with N,N-dimethylformamide dimethylacetal followed by cyclization with phenylhydrazine afforded 2-(methylthio)-4-(1-phenyl-1H-pyrazol-3/5-yl)pyrimidine. Oxidation with oxone and reaction with 3-chloroaniline provided the 4-(pyrazolyl)-2-pyrimidinamine II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 μ M and 5.0 μ M. Thus, I are useful for

the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).


IT 1055062-51-5 1055062-60-6 1055062-64-0
1055062-65-1 1055062-67-3 1055062-68-4

RL: PRPH (Prophetic)

(Preparation of 4-(pyrazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors)


RN 1055062-51-5 CAPLUS

CN Ethanone, 1-[4-[[6-methyl-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1055062-60-6 CAPLUS

CN 2-Pyrimidinamine, N-[2-methyl-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]-4-(1-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 1055062-64-0 CAPLUS

CN Ethanone, 1-[4-[[6-chloro-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-1-piperazinyl]-N-methyl- (CA INDEX NAME)




RN 1055062-65-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[6-chloro-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055062-67-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-chloro-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]-4-(1-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 1055062-68-4 CAPLUS

CN 1-Piperazinecarboxamide, N-methyl-4-[[6-methyl-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]- (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 64 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:117806 CAPLUS
 DN 138:153547
 TI Preparation of 4-(imidazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Bilodeau, Mark T.; Manley, Peter J.; Balitza, Adrienne; Rodman, Leonard; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011836	A1	20030213	WO 2002-US23764	20020726
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002327342	A1	20030217	AU 2002-327342	20020726
	US 20040220201	A1	20041104	US 2004-485170	20040129
	US 6958340	B2	20051025		
PRAI	US 2001-309400P	P	20010801		
	WO 2002-US23764	W	20020726		
OS	MARPAT 138:153547				

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, or OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)tCONR7R8, CO2R8, (CH2)tSOq(CH2)tNR7R8, oxido, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = H, CN, halo, N(R8)2, (CH2)tOR8, or (un)substituted (ar)alkyl or aryl; R7 = independently H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted heterocyclyl, alkyl, or aryl; V = bond, aryl, or heterocyclyl; W = aryl or heterocyclyl; m = 0-3; n = 0-6; p = 0-4; q = undefined; t = 0-6; or pharmaceutically acceptable salts, hydrates or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, 2-phenylimidazole was coupled with 4-chloro-2-(methylthio)pyrimidine in the presence of NaH in DMF and the product oxidized using sodium tungstate dihydrate and H2O2 in EtOAc to give 2-(methylsulfonyl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine. Substitution with 2-methylaniline and purification by reverse phase chromatog. afforded II•TFA. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 μ M and 5.0 μ M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).


IT 496795-25-6P, 4-(2-Phenyl-1H-imidazol-1-yl)-N-(pyridin-4-yl)pyrimidin-2-amine 496795-34-7P,
 N-(2-Methylpyridin-4-yl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine
 496795-35-8P, N-(2,6-Dimethylpyridin-4-yl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tyrosine kinase inhibitor; preparation of (imidazolyl)pyrimidinamines as tyrosine kinase inhibitors)
 RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)



RN 496795-34-7 CAPLUS
 CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 496795-35-8 CAPLUS
 CN 2-Pyrimidinamine, N-(2,6-dimethyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 65 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:746614 CAPLUS
 DN 136:95578
 TI Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
 AU Adams, J. L.; Boehm, J. C.; Gallagher, T. F.; Kassis, S.; Webb, E. F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D. E.; Lee, J. C.
 CS Department of Medicinal Chemistry, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(21), 2867-2870
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Optimization of a series of N-1-cycloalkyl-4-aryl-5-(pyrimidin-4-yl)imidazole inhibitors of p38 kinase is reported. Oral administration of inhibitors possessing a cyclohexan-4-ol or piperidin-4-yl group at N-1 in combination with alkoxy, amino(alkyl), phenoxy and anilino substitution at the 2-position of the pyrimidine was found to potently inhibit LPS-induced TNF in mice and rats. The selectivity of these new inhibitors for p38 kinase vs. eight other protein kinases is high and in all cases exceeds that of SB 203580.
 IT 186314-88-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyrimidinylimidazole inhibitors of p38, cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity)
 RN 186314-88-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



proviso

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 66 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:278036 CAPLUS

DN 134:295821

TI Imidazole compounds useful as cytokine inhibitors.

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Osifo, Irennegbe Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corporation, USA

SO U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 636,779, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6218537	B1	20010417	US 1998-973594	19980513
	ZA 9604723	A	19970617	ZA 1996-4723	19960606
	WO 9640143	A1	19961219	WO 1996-US10039	19960607
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	EP 1314728	A1	20030528	EP 2002-79535	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	IN 1996DE01674	A	20050311	IN 1996-DE1674	19960726
FRAI	US 1995-473396	A2	19950607		
	US 1996-636779	B2	19960419		
	WO 1996-US10039	W	19960607		
	EP 1996-921517	A3	19961219		
OS	CASREACT 134:295821; MARPAT 134:295821				
AB	Novel 1,4,5-trisubstituted imidazole compds. I and their compns. for use in therapy as cytokine inhibitors are disclosed [wherein R1 = 4-pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl, all bearing a substituted amino group, plus an optional addnl. substituent; R2 = alkyl, N3, heterocyclyl, alk(en/yn)yl, haloalkyl, etc.; R4 = (un)substituted Ph, 1- or 2-naphthyl, heteroaryl]. I are useful for treating a variety of cytokine-mediated diseases, particularly those mediated by CSBP/RK/p38 kinase, and may also be useful as antivirals (no data). For example, 2-(methylthio)pyrimidine-4-carboxaldehyde (preparation given) was condensed with 4-amino-1-methylpiperidine-2HCl to give the imine (98%), which was cyclized with the tosylmethyl isocyanide derivative 4-FC6H4CH(Tos)N.tpbond.C (50%) to give imidazole derivative II [R = SMe]. This underwent S-oxidation with K persulfate to give 83% II [R = S(O)Me], which was condensed with PhCH2NH2 (82%) to give title compound II [R = NHCH2Ph].				
IT	186314-86-3P 186314-88-5P 186314-90-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of imidazole derivs. as cytokine inhibitors)				
RN	186314-86-3 CAPLUS				
CN	1-Piperidinecarboxylic acid, 4-[[4-(4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)				



proviso

RN 186314-88-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl-1-ethyl ester (CA INDEX NAME)



proviso

RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1-ethyl ester (CA INDEX NAME)




IT 186314-81-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazole derivs. as cytokine inhibitors)

RN 186314-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 67 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:137207 CAPLUS

DN 134:178569

TI Preparation of as isoxazolylypyrimidines and related compounds as inhibitors of c-JUN N-terminal kinases and other protein kinases.

IN Green, Jeremy; Bemis, Guy; Grillot, Anne-Laure; Ledebauer, Mark; Salituro, Francis; Harrington, Edmund; Gao, Hual; Baker, Christopher; Cao, Jingrong; Hale, Michael

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012621	A1	20010222	WO 2000-US22445	20000811
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2381882	A1	20010222	CA 2000-2381882	20000811
	EP 1218369	A1	20020703	EP 2000-957485	20000811
	EP 1218369	B1	20080723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013551	A	20030617	BR 2000-13551	20000811
	HU 2003000340	A2	20030628	HU 2003-340	20000811
	HU 2003000340	A3	20050428		
	JP 2003531103	T	20031021	JP 2001-517519	20000811
	NZ 517694	A	20050324	NZ 2000-517694	20000811
	CN 1222520	C	20051012	CN 2000-814178	20000811
	AT 402163	T	20080815	AT 2000-957485	20000811
	NO 2002000713	A	20020412	NO 2002-713	20020212
	US 20030149051	A1	20030807	US 2002-74177	20020212
	US 6693108	B2	20040217		
	ZA 2002001248	A	20030220	ZA 2002-1248	20020213
	MX 2002PA01565	A	20050714	MX 2002-PA1565	20020213
	IN 2002KN00245	A	20050916	IN 2002-KN245	20020219
	US 20050026967	A1	20050203	US 2004-779532	20040213
	US 7169798	B2	20070130		
	AU 2006203676	A1	20060921	AU 2006-203676	20060824
PRAI	US 1999-148795P	P	19990813		
	US 1999-166922P	P	19991122		
	US 2000-211517P	P	20000614		
	AU 2000-69096	A3	20000811		
	WO 2000-US22445	W	20000811		
	US 2002-74177	A3	20020212		
OS	MARPAT 134:178569				
AB	Title compds. [I; XYZ = NOCR2, ON:CR2, N:NNR3, OC(R2):CR2, NN(R3)CR2; R1 = H, CONH2, TnR, TnAr2; R = (substituted) aliphaty; n = 0, 1; T = CO, CO2, CONH, SO2, SO2NH, COCH2, CH2; R2 = H, R, CH2OR, CH2OH, CHO, CH2SR,				

CH₂SO₂R, CH₂NH₂, CH₂CN, (substituted) aryl, arylmethyl, heterocyclyl, heterocyclylmethyl, etc.; R₃ = H, R, COR, CO₂R, SO₂R; G = R, Ar1; Ar1 = (substituted) (fused) aryl, aralkyl, heterocyclyl; Q = Q1, Q2; A = N, CR₃; U = CR₃, O, S, NR₃; Ar₂ = (substituted) (fused) aryl, heterocyclyl], were prepared. Thus, 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylamine (preparation given) was refluxed with PhBr, tris(dibenzylideneacetone)dipalladium, BINAP, and NaOCMe₃ were refluxed together for 16 h to give 36% 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylphenylamine. Several I inhibited KNK3 at <0.1 μM.


IT 326819-56-1 326819-60-7 326819-61-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of as isoxazolylpyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)


RN 326819-56-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 326819-60-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 326819-61-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-4-piperidinyl- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 68 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:725459 CAPLUS

DN 133:296373

TI Preparation of 3-phenyl-4-(heterocyclylmethyl)pyrrolidine modulators of chemokine receptor activity

IN Caldwell, Charles; Chapman, Kevin; Hale, Jeffrey; Kim, Dooseop; Lynch, Christopher; Maccoss, Malcolm; Mills, Sander G.; Willoughby, Christopher; Berk, Scott; Kim, Ronald M.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059498	A1	20001012	WO 2000-US9074	20000405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6498161	B1	20021224	US 2000-543019	20000404
PRAI	US 1999-128172P	P	19990406		
OS	MARPAT 133:296373				

AB The title compds. (I) [wherein R1 = CO₂H, NO₂, tetrazolyl, hydroxyisoxazole, SO₂NH(alkyl)R₉, or PO₃H₂; R₉ = H, (cyclo)alkyl, benzyl, or (un)substituted phenyl; R₂ = (un)substituted piperidinyl, tetrahydropyridinyl, piperazinyl, or 1-oxa-8-azaspiro[4.5]decal; R₃ = (un)substituted Ph or heterocyclyl; R₄ = H or (un)substituted alkyl, (alkyl)cycloalkyl, alkenyl, alkynyl, Ph, alkylphenyl, naphthyl, biphenyl, heterocyclyl, cyclohexenyl, etc.; R₅ and R₆ = independently H or (un)substituted alkyl; or R₄ and R₅ may be joined together to form an (un)substituted C₃-8 cycloalkyl ring; n = 1-3] were prepared as modulators of chemokine receptors, especially the chemokine receptors CCR-5 and/or CCR-3. For example, 2-(R)-((3-(R)-formyl)-4-(S)-3-fluorophenylpyrrolidinyl-1-yl)-3-cyclobutanepropionic acid benzyl ester (preparation given) was treated with Pd/C and dissolved in ClCH₂CH₂Cl.

4-[N-(pyrimid-2-yl)-N-(prop-1-yl)amino]piperidine•HCl (4-step preparation given), NaBH(OAc)₃, and TEA were added, followed by di-tert-butylidicarbonate, to give II. I showed binding activity to the CCR-5 or the CCR-3 receptor, generally with IC₅₀ values of < 1 μM. The present invention is directed to compds. which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention and treatment of HIV infection and the resulting AIDS syndrome (no data). The invention is further directed to compds. which are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders, including asthma, allergic rhinitis, dermatitis, conjunctivitis, rheumatoid arthritis, and atherosclerosis (no data).

IT 301223-28-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-phenyl-4-(heterocyclylmethyl)pyrrolidine chemokine
receptor modulators by reaction of 3-phenyl-4-formylpyrrolidines with
heterocycles)

RN 301223-28-9 CAPLUS

CN 1-Pyrrolidineacetic acid, α -cyclohexyl-3-phenyl-4-[[4-[(4-phenyl-2-pyrimidinyl)propylamino]-1-piperidinyl]methyl]-, (α R,3S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 69 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:262172 CAPLUS
 DN 130:306613
 TI Cytokine production blockers for the management of uterine contractions
 IN Alvi, Samir Ahmed
 PA Imperial College Innovations Ltd., UK
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918942	A1	19990422	WO 1998-GB3015	19981008
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2316296	A1	19990422	CA 1998-2316296	19981008
	AU 9894493	A	19990503	AU 1998-94493	19981008
	EP 1021173	A1	20000726	EP 1998-947651	19981008
	R:	BE, CH, DE, ES, FR, GB, IT, LI, NL			
	JP 2001519381	T	20011023	JP 2000-515577	19981008
FRAI	US 1997-61614P	P	19971010		
	WO 1998-GB3015	W	19981008		
OS	MARPAT 130:306613				
AB	The present invention is to the novel use of a cytokine inhibitor for the prophylactic treatment, or management of excessive, undesired or inappropriate uterine activity, such as contractions, in a mammal in need thereof. An example of a cytokine-production blocker is SKF 86002 [6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo[2,1-b]thiazole], a CSBP/p38 protein kinase RK inhibitor.				
IT	186314-81-8 186314-86-3 186314-88-5				
	186314-90-9				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cytokine production blockers for the management of uterine contractions)				
RN	186314-81-8 CAPLUS				
CN	2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)				



proviso


RN 186314-86-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 186314-88-5 CAPLUS

CN 2-Pyrimidinamine, 4-[[4-(4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl]- (CA INDEX NAME)



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 70 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:7994 CAPLUS

DN 130:66503

TI Preparation of imidazolyl-cyclic acetals as TNF-alpha inhibitor

IN Bamborough, Paul Lindsay; Collis, Alan John; Halley, Frank; Lewis, Richard
Alan; Lythgoe, David John; McKenna, Jeffrey Mark; Mclay, Iain Mcfarlane;
Porter, Barry; Ratcliffe, Andrew James; Wallace, Paul Andrew

PA Rhone-Poulenc Rorer Limited, UK

SO PCT Int. Appl., 292 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9856788	A1	19981217	WO 1998-GB1711	19980612
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2293436	A1	19981217	CA 1998-2293436	19980612
	AU 9879259	A	19981230	AU 1998-79259	19980612
	AU 742293	B2	20011220		
	ZA 9805148	A	19991213	ZA 1998-5148	19980612
	EP 988301	A1	20000329	EP 1998-929548	19980612
	EP 988301	B1	20060809		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO, CY			
	TR 9903098	T2	20000721	TR 1999-3098	19980612
	BR 9810007	A	20000815	BR 1998-10007	19980612
	HU 2000003309	A2	20020128	HU 2000-3309	19980612
	HU 2000003309	A3	20020228		
	JP 2002503245	T	20020129	JP 1999-501908	19980612
	RU 2221795	C2	20040120	RU 2000-100951	19980612
	AT 335735	T	20060915	AT 1998-929548	19980612
	PT 988301	T	20061031	PT 1998-929548	19980612
	ES 2270520	T3	20070401	ES 1998-929548	19980612
	TW 235751	B	20050711	TW 1998-87112466	19980729
	US 6602877	B1	20030805	US 1999-456360	19991208
	NO 9906120	A	20000124	NO 1999-6120	19991210
	MX 9911515	A	20000430	MX 1999-11515	19991210
	US 20040038991	A1	20040226	US 2003-436609	20030513
	US 6989395	B2	20060124		
PRAI	GB 1997-12270	A	19970612		
	US 1997-52185P	P	19970710		
	GB 1997-24678	A	19971121		
	US 1998-85499P	P	19980514		
	WO 1998-GB1711	W	19980612		
	US 1999-456360	A3	19991208		

OS MARPAT 130:66503

AB Title Comps.[I]; are described in which R1 is optionally substituted heteroaryl, 4-pyridyl; R2 is optionally substituted aryl, 4-fluorophenyl, or optionally substituted heteroaryl; R3 is H, a group -L1-R7 or -L2-R8,

where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, etc.; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl; R4 is benzylaminocarbonyl, a group -L3-R14, where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy, cycloalkyloxy, heteroaryl, R5 is hydrogen, Me, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C:CH2; R6 represents H, alkyl; m is 0-2], N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates are prepared as TNF inhibitors and pharmaceuticals.


IT 218160-32-8P 218161-31-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl-1,3-dioxanes as TNF-alpha inhibitor)

RN 218160-32-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-(4-(4-fluorophenyl)-2-[trans-5-methyl-5-(4-morpholinylcarbonyl)-1,3-dioxan-2-yl]-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 218161-31-0 CAPLUS

CN 2-Pyrimidinamine, 4-[[2-(cis-5-amino-5-methyl-1,3-dioxan-2-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-N-4-piperidinyl]- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 71 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:226813 CAPLUS

DN 128:282837

OREF 128:55991a,55994a

TI Preparation of imidazoles as cytokine inhibitors

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Peng, Zhi Qiang; Osifo, Trennegbe Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corp., USA

SO U.S., 33 pp., Cont.-in-part of U.S. 5,658,903.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739143	A	19980414	US 1996-764003	19961211
	US 5658903	A	19970819	US 1996-659102	19960603
	ZA 9604723	A	19970617	ZA 1996-4723	19960606
	EP 1314728	A1	20030528	EP 2002-79535	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	IN 1996DE01674	A	20050311	IN 1996-DE1674	19960726
	ZA 9711092	A	19990722	ZA 1997-11092	19971210
	CA 2274655	A1	19980618	CA 1997-2274655	19971211
	WO 9825619	A1	19980618	WO 1997-US23157	19971211
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9857033	A	19980703	AU 1998-57033	19971211
	EP 961618	A1	19991208	EP 1997-953241	19971211
	EP 961618	B1	20040804		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001506239	T	20010515	JP 1998-527045	19971211
	ES 2226008	T3	20050316	ES 1997-953241	19971211
	US 5869660	A	19990209	US 1998-12946	19980123
	US 6369068	B1	20020409	US 1999-319859	19990611
PRAI	US 1995-473396	B2	19950607		
	US 1996-636779	B2	19960419		
	US 1996-659102	A2	19960603		
	US 1996-32766P	P	19961211		
	US 1996-764003	A	19961211		
	EP 1996-921517	A3	19961219		
	WO 1997-US23157	W	19971211		

OS MARPAT 128:282837

AB The title compds. [I; R1 = 4-pyridyl, pyrimidinyl, quinolinyl, etc.; R2 = heterocyclyl, C2-10 alkenyl, C3-7 cycloalkyl, etc.; R4 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, heteroaryl], useful in treatment, e.g., inflammation and osteoporosis as cytokine inhibitors, were prepared Thus, reaction of 4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-5-(2-methylsulfinyl)-4-pyrimidinylimidazole (preparation described) with PhCH2NH2 afforded 82% I [R1 = 2-benzylamino-4-pyrimidinyl; R2 = 1-methyl-4-piperinyl; R4 = 4-fluorophenyl] which showed IC50 of < 50 µM in cytokine specific binding protein assay.


IT 186314-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of imidazoles as cytokine inhibitors)

RN 186314-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



proviso


IT 186314-86-3P 186314-88-5P 186314-90-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazoles as cytokine inhibitors)


RN 186314-86-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 186314-88-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 72 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:650347 CAPLUS

DN 127:314828

OREF 127:61489a,61492a

TI 1,4,5-Substituted imidazole compounds for treatment of CNS injuries to the brain

IN Feuerstein, Giora Z.

PA Smithkline Beecham Corporation, USA; Feuerstein, Giora Z.

SO PCT Int. Appl., 40 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735856	A1	19971002	WO 1997-US5820	19970324
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	889888	A1	19990113	EP 1997-917899	19970324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	JP 2000507558	T	20000620	JP 1997-534693	19970324
	US 6096739	A	20000801	US 1998-142877	19980918
	US 6387898	B1	20020514	US 2000-627940	20000728
PRAI	US 1996-14137P	P	19960325		
	WO 1997-US5820	W	19970324		
	US 1998-142877	A3	19980918		
OS	MARPAT 127:314828				
AB	1,4,5-Substituted imidazole compds. and compns. are used for the treatment of CNS injuries to the brain. The preferred method of inhibition is the inhibition of the CSBP/p38/RK kinase pathway. Compds. of the invention were active (IC50<50 µM) in a cytokine specific binding protein (CSBP) assay.				
IT	186314-81-8 186314-86-3 186314-88-5 186314-90-9				
	RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)				
	(imidazole derivs. for treatment of CNS injuries to brain)				
RN	186314-81-8 CAPLUS				
CN	2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)				




RN 186314-86-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 186314-88-5 CAPLUS

CN 2-Pyrimidinamine, 4-[[4-(4-fluorophenyl)-1H-imidazol-5-yl]-N-4-piperidinyl]- (CA INDEX NAME)



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



L17 ANSWER 73 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:119170 CAPLUS

DN 126:144274

OREF 126:27881a,27884a

TI Imidazole compounds useful as cytokine inhibitors.

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Peng, Zhi-Qiang; Osifo, Irennegbee Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640143	A1	19961219	WO 1996-US10039	19960607
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	IL 118544	A	20010808	IL 1996-118544	19960603
	IN 186434	A1	20010901	IN 1996-DE1210	19960604
	ZA 9604723	A	19970617	ZA 1996-4723	19960606
	TW 442481	B	20010623	TW 1996-85106749	19960606
	CA 2223533	A1	19961219	CA 1996-2223533	19960607
	AU 9662726	A	19961230	AU 1996-62726	19960607
	AU 699646	B2	19981210		
	EP 831830	A1	19980401	EP 1996-921517	19960607
	EP 831830	B1	20030305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	CN 1192147	A	19980902	CN 1996-195882	19960607
	CN 1130358	C	20031210		
	BR 9608591	A	19990105	BR 1996-8591	19960607
	HU 9802259	A2	19990928	HU 1998-2259	19960607
	HU 9802259	A3	20020228		
	JP 11513017	T	19991109	JP 1996-502174	19960607
	AT 233561	T	20030315	AT 1996-921517	19960607
	EP 1314728	A1	20030528	EP 2002-79535	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	PL 185515	B1	20030530	PL 1996-323916	19960607
	ES 2194106	T3	20031116	ES 1996-921517	19960607
	IN 1996DE01674	A	20050311	IN 1996-DE1674	19960726
	NO 9705716	A	19980204	NO 1997-5716	19971205
	US 6218537	B1	20010417	US 1998-973594	19980513
	IN 2000DE00081	A	20050311	IN 2000-DE81	20000202
PRAI	US 1995-473396	A	19950607		
	US 1996-636779	A	19960419		
	WO 1996-US10039	W	19960607		
	EP 1996-921517	A3	19961219		

OS MARPAT 126:144274

AB Novel 1,4,5-trisubstituted imidazole compds. I and their compns. for use in therapy as cytokine inhibitors are disclosed [wherein R1 = 4-pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolin-4-yl, 1-imidazolyl,


1-benzimidazolyl, all bearing a substituted amino group, plus an optional addnl. substituent; R2 = alkyl, N3, heterocyclyl, alk(en/yn)yl, haloalkyl, etc.; R4 = (un)substituted Ph, 1- or 2-naphthyl, heteroaryl]. I are useful for treating a variety of cytokine-mediated diseases, particularly those mediated by CSBP/RK/p38 kinase, and may also be useful as antivirals (no data). For example, 2-(methylthio)pyrimidine-4-carboxaldehyde (preparation given) was condensed with 4-amino-1-methylpiperidine-2HCl to give the imine (98%), which was cyclized with the tosylmethyl isocyanide derivative 4-FC6H4CH(Tos)N.tplbond.C (50%) to give imidazole derivative II [R = SMe]. This underwent S-oxidation with K persulfate to give 83% II [R = S(O)Me], which was condensed with PhCH2NH2 (82%) to give title compound II [R = NHCH2Ph].

IT 186314-86-3P 186314-88-5P 186314-90-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as cytokine inhibitors)

RN 186314-86-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




proviso

RN 186314-88-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 186314-90-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



IT 186314-81-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazole derivs. as cytokine inhibitors)
 RN 186314-81-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 74 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1994:435528 CAPLUS

DN 121:35528

OREF 121:6563a,6566a

TI Synthesis and biological activity of some
4-(p-chlorophenyl)-6-(o-hydroxyphenyl)-2-aminopyrimidine derivatives: Part
1

AU Abdel-Halim, A. M.; Tawfik, A. M.; Ibrahim, S. S.; El-Kazak, A. M.

CS Fac. Educ., Ain Shams Univ., Cairo, Egypt

SO Indian Journal of Heterocyclic Chemistry (1994), 3(3), 165-70

CODEN: IJCHEI; ISSN: 0971-1627

DT Journal

LA English


AB 6-(O-Hydroxyphenyl)-4-(substituted-phenyl)-2-aminopyrimidines (e.g., I)
were prepared from their corresponding 2-(substituted-phenyl)chromones.
Acylation, alkylation, reaction with chloroacetyl chloride, phenacyl
bromide, and nucleophilic substitution reactions of I have been
investigated. The assigned structures were verified by elemental anal.,
IR and ¹H NMR. Some of the newly synthesized compds. were screened for in
vitro antibacterial and antifungal activities. Only I showed
antibacterial activity against gram-neg. bacteria.

IT 155733-42-9P 155733-43-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 155733-42-9 CAPLUS

CN Phenol, 2-[6-(4-chlorophenyl)-2-[(7-chloro-4-quinolinyl)amino]-4-
pyrimidinyl]- (CA INDEX NAME)



RN 155733-43-0 CAPLUS

CN Phenol, 2-[2-(9-acridinylamino)-6-(4-chlorophenyl)-4-pyrimidinyl]- (CA
INDEX NAME)



=>

---Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...